{"Proteins: CDKN1A, CREBBP, EP300, RBL1, TP53": {"keywords": [], "references": []}, "The system of interacting proteins primarily functions in the regulation of the cell cycle, specifically in controlling cell cycle progression and maintaining genomic stability. The proteins involved in this system are CDKN1A, CREBBP, EP300, RBL1, and TP53.": {"keywords": ["(CDKN1A[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) OR (TP53[Title]) AND (cell cycle[Title])", "(CDKN1A[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) OR (TP53[Title]) AND (genomic stability[Title])", "(CDKN1A[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) OR (TP53[Title]) AND (regulation[Title])", "(CDKN1A[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (regulation[Title/Abstract])"], "references": ["Bi, Guoshu, Liang, Jiaqi, Zhao, Mengnan, Zhang, Huan, Jin, Xing, Lu, Tao, Zheng, Yuansheng, Bian, Yunyi, Chen, Zhencong, Huang, Yiwei, Besskaya, Valeria, Zhan, Cheng, Wang, Qun, Tan, Lijie. \"miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.\" Molecular therapy. Nucleic acids, 2022, pp. 366-386.", "Lee, Jinkwon, Kim, Kwangho, Ryu, Tae Young, Jung, Cho-Rok, Lee, Moo-Seung, Lim, Jung Hwa, Park, Kunhyang, Kim, Dae-Soo, Son, Mi-Young, Hamamoto, Ryuji, Cho, Hyun-Soo. \"EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.\" Molecular oncology, 2021, pp. 2989-3002.", "Meireles Da Costa, Nathalia, Palumbo, Antonio, De Martino, Marco, Fusco, Alfredo, Ribeiro Pinto, Luis Felipe, Nasciutti, Luiz Eurico. \"Interplay between HMGA and TP53 in cell cycle control along tumor progression.\" Cellular and molecular life sciences : CMLS, 2021, pp. 817-831."]}, "1. CDKN1A (Cyclin-Dependent Kinase Inhibitor 1A) - CDKN1A, also known as p21, is a potent cyclin-dependent kinase inhibitor that plays a crucial role in cell cycle regulation. It inhibits the activity of cyclin-CDK2/4 complexes, leading to cell cycle arrest in the G1 phase. This arrest allows for DNA repair or, if the damage is irreparable, apoptosis. CDKN1A is a transcriptional target of TP53, which is activated in response to DNA damage.": {"keywords": ["(CDKN1A[Title]) OR (TP53[Title]) AND (cell cycle regulation[Title])", "(CDKN1A[Title]) OR (TP53[Title]) AND (DNA repair[Title])", "(CDKN1A[Title]) OR (TP53[Title]) AND (apoptosis[Title])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Cavic, Milena, Spasic, Jelena, Krivokuca, Ana, Boljevic, Ivana, Kuburovic, Mira, Radosavljevic, Davorin, Jankovic, Radmila. \"<i>TP53</i> and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool.\" Journal of clinical pathology, 2019, pp. 75-80.", "Lee, Jinkwon, Kim, Kwangho, Ryu, Tae Young, Jung, Cho-Rok, Lee, Moo-Seung, Lim, Jung Hwa, Park, Kunhyang, Kim, Dae-Soo, Son, Mi-Young, Hamamoto, Ryuji, Cho, Hyun-Soo. \"EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.\" Molecular oncology, 2021, pp. 2989-3002.", "Engeland, Kurt. \"Cell cycle regulation: p53-p21-RB signaling.\" Cell death and differentiation, 2022, pp. 946-960."]}, "2. TP53 (Tumor Protein p53) - TP53 is a transcription factor that plays a central role in maintaining genomic stability by preventing the propagation of cells with damaged DNA. It is activated in response to various stress signals, such as DNA damage, hypoxia, and oncogene activation. Upon activation, TP53 can induce cell cycle arrest, senescence, or apoptosis, depending on the cellular context and the extent of DNA damage. TP53 directly regulates the expression of CDKN1A, which contributes to cell cycle arrest.": {"keywords": ["(TP53[Title]) OR (CDKN1A[Title]) AND (genomic stability[Title])", "(TP53[Title]) OR (CDKN1A[Title]) AND (cell cycle arrest[Title])", "(TP53[Title]) OR (CDKN1A[Title]) AND (DNA damage[Title])", "(TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (cell cycle arrest[Title/Abstract])", "(TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (DNA damage[Title/Abstract])"], "references": ["Andersson, Natalie, Saba, Karim H, Magnusson, Linda, Nilsson, Jenny, Karlsson, Jenny, Nord, Karolin H, Gisselsson, David. \"Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.\" Genes, chromosomes & cancer, 2023, pp. 93-100.", "Bi, Guoshu, Liang, Jiaqi, Zhao, Mengnan, Zhang, Huan, Jin, Xing, Lu, Tao, Zheng, Yuansheng, Bian, Yunyi, Chen, Zhencong, Huang, Yiwei, Besskaya, Valeria, Zhan, Cheng, Wang, Qun, Tan, Lijie. \"miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.\" Molecular therapy. Nucleic acids, 2022, pp. 366-386.", "Xie, Haibiao, Ma, Kaifang, Zhang, Kenan, Zhou, Jingcheng, Li, Lei, Yang, Wuping, Gong, Yanqing, Cai, Lin, Gong, Kan. \"Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway.\" Cell death & disease, 2021, pp. 1."]}, "3. CREBBP (CREB Binding Protein) and EP300 (E1A Binding Protein p300) - CREBBP and EP300 are histone acetyltransferases that function as transcriptional coactivators. They play a role in the regulation of cell growth, differentiation, and apoptosis by modulating the activity of various transcription factors, including TP53. Acetylation of TP53 by CREBBP/EP300 enhances its DNA binding and transcriptional activity, leading to the activation of target genes such as CDKN1A.": {"keywords": ["(CREBBP[Title]) OR (EP300[Title]) OR (TP53[Title]) OR (CDKN1A[Title]) AND (histone acetyltransferases[Title])", "(CREBBP[Title]) OR (EP300[Title]) OR (TP53[Title]) OR (CDKN1A[Title]) AND (transcriptional coactivators[Title])", "(CREBBP[Title]) OR (EP300[Title]) OR (TP53[Title]) OR (CDKN1A[Title]) AND (cell growth[Title])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (histone acetyltransferases[Title/Abstract])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (transcriptional coactivators[Title/Abstract])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (cell growth[Title/Abstract])"], "references": ["Scialdone, Annarita, Khazaei, Somayeh, Hasni, Muhammad Sharif, Lennartsson, Andreas, Gullberg, Urban, Drott, Kristina. \"Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.\" Experimental hematology, 2019, pp. 35-46.e1.", "Akil, Abdellah, Ezzikouri, Sayeh, El Feydi, Abdellah Essaid, Benazzouz, Mustapha, Afifi, Rajaa, Diagne, Ama Gassama, Benjouad, Aziz, Dejean, Anne, Pineau, Pascal, Benjelloun, Soumaya. \"Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma.\" Cancer epidemiology, 2012, pp. e300-5.", "Saleh, Kochar Khasro, Kirbag, Sevda, Dalk\u0131l\u0131\u00e7, Semih. \"Inhibitory Effects of Terfezia (Ascomycota) Desert Truffles on PANC-1 Cell Growth via Upregulation of Proapoptotic Genes TP53, CDKN1A, and BAX and Downregulation of Antiapoptotic Gene BCL2.\" International journal of medicinal mushrooms, 2022, pp. 61-70."]}, "4. RBL1 (Retinoblastoma-Like 1) - RBL1, also known as p107, is a member of the retinoblastoma (RB) family of proteins that regulate cell cycle progression. RBL1 interacts with E2F transcription factors and represses their activity, leading to cell cycle arrest in the G1 phase. RBL1 is functionally similar to the retinoblastoma protein (RB1) and can compensate for its loss in certain contexts. The activity of RBL1 is regulated by cyclin-CDK complexes, which are in turn regulated by CDKN1A.": {"keywords": ["(RBL1[Title]) OR (RB1[Title]) OR (CDKN1A[Title]) AND (cell cycle[Title])", "(RBL1[Title]) OR (RB1[Title]) OR (CDKN1A[Title]) AND (retinoblastoma[Title])", "(RBL1[Title]) OR (RB1[Title]) OR (CDKN1A[Title]) AND (E2F[Title])", "(RBL1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(RBL1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (retinoblastoma[Title/Abstract])", "(RBL1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) AND (E2F[Title/Abstract])"], "references": ["Knudsen, Erik S, Pruitt, Steven C, Hershberger, Pamela A, Witkiewicz, Agnieszka K, Goodrich, David W. \"Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.\" Trends in cancer, 2019, pp. 308-324.", "Azimi, Fatemeh, Naseripour, Masood, Sedaghat, Ahad, Kachoei, Zohre Ataei, Khakpoor, Golnaz. \"Association of RB1 rs9568036 and CDKN1A rs1801270 Polymorphisms with Retinoblastoma Susceptibility.\" Journal of current ophthalmology, 2022, pp. 328-332.", "Naert, Thomas, Colpaert, Robin, Van Nieuwenhuysen, Tom, Dimitrakopoulou, Dionysia, Leoen, Jannick, Haustraete, Jurgen, Boel, Annekatrien, Steyaert, Wouter, Lepez, Trees, Deforce, Dieter, Willaert, Andy, Creytens, David, Vleminckx, Kris. \"CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis.\" Scientific reports, 2016, pp. 35264."]}, "In summary, this system of interacting proteins is involved in the regulation of the cell cycle, with a focus on controlling cell cycle progression and maintaining genomic stability. The most prominent biological process performed by this system is cell cycle regulation, which is mediated by the interplay between CDKN1A, TP53, CREBBP/EP300, and RBL1.": {"keywords": ["(CDKN1A[Title]) OR (TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) AND (cell cycle regulation[Title])", "(CDKN1A[Title]) OR (TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) AND (genomic stability[Title])", "(CDKN1A[Title]) OR (TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RBL1[Title]) AND (interacting proteins[Title])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RBL1[Title/Abstract]) AND (interacting proteins[Title/Abstract])"], "references": ["Schultz-Rogers, Laura E, Thayer, Michelle L, Kambakam, Sekhar, Wierson, Wesley A, Helmer, Jordan A, Wishman, Mark D, Wall, Kristen A, Greig, Jessica L, Forsman, Jaimie L, Puchhalapalli, Kavya, Nair, Siddharth, Weiss, Trevor J, Luiken, Jon M, Blackburn, Patrick R, Ekker, Stephen C, Kool, Marcel, McGrail, Maura. \"Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis.\" Developmental dynamics : an official publication of the American Association of Anatomists, 2022, pp. 1267-1290.", "Andersson, Natalie, Saba, Karim H, Magnusson, Linda, Nilsson, Jenny, Karlsson, Jenny, Nord, Karolin H, Gisselsson, David. \"Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.\" Genes, chromosomes & cancer, 2023, pp. 93-100.", "Engeland, Kurt. \"Cell cycle regulation: p53-p21-RB signaling.\" Cell death and differentiation, 2022, pp. 946-960."]}, "The primary biological process performed by this system of interacting proteins is the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This pathway is crucial for regulating cell survival, growth, and proliferation.": {"keywords": ["(PI3K[Title]) OR (AKT[Title]) AND (cell survival[Title])", "(PI3K[Title]) OR (AKT[Title]) AND (PI3K/AKT pathway[Title])", "(PI3K[Title]) OR (AKT[Title]) AND (cell growth[Title])", "(PI3K[Title/Abstract]) OR (AKT[Title/Abstract]) AND (cell survival[Title/Abstract])", "(PI3K[Title/Abstract]) OR (AKT[Title/Abstract]) AND (PI3K/AKT pathway[Title/Abstract])", "(PI3K[Title/Abstract]) OR (AKT[Title/Abstract]) AND (cell growth[Title/Abstract])"], "references": ["Brunet, A, Bonni, A, Zigmond, M J, Lin, M Z, Juo, P, Hu, L S, Anderson, M J, Arden, K C, Blenis, J, Greenberg, M E. \"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.\" Cell, 1999, pp. 857-68.", "Nie, Xin, Liu, Dawo, Zheng, Mingjun, Li, Xiao, Liu, Ouxuan, Guo, Qian, Zhu, Liancheng, Lin, Bei. \"HERPUD1 promotes ovarian cancer cell survival by sustaining autophagy and inhibit apoptosis via PI3K/AKT/mTOR and p38 MAPK signaling pathways.\" BMC cancer, 2022, pp. 1338.", "Gao, Haoji, Wang, Weige, Li, Qinyu. \"GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.\" Cancer biology & therapy, 2022, pp. 369-377."]}, "1. EGF and EGFR interaction: EGF (epidermal growth factor) is a ligand that binds to its receptor, EGFR (epidermal growth factor receptor), activating the receptor's intrinsic kinase activity. This activation initiates a signaling cascade, including the PI3K/AKT pathway.": {"keywords": ["(EGF[Title]) OR (EGFR[Title]) AND (EGF-EGFR interaction[Title])", "(EGF[Title]) OR (EGFR[Title]) AND (kinase activity[Title])", "(EGF[Title]) OR (EGFR[Title]) AND (PI3K/AKT pathway[Title])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (EGF-EGFR interaction[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (kinase activity[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (PI3K/AKT pathway[Title/Abstract])"], "references": ["Guardiola, Salvador, D\u00edaz-Lobo, Mireia, Seco, Jes\u00fas, Garc\u00eda, Jes\u00fas, Nevola, Laura, Giralt, Ernest. \"Peptides Targeting EGF Block the EGF-EGFR Interaction.\" Chembiochem : a European journal of chemical biology, 2016, pp. 702-11.", "Bj\u00f6rkelund, Hanna, Gedda, Lars, Malmqvist, Magnus, Andersson, Karl. \"Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.\" Molecular and clinical oncology, 2013, pp. 343-352.", "Yu, Chenxu, Hale, Jacob, Ritchie, Kenneth, Prasad, Nagendra K, Irudayaraj, Joseph. \"Receptor overexpression or inhibition alters cell surface dynamics of EGF-EGFR interaction: new insights from real-time single molecule analysis.\" Biochemical and biophysical research communications, 2009, pp. 376-82."]}, "2. Activation of AKT1: The PI3K enzyme, activated by EGFR, generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) from phosphatidylinositol (4,5)-bisphosphate (PIP2). PIP3 recruits AKT1 (a serine/threonine kinase) to the plasma membrane, where it is phosphorylated and activated.": {"keywords": ["(EGFR[Title]) OR (AKT1[Title]) OR (PI3K[Title]) AND (PI3K enzyme[Title])", "(EGFR[Title]) OR (AKT1[Title]) OR (PI3K[Title]) AND (AKT1 activation[Title])", "(EGFR[Title]) OR (AKT1[Title]) OR (PI3K[Title]) AND (plasma membrane[Title])", "(EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PI3K[Title/Abstract]) AND (PI3K enzyme[Title/Abstract])", "(EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PI3K[Title/Abstract]) AND (AKT1 activation[Title/Abstract])", "(EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PI3K[Title/Abstract]) AND (plasma membrane[Title/Abstract])"], "references": ["Eke, Iris, Koch, Ulrike, Hehlgans, Stephanie, Sandfort, Veit, Stanchi, Fabio, Zips, Daniel, Baumann, Michael, Shevchenko, Anna, Pilarsky, Christian, Haase, Michael, Baretton, Gustavo B, Calleja, V\u00e9ronique, Larijani, Banafsh\u00e9, F\u00e4ssler, Reinhard, Cordes, Nils. \"PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.\" The Journal of clinical investigation, 2010, pp. 2516-27.", "Lu, Xiaoqing, An, Liwei, Fan, Guangjian, Zang, Lijuan, Huang, Weiyi, Li, Junjian, Liu, Jun, Ge, Weiyu, Huang, Yuwei, Xu, Jingxuan, Du, Shaoqian, Cao, Yuan, Zhou, Tianhao, Yin, Huijing, Yu, Li, Jiao, Shi, Wang, Hongxia. \"EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription.\" Cell research, 2022, pp. 359-374.", "Kim, Do-Hyeon, Triet, Hong Minh, Ryu, Sung Ho. \"Regulation of EGFR activation and signaling by lipids on the plasma membrane.\" Progress in lipid research, 2021, pp. 101115."]}, "3. PTEN's role as a negative regulator: PTEN (phosphatase and tensin homolog) is a tumor suppressor that acts as a negative regulator of the PI3K/AKT pathway. It dephosphorylates PIP3 back to PIP2, reducing AKT1 activation and dampening the signaling cascade.": {"keywords": ["(PTEN[Title]) OR (PI3K[Title]) OR (AKT1[Title]) AND (tumor suppressor[Title])", "(PTEN[Title]) OR (PI3K[Title]) OR (AKT1[Title]) AND (PI3K/AKT pathway[Title])", "(PTEN[Title]) OR (PI3K[Title]) OR (AKT1[Title]) AND (dephosphorylates[Title])", "(PTEN[Title/Abstract]) OR (PI3K[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(PTEN[Title/Abstract]) OR (PI3K[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (PI3K/AKT pathway[Title/Abstract])", "(PTEN[Title/Abstract]) OR (PI3K[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (dephosphorylates[Title/Abstract])"], "references": ["Chen, Chien-Yu, Chen, Jingyu, He, Lina, Stiles, Bangyan L. \"PTEN: Tumor Suppressor and Metabolic Regulator.\" Frontiers in endocrinology, 2018, pp. 338.", "Huang, Xingjun, Liu, Guihua, Guo, Jiao, Su, Zhengquan. \"The PI3K/AKT pathway in obesity and type 2 diabetes.\" International journal of biological sciences, 2018, pp. 1483-1496.", "Kma, Lakhan, Baruah, Taranga Jyoti. \"The interplay of ROS and the PI3K/Akt pathway in autophagy regulation.\" Biotechnology and applied biochemistry, 2022, pp. 248-264."]}, "4. CTNNB1 and Wnt signaling: CTNNB1 (beta-catenin) is a multifunctional protein involved in cell adhesion and the Wnt signaling pathway. While not directly involved in the PI3K/AKT pathway, CTNNB1 can interact with AKT1, which can phosphorylate and stabilize CTNNB1, promoting its nuclear translocation and transcriptional activity.": {"keywords": ["(CTNNB1[Title]) OR (AKT1[Title]) AND (Wnt signaling[Title])", "(CTNNB1[Title]) OR (AKT1[Title]) AND (cell adhesion[Title])", "(CTNNB1[Title]) OR (AKT1[Title]) AND (transcriptional activity[Title])", "(CTNNB1[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (Wnt signaling[Title/Abstract])", "(CTNNB1[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (cell adhesion[Title/Abstract])", "(CTNNB1[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (transcriptional activity[Title/Abstract])"], "references": ["Sehgal, Priyanka, Lanauze, Claudia, Wang, Xin, Hayer, Katharina E, Torres-Diz, Manuel, Leu, N Adrian, Sela, Yogev, Stanger, Ben Z, Lengner, Christopher J, Thomas-Tikhonenko, Andrei. \"MYC Hyperactivates Wnt Signaling in <i>APC</i>/<i>CTNNB1</i>-Mutated Colorectal Cancer Cells through miR-92a-Dependent Repression of <i>DKK3</i>.\" Molecular cancer research : MCR, 2021, pp. 2003-2014.", "Huang, Qian, Wang, Chao-Cai, Liu, Yun-Guang, Zhao, Chang-Ming, Zhang, Tian-Ping, Liu, Yan, Wang, Hua. \"Clinical relevance of genetic polymorphisms in WNT signaling pathway (<i>SFRP1</i>, <i>WNT3A</i>, <i>CTNNB1, WIF-1</i>, <i>DKK-1</i>, <i>LRP5</i>, <i>LRP6</i>) on pulmonary tuberculosis in a Chinese population.\" Frontiers in immunology, 2022, pp. 1011700.", "Basson, M D, Zeng, B, Wang, S. \"The C-terminal region of the focal adhesion kinase F1 domain binds Akt1 and inhibits pressure-induced cell adhesion.\" Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2017, pp. 375-383."]}, "5. NF2 and the Hippo pathway: NF2 (neurofibromin 2) is a tumor suppressor protein that regulates the Hippo signaling pathway, controlling organ size and cell proliferation. NF2 can interact with AKT1, and its loss can lead to increased AKT1 activation, promoting cell survival and growth.": {"keywords": ["(NF2[Title]) OR (AKT1[Title]) AND (Hippo pathway[Title])", "(NF2[Title]) OR (AKT1[Title]) AND (tumor suppressor[Title])", "(NF2[Title]) OR (AKT1[Title]) AND (cell proliferation[Title])", "(NF2[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (Hippo pathway[Title/Abstract])", "(NF2[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(NF2[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (cell proliferation[Title/Abstract])"], "references": ["Hong, Audrey W, Meng, Zhipeng, Plouffe, Steven W, Lin, Zhijie, Zhang, Mingjie, Guan, Kun-Liang. \"Critical roles of phosphoinositides and NF2 in Hippo pathway regulation.\" Genes & development, 2020, pp. 511-525.", "Reginensi, Antoine, Enderle, Leonie, Gregorieff, Alex, Johnson, Randy L, Wrana, Jeffrey L, McNeill, Helen. \"A critical role for NF2 and the Hippo pathway in branching morphogenesis.\" Nature communications, 2016, pp. 12309.", "Shi, Xianle, Yin, Zixi, Ling, Bin, Wang, Lingling, Liu, Chang, Ruan, Xianhui, Zhang, Weiyu, Chen, Lingyi. \"Rho differentially regulates the Hippo pathway by modulating the interaction between Amot and Nf2 in the blastocyst.\" Development (Cambridge, England), 2017, pp. 3957-3967."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is the PI3K/AKT signaling pathway, which is crucial for cell survival, growth, and proliferation. The proteins EGF, EGFR, AKT1, PTEN, CTNNB1, and NF2 play essential roles in regulating this pathway and its crosstalk with other signaling pathways, such as Wnt and Hippo.": {"keywords": ["(EGF[Title]) OR (EGFR[Title]) OR (AKT1[Title]) OR (PTEN[Title]) OR (CTNNB1[Title]) OR (NF2[Title]) AND (PI3K/AKT signaling[Title])", "(EGF[Title]) OR (EGFR[Title]) OR (AKT1[Title]) OR (PTEN[Title]) OR (CTNNB1[Title]) OR (NF2[Title]) AND (cell survival[Title])", "(EGF[Title]) OR (EGFR[Title]) OR (AKT1[Title]) OR (PTEN[Title]) OR (CTNNB1[Title]) OR (NF2[Title]) AND (crosstalk[Title])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PTEN[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (NF2[Title/Abstract]) AND (PI3K/AKT signaling[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PTEN[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (NF2[Title/Abstract]) AND (cell survival[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (PTEN[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (NF2[Title/Abstract]) AND (crosstalk[Title/Abstract])"], "references": ["Xu, Zhaoxia, Jia, Keqi, Wang, Hui, Gao, Feng, Zhao, Song, Li, Fan, Hao, Jun. \"METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease.\" Cell death & disease, 2021, pp. 32.", "Liu, Bu-Hui, Tu, Yue, Ni, Guang-Xia, Yan, Jin, Yue, Liang, Li, Zi-Lin, Wu, Jing-Jing, Cao, Yu-Ting, Wan, Zi-Yue, Sun, Wei, Wan, Yi-Gang. \"Total Flavones of <i>Abelmoschus manihot</i> Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent m<sup>6</sup>A Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling.\" Frontiers in pharmacology, 2021, pp. 667644.", "Chai, Chang, Song, Lai-Jun, Han, Shuang-Yin, Li, Xi-Qing, Li, Ming. \"MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.\" CNS neuroscience & therapeutics, 2018, pp. 369-380."]}, "The system of interacting proteins primarily performs the biological process of cell cycle regulation and DNA repair. ": {"keywords": [], "references": []}, "1. Cell cycle regulation: Many proteins in the system are involved in the regulation of the cell cycle, ensuring proper cell division and preventing uncontrolled cell growth. Key proteins include CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CCND1, CCND2, CCND3, CCNE1, and CCNE2. These proteins function as cyclin-dependent kinases (CDKs), cyclins, and cyclin-dependent kinase inhibitors (CDKIs), which together control cell cycle progression.": {"keywords": ["(CDK4[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) AND (cell cycle[Title])", "(CDK4[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) AND (regulation[Title])", "(CDK4[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) AND (proteins[Title])", "(CDK4[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(CDK4[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) AND (regulation[Title/Abstract])", "(CDK4[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) AND (proteins[Title/Abstract])"], "references": ["Goel, Shom, DeCristo, Molly J, McAllister, Sandra S, Zhao, Jean J. \"CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.\" Trends in cell biology, 2018, pp. 911-925.", "Bi, Guoshu, Liang, Jiaqi, Zhao, Mengnan, Zhang, Huan, Jin, Xing, Lu, Tao, Zheng, Yuansheng, Bian, Yunyi, Chen, Zhencong, Huang, Yiwei, Besskaya, Valeria, Zhan, Cheng, Wang, Qun, Tan, Lijie. \"miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.\" Molecular therapy. Nucleic acids, 2022, pp. 366-386.", "Wang, Yun-Long, Liu, Jin-Yu, Yang, Jin-E, Yu, Xiao-Man, Chen, Zhan-Li, Chen, Ya-Jing, Kuang, Ming, Zhu, Ying, Zhuang, Shi-Mei. \"Lnc-UCID Promotes G1/S Transition and Hepatoma Growth by Preventing DHX9-Mediated CDK6 Down-regulation.\" Hepatology (Baltimore, Md.), 2019, pp. 259-275."]}, "2. DNA repair: The system contains numerous proteins involved in the detection and repair of DNA damage, which is crucial for maintaining genomic stability. Key proteins include ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH3, MSH6, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, and XRCC1. These proteins are involved in various DNA repair pathways, such as homologous recombination, non-homologous end joining, nucleotide excision repair, and mismatch repair.": {"keywords": ["(ATM[Title]) OR (ATR[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK1[Title]) OR (CHEK2[Title]) OR (ERCC1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC4[Title]) OR (ERCC5[Title]) OR (FANCA[Title]) OR (FANCB[Title]) OR (FANCC[Title]) OR (FANCD2[Title]) OR (FANCE[Title]) OR (FANCF[Title]) OR (FANCG[Title]) OR (FANCI[Title]) OR (FANCL[Title]) OR (FANCM[Title]) OR (MLH1[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (NBN[Title]) OR (PALB2[Title]) OR (RAD50[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) OR (RAD52[Title]) OR (XRCC1[Title]) AND (DNA repair[Title])", "(ATM[Title]) OR (ATR[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK1[Title]) OR (CHEK2[Title]) OR (ERCC1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC4[Title]) OR (ERCC5[Title]) OR (FANCA[Title]) OR (FANCB[Title]) OR (FANCC[Title]) OR (FANCD2[Title]) OR (FANCE[Title]) OR (FANCF[Title]) OR (FANCG[Title]) OR (FANCI[Title]) OR (FANCL[Title]) OR (FANCM[Title]) OR (MLH1[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (NBN[Title]) OR (PALB2[Title]) OR (RAD50[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) OR (RAD52[Title]) OR (XRCC1[Title]) AND (genomic stability[Title])", "(ATM[Title]) OR (ATR[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK1[Title]) OR (CHEK2[Title]) OR (ERCC1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC4[Title]) OR (ERCC5[Title]) OR (FANCA[Title]) OR (FANCB[Title]) OR (FANCC[Title]) OR (FANCD2[Title]) OR (FANCE[Title]) OR (FANCF[Title]) OR (FANCG[Title]) OR (FANCI[Title]) OR (FANCL[Title]) OR (FANCM[Title]) OR (MLH1[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (NBN[Title]) OR (PALB2[Title]) OR (RAD50[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) OR (RAD52[Title]) OR (XRCC1[Title]) AND (homologous recombination[Title])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC4[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (FANCA[Title/Abstract]) OR (FANCB[Title/Abstract]) OR (FANCC[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (FANCE[Title/Abstract]) OR (FANCF[Title/Abstract]) OR (FANCG[Title/Abstract]) OR (FANCI[Title/Abstract]) OR (FANCL[Title/Abstract]) OR (FANCM[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (NBN[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) OR (RAD52[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC4[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (FANCA[Title/Abstract]) OR (FANCB[Title/Abstract]) OR (FANCC[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (FANCE[Title/Abstract]) OR (FANCF[Title/Abstract]) OR (FANCG[Title/Abstract]) OR (FANCI[Title/Abstract]) OR (FANCL[Title/Abstract]) OR (FANCM[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (NBN[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) OR (RAD52[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC4[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (FANCA[Title/Abstract]) OR (FANCB[Title/Abstract]) OR (FANCC[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (FANCE[Title/Abstract]) OR (FANCF[Title/Abstract]) OR (FANCG[Title/Abstract]) OR (FANCI[Title/Abstract]) OR (FANCL[Title/Abstract]) OR (FANCM[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (NBN[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) OR (RAD52[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (homologous recombination[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Jin, Mei Hua, Oh, Do-Youn. \"ATM in DNA repair in cancer.\" Pharmacology & therapeutics, 2019, pp. 107391.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299."]}, "3. Chromatin remodeling: Several proteins in the system are involved in chromatin remodeling, which is essential for regulating gene expression and ensuring proper DNA replication and repair. Key proteins include ARID1A, ARID1B, ARID2, ASXL1, ASXL2, BAP1, CHD2, CHD4, EP300, EZH2, HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, KDM5A, KDM5C, KDM6A, KMT2A, KMT2B, KMT2C, KMT2D, MLLT3, SMARCA1, SMARCA4, SMARCB1, and SMARCE1. These proteins function as histone modifiers, ATP-dependent chromatin remodelers, and members of chromatin remodeling complexes.": {"keywords": ["(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (BAP1[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) OR (KDM5A[Title]) OR (KDM5C[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (MLLT3[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (chromatin remodeling[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (BAP1[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) OR (KDM5A[Title]) OR (KDM5C[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (MLLT3[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (gene expression[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (BAP1[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) OR (KDM5A[Title]) OR (KDM5C[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (MLLT3[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (histone modifiers[Title])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (BAP1[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM5C[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (MLLT3[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (BAP1[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM5C[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (MLLT3[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (gene expression[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (BAP1[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM5C[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (MLLT3[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (histone modifiers[Title/Abstract])"], "references": ["Mardinian, Kristina, Adashek, Jacob J, Botta, Gregory P, Kato, Shumei, Kurzrock, Razelle. \"<i>SMARCA4</i>: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.\" Molecular cancer therapeutics, 2021, pp. 2341-2351.", "Jiang, Hao, Cao, Hui-Jun, Ma, Ning, Bao, Wen-Dai, Wang, Jing-Jing, Chen, Tian-Wei, Zhang, Er-Bin, Yuan, Yan-Mei, Ni, Qian-Zhi, Zhang, Feng-Kun, Ding, Xu-Fen, Zheng, Qian-Wen, Wang, Yi-Kang, Zhu, Min, Wang, Xiang, Feng, Jing, Zhang, Xue-Li, Cheng, Shu-Qun, Ma, Dan-Jun, Qiu, Lin, Li, Jing-Jing, Xie, Dong. \"Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 4770-4780.", "Zhang, Shanshan, Zhou, Yu-Feng, Cao, Jian, Burley, Stephen K, Wang, Hui-Yun, Zheng, X F Steven. \"mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.\" Cancer research, 2021, pp. 5652-5665."]}, "4. Transcription regulation: The system includes proteins that regulate transcription, which is crucial for controlling gene expression and cellular processes. Key proteins include E2F1, E2F2, E2F3, E2F4, E2F5, E2F6, MYC, MYCN, NCOA3, NCOR1, NCOR2, RUNX1, RUNX1T1, and STAT3. These proteins function as transcription factors, coactivators, and corepressors, modulating the expression of target genes.": {"keywords": ["(E2F1[Title]) OR (E2F2[Title]) OR (E2F3[Title]) OR (E2F4[Title]) OR (E2F5[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (MYCN[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RUNX1[Title]) OR (RUNX1T1[Title]) OR (STAT3[Title]) AND (transcription regulation[Title])", "(E2F1[Title]) OR (E2F2[Title]) OR (E2F3[Title]) OR (E2F4[Title]) OR (E2F5[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (MYCN[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RUNX1[Title]) OR (RUNX1T1[Title]) OR (STAT3[Title]) AND (gene expression[Title])", "(E2F1[Title]) OR (E2F2[Title]) OR (E2F3[Title]) OR (E2F4[Title]) OR (E2F5[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (MYCN[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RUNX1[Title]) OR (RUNX1T1[Title]) OR (STAT3[Title]) AND (target genes[Title])", "(E2F1[Title/Abstract]) OR (E2F2[Title/Abstract]) OR (E2F3[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (E2F5[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (RUNX1T1[Title/Abstract]) OR (STAT3[Title/Abstract]) AND (transcription regulation[Title/Abstract])", "(E2F1[Title/Abstract]) OR (E2F2[Title/Abstract]) OR (E2F3[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (E2F5[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (RUNX1T1[Title/Abstract]) OR (STAT3[Title/Abstract]) AND (gene expression[Title/Abstract])", "(E2F1[Title/Abstract]) OR (E2F2[Title/Abstract]) OR (E2F3[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (E2F5[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (RUNX1T1[Title/Abstract]) OR (STAT3[Title/Abstract]) AND (target genes[Title/Abstract])"], "references": ["Mimaki, Sachiyo, Mori-Furukawa, Yuko, Katsuno, Hikari, Kishimoto, Toshihiko. \"A transcriptional regulatory element screening system reveals a novel E2F1/pRb transcription regulation pathway.\" Analytical biochemistry, 2005, pp. 268-80.", "Wu, Hua, Yang, Tian-Yu, Li, Yi, Ye, Wen-Long, Liu, Feng, He, Xiao-Shun, Wang, Jing-Ru, Gan, Wen-Juan, Li, Xiu-Ming, Zhang, Shen, Zhao, Yuan-Yuan, Li, Jian-Ming. \"Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.\" Hepatology (Baltimore, Md.), 2020, pp. 148-163.", "Li, Shi-Ting, Huang, De, Shen, Shengqi, Cai, Yongping, Xing, Songge, Wu, Gongwei, Jiang, Zetan, Hao, Yijie, Yuan, Mengqiu, Wang, Nana, Zhu, Lianbang, Yan, Ronghui, Yang, Dongdong, Wang, Lin, Liu, Zhaoji, Hu, Xin, Zhou, Rongbin, Qu, Kun, Li, Ailing, Duan, Xiaotao, Zhang, Huafeng, Gao, Ping. \"Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis.\" Nature metabolism, 2020, pp. 256-269."]}, "5. Signal transduction: Several proteins in the system are involved in signal transduction pathways, which transmit extracellular signals to the cell's interior, regulating various cellular processes. Key proteins include ABL1, AKT1, ARAF, BRAF, HRAS, KRAS, RAF1, and RHOA. These proteins function as kinases, GTPases, and other signaling molecules, participating in pathways such as the MAPK, PI3K-AKT, and RAS-RAF-MEK-ERK pathways.": {"keywords": ["(ABL1[Title]) OR (AKT1[Title]) OR (ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (RAF1[Title]) OR (RHOA[Title]) AND (signal transduction[Title])", "(ABL1[Title]) OR (AKT1[Title]) OR (ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (RAF1[Title]) OR (RHOA[Title]) AND (kinases[Title])", "(ABL1[Title]) OR (AKT1[Title]) OR (ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (RAF1[Title]) OR (RHOA[Title]) AND (pathways[Title])", "(ABL1[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (signal transduction[Title/Abstract])", "(ABL1[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (kinases[Title/Abstract])", "(ABL1[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (pathways[Title/Abstract])"], "references": ["Herrero, Ana, Reis-Cardoso, Mariana, Jim\u00e9nez-G\u00f3mez, I\u00f1aki, Doherty, Carolanne, Agudo-Iba\u00f1ez, Lorena, Pinto, Ad\u00e1n, Calvo, Fernando, Kolch, Walter, Crespo, Piero, Matallanas, David. \"Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors.\" Small GTPases, 2020, pp. 371-383.", "Bocanegra, Victoria, Gil Lorenzo, Andrea Fernanda, Cacciamani, Valeria, Benard\u00f3n, Mar\u00eda Eugenia, Costantino, Valeria Victoria, Vall\u00e9s, Patricia G. \"RhoA and MAPK signal transduction pathways regulate NHE1-dependent proximal tubule cell apoptosis after mechanical stretch.\" American journal of physiology. Renal physiology, 2014, pp. F881-9.", "Yadav, Vipin, Chen, Shih-Hsun, Yue, Yong Gong, Buchanan, Sean, Beckmann, Richard P, Peng, Sheng-Bin. \"Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.\" Pharmacology & therapeutics, 2015, pp. 139-49."]}, "In summary, the most prominent biological process performed by this system of interacting proteins is cell cycle regulation and DNA repair, with additional involvement in chromatin remodeling, transcription regulation, and signal transduction.": {"keywords": [], "references": []}, "The system of interacting proteins primarily performs the biological process of immune response regulation. This process involves the modulation of immune cell activation, differentiation, and function in response to various stimuli.": {"keywords": [], "references": []}, "1. Presence of immune cell surface receptors and signaling proteins: CD19, CD22, CD40, CD70, CD79A, CD79B, FCGR2A, FCGR3A, IL2RA, IL6R, IL7R, IL10RA, and CTLA4 are all surface receptors or signaling proteins involved in immune cell activation and regulation. These proteins play crucial roles in B cell, T cell, and natural killer (NK) cell function, as well as in the regulation of cytokine signaling.": {"keywords": ["(CD19[Title]) OR (CD22[Title]) OR (CD40[Title]) OR (CD70[Title]) OR (CD79A[Title]) OR (CD79B[Title]) OR (FCGR2A[Title]) OR (FCGR3A[Title]) OR (IL2RA[Title]) OR (IL6R[Title]) OR (IL7R[Title]) OR (IL10RA[Title]) OR (CTLA4[Title]) AND (immune cell activation[Title])", "(CD19[Title]) OR (CD22[Title]) OR (CD40[Title]) OR (CD70[Title]) OR (CD79A[Title]) OR (CD79B[Title]) OR (FCGR2A[Title]) OR (FCGR3A[Title]) OR (IL2RA[Title]) OR (IL6R[Title]) OR (IL7R[Title]) OR (IL10RA[Title]) OR (CTLA4[Title]) AND (surface receptors[Title])", "(CD19[Title]) OR (CD22[Title]) OR (CD40[Title]) OR (CD70[Title]) OR (CD79A[Title]) OR (CD79B[Title]) OR (FCGR2A[Title]) OR (FCGR3A[Title]) OR (IL2RA[Title]) OR (IL6R[Title]) OR (IL7R[Title]) OR (IL10RA[Title]) OR (CTLA4[Title]) AND (cytokine signaling[Title])", "(CD19[Title/Abstract]) OR (CD22[Title/Abstract]) OR (CD40[Title/Abstract]) OR (CD70[Title/Abstract]) OR (CD79A[Title/Abstract]) OR (CD79B[Title/Abstract]) OR (FCGR2A[Title/Abstract]) OR (FCGR3A[Title/Abstract]) OR (IL2RA[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (IL7R[Title/Abstract]) OR (IL10RA[Title/Abstract]) OR (CTLA4[Title/Abstract]) AND (immune cell activation[Title/Abstract])", "(CD19[Title/Abstract]) OR (CD22[Title/Abstract]) OR (CD40[Title/Abstract]) OR (CD70[Title/Abstract]) OR (CD79A[Title/Abstract]) OR (CD79B[Title/Abstract]) OR (FCGR2A[Title/Abstract]) OR (FCGR3A[Title/Abstract]) OR (IL2RA[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (IL7R[Title/Abstract]) OR (IL10RA[Title/Abstract]) OR (CTLA4[Title/Abstract]) AND (surface receptors[Title/Abstract])", "(CD19[Title/Abstract]) OR (CD22[Title/Abstract]) OR (CD40[Title/Abstract]) OR (CD70[Title/Abstract]) OR (CD79A[Title/Abstract]) OR (CD79B[Title/Abstract]) OR (FCGR2A[Title/Abstract]) OR (FCGR3A[Title/Abstract]) OR (IL2RA[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (IL7R[Title/Abstract]) OR (IL10RA[Title/Abstract]) OR (CTLA4[Title/Abstract]) AND (cytokine signaling[Title/Abstract])"], "references": ["Diggs, Laurence P, Ruf, Benjamin, Ma, Chi, Heinrich, Bernd, Cui, Linda, Zhang, Qianfei, McVey, John C, Wabitsch, Simon, Heinrich, Sophia, Rosato, Umberto, Lai, Walter, Subramanyam, Varun, Longerich, Thomas, Loosen, Sven H, Luedde, Tom, Neumann, Ulf Peter, Desar, Sabina, Kleiner, David, Gores, Gregory, Wang, Xin Wei, Greten, Tim F. \"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.\" Journal of hepatology, 2021, pp. 1145-1154.", "Mega, Alessandro, Mebrahtu, Aman, Aniander, Gustav, Ryer, Eva, Sk\u00f6ld, Annette, Sandegren, Anna, Backstr\u00f6m Rydin, Eva, Rockberg, Johan, \u00d6stman, Arne, Frejd, Fredrik Y. \"A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation.\" mAbs, 2023, pp. 2223750.", "Peach, R J, Bajorath, J, Naemura, J, Leytze, G, Greene, J, Aruffo, A, Linsley, P S. \"Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.\" The Journal of biological chemistry, 1995, pp. 21181-7."]}, "2. Involvement of transcription factors and regulatory proteins: FOXP1, GATA3, IRF1, IRF4, MAFB, and PRDM1 are transcription factors that regulate the expression of genes involved in immune cell differentiation and function. Additionally, proteins such as IKZF1, IKZF3, and NFKBIA are involved in the regulation of transcription factor activity, further modulating immune responses.": {"keywords": ["(FOXP1[Title]) OR (GATA3[Title]) OR (IRF1[Title]) OR (IRF4[Title]) OR (MAFB[Title]) OR (PRDM1[Title]) OR (IKZF1[Title]) OR (IKZF3[Title]) OR (NFKBIA[Title]) AND (transcription factors[Title])", "(FOXP1[Title]) OR (GATA3[Title]) OR (IRF1[Title]) OR (IRF4[Title]) OR (MAFB[Title]) OR (PRDM1[Title]) OR (IKZF1[Title]) OR (IKZF3[Title]) OR (NFKBIA[Title]) AND (immune cell differentiation[Title])", "(FOXP1[Title]) OR (GATA3[Title]) OR (IRF1[Title]) OR (IRF4[Title]) OR (MAFB[Title]) OR (PRDM1[Title]) OR (IKZF1[Title]) OR (IKZF3[Title]) OR (NFKBIA[Title]) AND (regulatory proteins[Title])", "(FOXP1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (IRF1[Title/Abstract]) OR (IRF4[Title/Abstract]) OR (MAFB[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (IKZF1[Title/Abstract]) OR (IKZF3[Title/Abstract]) OR (NFKBIA[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(FOXP1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (IRF1[Title/Abstract]) OR (IRF4[Title/Abstract]) OR (MAFB[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (IKZF1[Title/Abstract]) OR (IKZF3[Title/Abstract]) OR (NFKBIA[Title/Abstract]) AND (immune cell differentiation[Title/Abstract])", "(FOXP1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (IRF1[Title/Abstract]) OR (IRF4[Title/Abstract]) OR (MAFB[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (IKZF1[Title/Abstract]) OR (IKZF3[Title/Abstract]) OR (NFKBIA[Title/Abstract]) AND (regulatory proteins[Title/Abstract])"], "references": ["Ren, Gang, Lai, Binbin, Harly, Christelle, Baek, Songjoon, Ding, Yi, Zheng, Mingzhu, Cao, Yaqiang, Cui, Kairong, Yang, Yu, Zhu, Jinfang, Hager, Gordon L, Bhandoola, Avinash, Zhao, Keji. \"Transcription factors TCF-1 and GATA3 are key factors for the epigenetic priming of early innate lymphoid progenitors toward distinct cell fates.\" Immunity, 2022, pp. 1402-1413.e4.", "Morito, Naoki, Usui, Toshiaki, Ishibashi, Shun, Yamagata, Kunihiro. \"Podocyte-specific Transcription Factors: Could MafB Become a Therapeutic Target for Kidney Disease?\" Internal medicine (Tokyo, Japan), 2023, pp. 11-19.", "Guan, Yun, Li, Weiqun, Hou, Zhaohua, Han, Qiuju, Lan, Peixiang, Zhang, Jian, Tian, Zhigang, Zhang, Cai. \"HBV suppresses expression of MICA/B on hepatoma cells through up-regulation of transcription factors GATA2 and GATA3 to escape from NK cell surveillance.\" Oncotarget, 2016, pp. 56107-56119."]}, "3. Role of kinases and phosphatases in signaling pathways: BTK, FYN, JAK2, JAK3, LYN, SYK, and PTPN22 are kinases and phosphatases that participate in signaling pathways essential for immune cell activation and function. These proteins are involved in the regulation of B cell receptor (BCR) and T cell receptor (TCR) signaling, as well as cytokine receptor signaling.": {"keywords": ["(BTK[Title]) OR (FYN[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (LYN[Title]) OR (SYK[Title]) OR (PTPN22[Title]) AND (signaling pathways[Title])", "(BTK[Title]) OR (FYN[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (LYN[Title]) OR (SYK[Title]) OR (PTPN22[Title]) AND (immune cell activation[Title])", "(BTK[Title]) OR (FYN[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (LYN[Title]) OR (SYK[Title]) OR (PTPN22[Title]) AND (kinases and phosphatases[Title])", "(BTK[Title/Abstract]) OR (FYN[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (LYN[Title/Abstract]) OR (SYK[Title/Abstract]) OR (PTPN22[Title/Abstract]) AND (signaling pathways[Title/Abstract])", "(BTK[Title/Abstract]) OR (FYN[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (LYN[Title/Abstract]) OR (SYK[Title/Abstract]) OR (PTPN22[Title/Abstract]) AND (immune cell activation[Title/Abstract])", "(BTK[Title/Abstract]) OR (FYN[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (LYN[Title/Abstract]) OR (SYK[Title/Abstract]) OR (PTPN22[Title/Abstract]) AND (kinases and phosphatases[Title/Abstract])"], "references": ["Wang, Li-Na, Zhang, Zi-Teng, Wang, Li, Wei, Hai-Xiang, Zhang, Tao, Zhang, Li-Ming, Lin, Hang, Zhang, Heng, Wang, Shao-Qiang. \"TGF-\u03b21/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways.\" Cell death & disease, 2022, pp. 472.", "Hu, Qing-Peng, Yan, Hong-Xia, Peng, Fang, Feng, Wei, Chen, Fen-Fang, Huang, Xiang-Yi, Zhang, Xin, Zhou, Yang-Yu, Chen, Yi-Shui. \"Genistein protects epilepsy-induced brain injury through regulating the JAK2/STAT3 and Keap1/Nrf2 signaling pathways in the developing rats.\" European journal of pharmacology, 2021, pp. 174620.", "Xue, Zhifeng, Zhao, Fangzhe, Sang, Xiaoqing, Qiao, Yuchuan, Shao, Rui, Wang, Yuanyuan, Gao, Shan, Fan, Guanwei, Zhu, Yan, Yang, Jian. \"Combination therapy of tanshinone IIA and puerarin for pulmonary fibrosis via targeting IL6-JAK2-STAT3/STAT1 signaling pathways.\" Phytotherapy research : PTR, 2021, pp. 5883-5898."]}, "4. Involvement of proteins in antigen presentation and processing: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-E, HLA-F, HLA-G, TAP1, and TAP2 are involved in antigen presentation and processing, which is essential for the activation of adaptive immune responses.": {"keywords": ["(HLA-A[Title]) OR (HLA-B[Title]) OR (HLA-C[Title]) OR (HLA-DMA[Title]) OR (HLA-DMB[Title]) OR (HLA-DOA[Title]) OR (HLA-DOB[Title]) OR (HLA-DPA1[Title]) OR (HLA-DPB1[Title]) OR (HLA-DQA1[Title]) OR (HLA-DQA2[Title]) OR (HLA-DQB1[Title]) OR (HLA-DQB2[Title]) OR (HLA-DRA[Title]) OR (HLA-DRB1[Title]) OR (HLA-DRB5[Title]) OR (HLA-E[Title]) OR (HLA-F[Title]) OR (HLA-G[Title]) OR (TAP1[Title]) OR (TAP2[Title]) AND (antigen presentation[Title])", "(HLA-A[Title]) OR (HLA-B[Title]) OR (HLA-C[Title]) OR (HLA-DMA[Title]) OR (HLA-DMB[Title]) OR (HLA-DOA[Title]) OR (HLA-DOB[Title]) OR (HLA-DPA1[Title]) OR (HLA-DPB1[Title]) OR (HLA-DQA1[Title]) OR (HLA-DQA2[Title]) OR (HLA-DQB1[Title]) OR (HLA-DQB2[Title]) OR (HLA-DRA[Title]) OR (HLA-DRB1[Title]) OR (HLA-DRB5[Title]) OR (HLA-E[Title]) OR (HLA-F[Title]) OR (HLA-G[Title]) OR (TAP1[Title]) OR (TAP2[Title]) AND (processing[Title])", "(HLA-A[Title]) OR (HLA-B[Title]) OR (HLA-C[Title]) OR (HLA-DMA[Title]) OR (HLA-DMB[Title]) OR (HLA-DOA[Title]) OR (HLA-DOB[Title]) OR (HLA-DPA1[Title]) OR (HLA-DPB1[Title]) OR (HLA-DQA1[Title]) OR (HLA-DQA2[Title]) OR (HLA-DQB1[Title]) OR (HLA-DQB2[Title]) OR (HLA-DRA[Title]) OR (HLA-DRB1[Title]) OR (HLA-DRB5[Title]) OR (HLA-E[Title]) OR (HLA-F[Title]) OR (HLA-G[Title]) OR (TAP1[Title]) OR (TAP2[Title]) AND (adaptive immune[Title])", "(HLA-A[Title/Abstract]) OR (HLA-B[Title/Abstract]) OR (HLA-C[Title/Abstract]) OR (HLA-DMA[Title/Abstract]) OR (HLA-DMB[Title/Abstract]) OR (HLA-DOA[Title/Abstract]) OR (HLA-DOB[Title/Abstract]) OR (HLA-DPA1[Title/Abstract]) OR (HLA-DPB1[Title/Abstract]) OR (HLA-DQA1[Title/Abstract]) OR (HLA-DQA2[Title/Abstract]) OR (HLA-DQB1[Title/Abstract]) OR (HLA-DQB2[Title/Abstract]) OR (HLA-DRA[Title/Abstract]) OR (HLA-DRB1[Title/Abstract]) OR (HLA-DRB5[Title/Abstract]) OR (HLA-E[Title/Abstract]) OR (HLA-F[Title/Abstract]) OR (HLA-G[Title/Abstract]) OR (TAP1[Title/Abstract]) OR (TAP2[Title/Abstract]) AND (antigen presentation[Title/Abstract])", "(HLA-A[Title/Abstract]) OR (HLA-B[Title/Abstract]) OR (HLA-C[Title/Abstract]) OR (HLA-DMA[Title/Abstract]) OR (HLA-DMB[Title/Abstract]) OR (HLA-DOA[Title/Abstract]) OR (HLA-DOB[Title/Abstract]) OR (HLA-DPA1[Title/Abstract]) OR (HLA-DPB1[Title/Abstract]) OR (HLA-DQA1[Title/Abstract]) OR (HLA-DQA2[Title/Abstract]) OR (HLA-DQB1[Title/Abstract]) OR (HLA-DQB2[Title/Abstract]) OR (HLA-DRA[Title/Abstract]) OR (HLA-DRB1[Title/Abstract]) OR (HLA-DRB5[Title/Abstract]) OR (HLA-E[Title/Abstract]) OR (HLA-F[Title/Abstract]) OR (HLA-G[Title/Abstract]) OR (TAP1[Title/Abstract]) OR (TAP2[Title/Abstract]) AND (processing[Title/Abstract])", "(HLA-A[Title/Abstract]) OR (HLA-B[Title/Abstract]) OR (HLA-C[Title/Abstract]) OR (HLA-DMA[Title/Abstract]) OR (HLA-DMB[Title/Abstract]) OR (HLA-DOA[Title/Abstract]) OR (HLA-DOB[Title/Abstract]) OR (HLA-DPA1[Title/Abstract]) OR (HLA-DPB1[Title/Abstract]) OR (HLA-DQA1[Title/Abstract]) OR (HLA-DQA2[Title/Abstract]) OR (HLA-DQB1[Title/Abstract]) OR (HLA-DQB2[Title/Abstract]) OR (HLA-DRA[Title/Abstract]) OR (HLA-DRB1[Title/Abstract]) OR (HLA-DRB5[Title/Abstract]) OR (HLA-E[Title/Abstract]) OR (HLA-F[Title/Abstract]) OR (HLA-G[Title/Abstract]) OR (TAP1[Title/Abstract]) OR (TAP2[Title/Abstract]) AND (adaptive immune[Title/Abstract])"], "references": ["Van Kaer, L, Ashton-Rickardt, P G, Ploegh, H L, Tonegawa, S. \"TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells.\" Cell, 1992, pp. 1205-14.", "Bauz\u00e1-Martinez, Julia, Heck, Albert J R, Wu, Wei. \"HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles.\" Communications biology, 2021, pp. 825.", "Balas, A, Garc\u00eda-S\u00e1nchez, F, Vicario, J L. \"RNA processing and protein expression of HLA-B*07:44N.\" HLA, 2017, pp. 230-234."]}, "5. Role of proteins in immune cell survival and apoptosis: BIRC3, FAS, MYD88, and TNFAIP3 are proteins involved in the regulation of immune cell survival and apoptosis. These proteins play a role in maintaining immune cell homeostasis and preventing excessive immune activation.": {"keywords": ["(BIRC3[Title]) OR (FAS[Title]) OR (MYD88[Title]) OR (TNFAIP3[Title]) AND (immune cell survival[Title])", "(BIRC3[Title]) OR (FAS[Title]) OR (MYD88[Title]) OR (TNFAIP3[Title]) AND (apoptosis[Title])", "(BIRC3[Title]) OR (FAS[Title]) OR (MYD88[Title]) OR (TNFAIP3[Title]) AND (homeostasis[Title])", "(BIRC3[Title/Abstract]) OR (FAS[Title/Abstract]) OR (MYD88[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (immune cell survival[Title/Abstract])", "(BIRC3[Title/Abstract]) OR (FAS[Title/Abstract]) OR (MYD88[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (apoptosis[Title/Abstract])", "(BIRC3[Title/Abstract]) OR (FAS[Title/Abstract]) OR (MYD88[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (homeostasis[Title/Abstract])"], "references": ["Wang, Juan, Cao, Zeyuan, Wang, Panpan, Zhang, Xiao, Tang, Jianxia, He, Yifan, Huang, Zhiqing, Mao, Xueli, Shi, Songtao, Kou, Xiaoxing. \"Apoptotic Extracellular Vesicles Ameliorate Multiple Myeloma by Restoring Fas-Mediated Apoptosis.\" ACS nano, 2021, pp. 14360-14372.", "Nagata, S. \"Fas-mediated apoptosis.\" Advances in experimental medicine and biology, 1996, pp. 119-24.", "Nagata, S. \"Fas ligand-induced apoptosis.\" Annual review of genetics, 1999, pp. 29-55."]}, "6. Involvement of immune checkpoint proteins: PDCD1, PDCD1LG2, TIGIT, LAG3, and HAVCR2 are immune checkpoint proteins that regulate the activation and function of immune cells, particularly T cells. These proteins are essential for maintaining immune tolerance and preventing autoimmunity.": {"keywords": ["(PDCD1[Title]) OR (PDCD1LG2[Title]) OR (TIGIT[Title]) OR (LAG3[Title]) OR (HAVCR2[Title]) AND (immune checkpoint proteins[Title])", "(PDCD1[Title]) OR (PDCD1LG2[Title]) OR (TIGIT[Title]) OR (LAG3[Title]) OR (HAVCR2[Title]) AND (immune cells[Title])", "(PDCD1[Title]) OR (PDCD1LG2[Title]) OR (TIGIT[Title]) OR (LAG3[Title]) OR (HAVCR2[Title]) AND (immune tolerance[Title])", "(PDCD1[Title/Abstract]) OR (PDCD1LG2[Title/Abstract]) OR (TIGIT[Title/Abstract]) OR (LAG3[Title/Abstract]) OR (HAVCR2[Title/Abstract]) AND (immune checkpoint proteins[Title/Abstract])", "(PDCD1[Title/Abstract]) OR (PDCD1LG2[Title/Abstract]) OR (TIGIT[Title/Abstract]) OR (LAG3[Title/Abstract]) OR (HAVCR2[Title/Abstract]) AND (immune cells[Title/Abstract])", "(PDCD1[Title/Abstract]) OR (PDCD1LG2[Title/Abstract]) OR (TIGIT[Title/Abstract]) OR (LAG3[Title/Abstract]) OR (HAVCR2[Title/Abstract]) AND (immune tolerance[Title/Abstract])"], "references": ["Tu, Lei, Guan, Renguo, Yang, Hanting, Zhou, Yu, Hong, Weifeng, Ma, Liheng, Zhao, Guangzhe, Yu, Min. \"Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.\" International journal of cancer, 2020, pp. 423-439.", "Lee, Soo Jung, Jun, Sun-Young, Lee, In Hee, Kang, Byung Woog, Park, Su Yeon, Kim, Hye Jin, Park, Jun Seok, Choi, Gyu-Seog, Yoon, Ghilsuk, Kim, Jong Gwang. \"CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.\" Journal of cancer research and clinical oncology, 2018, pp. 1005-1014.", "Chen, Shao-Hua, Zha, Xiang-Feng, Li, Yang-Qiu. \"[Immune Tolerance Mediated by TIM-3,LAG-3 and BTLA and Their Reversion in Hematological Malignancies-Review].\" Zhongguo shi yan xue ye xue za zhi, 2016, pp. 1594-1597."]}, "In conclusion, the system of interacting proteins is primarily involved in the regulation of immune responses, including immune cell activation, differentiation, and function. The presence of immune cell surface receptors, signaling proteins, transcription factors, kinases, phosphatases, antigen presentation proteins, and immune checkpoint proteins supports the critical role of this system in immune response regulation.": {"keywords": [], "references": []}, "The system of interacting proteins consists of EPHA2, EPHA3, EPHA5, EPHA7, EPHB1, EPHB2, PTPRD, and SLIT2. The most prominent biological process performed by this system is Ephrin receptor signaling.": {"keywords": ["(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (Ephrin receptor signaling[Title])", "(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (interacting proteins[Title])", "(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (biological process[Title])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (Ephrin receptor signaling[Title/Abstract])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (interacting proteins[Title/Abstract])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (biological process[Title/Abstract])"], "references": ["Wu, Yu, Wei, Zhenhong, Li, Yonghong, Wei, Chaojun, Li, Yuanting, Cheng, Pengfei, Xu, Hui, Li, Zhenhao, Guo, Rui, Qi, Xiaoming, Jia, Jing, Jia, Yanjuan, Wang, Wanxia, Gao, Xiaoling. \"Perturbation of Ephrin Receptor Signaling and Glutamatergic Transmission in the Hypothalamus in Depression Using Proteomics Integrated With Metabolomics.\" Frontiers in neuroscience, 2019, pp. 1359.", "Akaneya, Yukio, Sohya, Kazuhiro, Kitamura, Akihiko, Kimura, Fumitaka, Washburn, Chris, Zhou, Renping, Ninan, Ipe, Tsumoto, Tadaharu, Ziff, Edward B. \"Ephrin-A5 and EphA5 interaction induces synaptogenesis during early hippocampal development.\" PloS one, 2010, pp. e12486.", "Light, Taylor P, Brun, Delphine, Guardado-Calvo, Pablo, Pederzoli, Riccardo, Haouz, Ahmed, Neipel, Frank, Rey, F\u00e9lix A, Hristova, Kalina, Backovic, Marija. \"Human herpesvirus 8 molecular mimicry of ephrin ligands facilitates cell entry and triggers EphA2 signaling.\" PLoS biology, 2021, pp. e3001392."]}, "1. Ephrin receptor family: EPHA2, EPHA3, EPHA5, EPHA7, EPHB1, and EPHB2 are all members of the Ephrin receptor family. These proteins are receptor tyrosine kinases that play crucial roles in cell-cell communication, regulating processes such as cell adhesion, migration, and differentiation. The presence of multiple Ephrin receptors in this system suggests that the primary function is related to Ephrin receptor signaling.": {"keywords": ["(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) AND (Ephrin receptor signaling[Title])", "(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) AND (cell-cell communication[Title])", "(EPHA2[Title]) OR (EPHA3[Title]) OR (EPHA5[Title]) OR (EPHA7[Title]) OR (EPHB1[Title]) OR (EPHB2[Title]) AND (cell adhesion[Title])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (Ephrin receptor signaling[Title/Abstract])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (cell-cell communication[Title/Abstract])", "(EPHA2[Title/Abstract]) OR (EPHA3[Title/Abstract]) OR (EPHA5[Title/Abstract]) OR (EPHA7[Title/Abstract]) OR (EPHB1[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (cell adhesion[Title/Abstract])"], "references": ["Sullivan, Chelsea S, K\u00fcmper, Maike, Temple, Brenda S, Maness, Patricia F. \"The Neural Cell Adhesion Molecule (NCAM) Promotes Clustering and Activation of EphA3 Receptors in GABAergic Interneurons to Induce Ras Homolog Gene Family, Member A (RhoA)/Rho-associated protein kinase (ROCK)-mediated Growth Cone Collapse.\" The Journal of biological chemistry, 2016, pp. 26262-26272.", "Yoon, Sarah, Choi, Ji-Hye, Kim, Sung Joo, Lee, Eun-Ju, Shah, Masaud, Choi, Sangdun, Woo, Hyun Goo. \"EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.\" Experimental & molecular medicine, 2019, pp. 1-12.", "Smith, Loraine M, Walsh, Patrick T, R\u00fcdiger, Thomas, Cotter, Thomas G, Mc Carthy, Tommie V, Marx, Alexander, O'Connor, Rosemary. \"EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion.\" Experimental cell research, 2004, pp. 295-303."]}, "2. PTPRD interaction: PTPRD is a protein tyrosine phosphatase that has been shown to interact with Ephrin receptors, specifically EPHA3. PTPRD can dephosphorylate Ephrin receptors, modulating their signaling activity. This interaction further supports the importance of Ephrin receptor signaling in this system.": {"keywords": ["(EPHA3[Title]) OR (PTPRD[Title]) AND (PTPRD interaction[Title])", "(EPHA3[Title]) OR (PTPRD[Title]) AND (Ephrin receptor[Title])", "(EPHA3[Title]) OR (PTPRD[Title]) AND (signaling activity[Title])", "(EPHA3[Title/Abstract]) OR (PTPRD[Title/Abstract]) AND (PTPRD interaction[Title/Abstract])", "(EPHA3[Title/Abstract]) OR (PTPRD[Title/Abstract]) AND (Ephrin receptor[Title/Abstract])", "(EPHA3[Title/Abstract]) OR (PTPRD[Title/Abstract]) AND (signaling activity[Title/Abstract])"], "references": ["Davis, Tara L, Walker, John R, Loppnau, Peter, Butler-Cole, Christine, Allali-Hassani, Abdellah, Dhe-Paganon, Sirano. \"Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3).\" Structure (London, England : 1993), 2008, pp. 873-84.", "Sun, Yiting, Duan, Jianchun, Fang, Wenfeng, Wang, Zhijie, Du, Xinyang, Wang, Xin, Li, Chengcheng, Cai, Shangli, Zhao, Jie, Li, Sini, Zhang, Li, Bai, Hua, Wang, Jie. \"Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.\" BMC medicine, 2021, pp. 239.", "Zhang, Fan, Wang, Jinliang, Xu, Yu, Cai, Shangli, Li, Tao, Wang, Guoqiang, Li, Chengcheng, Zhao, Lei, Hu, Yi. \"Co-occurring genomic alterations and immunotherapy efficacy in NSCLC.\" NPJ precision oncology, 2022, pp. 4."]}, "3. SLIT2 involvement: SLIT2 is a secreted protein that functions as a ligand for the Roundabout (ROBO) family of receptors. SLIT2 has been reported to interact with Ephrin receptors, particularly EPHB2, and modulate their signaling. This interaction suggests a potential crosstalk between SLIT2-ROBO and Ephrin receptor signaling pathways in this system.": {"keywords": ["(SLIT2[Title]) OR (ROBO[Title]) OR (EPHB2[Title]) AND (ligand[Title])", "(SLIT2[Title]) OR (ROBO[Title]) OR (EPHB2[Title]) AND (SLIT2-ROBO[Title])", "(SLIT2[Title]) OR (ROBO[Title]) OR (EPHB2[Title]) AND (Ephrin receptor[Title])", "(SLIT2[Title/Abstract]) OR (ROBO[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (ligand[Title/Abstract])", "(SLIT2[Title/Abstract]) OR (ROBO[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (SLIT2-ROBO[Title/Abstract])", "(SLIT2[Title/Abstract]) OR (ROBO[Title/Abstract]) OR (EPHB2[Title/Abstract]) AND (Ephrin receptor[Title/Abstract])"], "references": ["Smith-Berdan, Stephanie, Schepers, Koen, Ly, Alan, Passegu\u00e9, Emmanuelle, Forsberg, E Camilla. \"Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations.\" Cell cycle (Georgetown, Tex.), 2012, pp. 675-82.", "Litterst, Claudia, Georgakopoulos, Anastasios, Shioi, Junichi, Ghersi, Enrico, Wisniewski, Thomas, Wang, Rong, Ludwig, Andreas, Robakis, Nikolaos K. \"Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor.\" The Journal of biological chemistry, 2007, pp. 16155-63.", "Tanaka, M, Wang, D Y, Kamo, T, Igarashi, H, Wang, Y, Xiang, Y Y, Tanioka, F, Naito, Y, Sugimura, H. \"Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development.\" Oncogene, 1998, pp. 1509-16."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is Ephrin receptor signaling, which is supported by the presence of multiple Ephrin receptors, the interaction with PTPRD, and the involvement of SLIT2. This process plays a critical role in cell-cell communication and the regulation of various cellular processes such as adhesion, migration, and differentiation.": {"keywords": ["(Ephrin[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (Ephrin receptor signaling[Title])", "(Ephrin[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (cell-cell communication[Title])", "(Ephrin[Title]) OR (PTPRD[Title]) OR (SLIT2[Title]) AND (cellular processes[Title])", "(Ephrin[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (Ephrin receptor signaling[Title/Abstract])", "(Ephrin[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (cell-cell communication[Title/Abstract])", "(Ephrin[Title/Abstract]) OR (PTPRD[Title/Abstract]) OR (SLIT2[Title/Abstract]) AND (cellular processes[Title/Abstract])"], "references": ["Wu, Yu, Wei, Zhenhong, Li, Yonghong, Wei, Chaojun, Li, Yuanting, Cheng, Pengfei, Xu, Hui, Li, Zhenhao, Guo, Rui, Qi, Xiaoming, Jia, Jing, Jia, Yanjuan, Wang, Wanxia, Gao, Xiaoling. \"Perturbation of Ephrin Receptor Signaling and Glutamatergic Transmission in the Hypothalamus in Depression Using Proteomics Integrated With Metabolomics.\" Frontiers in neuroscience, 2019, pp. 1359.", "Cecchini, Alessandra, Cornelison, D D W. \"Eph/Ephrin-Based Protein Complexes: The Importance of <i>cis</i> Interactions in Guiding Cellular Processes.\" Frontiers in molecular biosciences, 2021, pp. 809364.", "Garman, Lori, Pelikan, Richard C, Rasmussen, Astrid, Lareau, Caleb A, Savoy, Kathryn A, Deshmukh, Umesh S, Bagavant, Harini, Levin, Albert M, Daouk, Salim, Drake, Wonder P, Montgomery, Courtney G. \"Single Cell Transcriptomics Implicate Novel Monocyte and T Cell Immune Dysregulation in Sarcoidosis.\" Frontiers in immunology, 2020, pp. 567342."]}, "The JAK-STAT signaling pathway is the most prominent biological process performed by this system of interacting proteins. This pathway is crucial for transmitting information from extracellular chemical signals to the nucleus, resulting in DNA transcription and expression of specific genes.": {"keywords": [], "references": []}, "1. Receptor activation: CSF3R, EPOR, IFNAR2, and IL6R are cytokine receptors that initiate the JAK-STAT signaling pathway upon ligand binding. These receptors are associated with JAK family members (JAK1, JAK2, and JAK3), which become activated upon receptor dimerization.": {"keywords": ["(CSF3R[Title]) OR (EPOR[Title]) OR (IFNAR2[Title]) OR (IL6R[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) AND (cytokine receptors[Title])", "(CSF3R[Title]) OR (EPOR[Title]) OR (IFNAR2[Title]) OR (IL6R[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) AND (JAK-STAT signaling[Title])", "(CSF3R[Title]) OR (EPOR[Title]) OR (IFNAR2[Title]) OR (IL6R[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) AND (receptor dimerization[Title])", "(CSF3R[Title/Abstract]) OR (EPOR[Title/Abstract]) OR (IFNAR2[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) AND (cytokine receptors[Title/Abstract])", "(CSF3R[Title/Abstract]) OR (EPOR[Title/Abstract]) OR (IFNAR2[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) AND (JAK-STAT signaling[Title/Abstract])", "(CSF3R[Title/Abstract]) OR (EPOR[Title/Abstract]) OR (IFNAR2[Title/Abstract]) OR (IL6R[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) AND (receptor dimerization[Title/Abstract])"], "references": ["Staerk, J, Kallin, A, Royer, Y, Diaconu, C C, Dusa, A, Demoulin, J-B, Vainchenker, W, Constantinescu, S N. \"JAK2, the JAK2 V617F mutant and cytokine receptors.\" Pathologie-biologie, 2007, pp. 88-91.", "Waters, Michael J, Brooks, Andrew J, Chhabra, Yash. \"A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors.\" JAK-STAT, 2014, pp. e29569.", "Pradhan, Anuradha, Lambert, Que T, Griner, Lori N, Reuther, Gary W. \"Activation of JAK2-V617F by components of heterodimeric cytokine receptors.\" The Journal of biological chemistry, 2010, pp. 16651-63."]}, "2. JAK activation: JAK1, JAK2, and JAK3 are non-receptor tyrosine kinases that phosphorylate and activate STAT proteins (STAT3, STAT5A, STAT5B, and STAT6). JAK activation is a critical step in the pathway, as it directly influences the activation of downstream STAT proteins.": {"keywords": ["(JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (JAK activation[Title])", "(JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (tyrosine kinases[Title])", "(JAK1[Title]) OR (JAK2[Title]) OR (JAK3[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (STAT proteins[Title])", "(JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (JAK activation[Title/Abstract])", "(JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (tyrosine kinases[Title/Abstract])", "(JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (JAK3[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (STAT proteins[Title/Abstract])"], "references": ["Oh, Keunhee, Joo, Kyeung Min, Jung, Yong Sik, Lee, Jaehwan, Kang, Heonjoong, Lee, Hee-Yoon, Lee, Dong-Sup. \"A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.\" Journal of immunological methods, 2010, pp. 45-52.", "Haan, Serge, Margue, Christiane, Engrand, Arnaud, Rolvering, Catherine, Schmitz-Van de Leur, Hildegard, Heinrich, Peter C, Behrmann, Iris, Haan, Claude. \"Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation.\" Journal of immunology (Baltimore, Md. : 1950), 2008, pp. 998-1007.", "Vassilev, Alexei O, Tibbles, Heather E, DuMez, Darin, Venkatachalam, Taracad K, Uckun, Fatih M. \"Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.\" Current drug targets, 2006, pp. 327-43."]}, "3. STAT activation: STAT3, STAT5A, STAT5B, and STAT6 are transcription factors that become activated upon phosphorylation by JAKs. Once activated, they dimerize and translocate to the nucleus, where they bind to specific DNA sequences and regulate gene expression.": {"keywords": ["(STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (transcription factors[Title])", "(STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (phosphorylation[Title])", "(STAT3[Title]) OR (STAT5A[Title]) OR (STAT5B[Title]) OR (STAT6[Title]) AND (gene expression[Title])", "(STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (phosphorylation[Title/Abstract])", "(STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) OR (STAT5B[Title/Abstract]) OR (STAT6[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Hennighausen, Lothar, Robinson, Gertraud W. \"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.\" Genes & development, 2008, pp. 711-21.", "Bosch-Barrera, Joaquim, Menendez, Javier A. \"Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.\" Cancer treatment reviews, 2015, pp. 540-6.", "Sun, Hai-Jian, Xiong, Si-Ping, Cao, Xu, Cao, Lei, Zhu, Meng-Yuan, Wu, Zhi-Yuan, Bian, Jin-Song. \"Polysulfide-mediated sulfhydration of SIRT1 prevents diabetic nephropathy by suppressing phosphorylation and acetylation of p65 NF-\u03baB and STAT3.\" Redox biology, 2021, pp. 101813."]}, "4. Negative regulation: SOCS1 and PTPN11 are negative regulators of the JAK-STAT pathway. SOCS1 inhibits JAK activity by binding to the kinase domain, while PTPN11 dephosphorylates and inactivates JAKs and STATs, preventing excessive signaling.": {"keywords": ["(SOCS1[Title]) OR (PTPN11[Title]) AND (negative regulation[Title])", "(SOCS1[Title]) OR (PTPN11[Title]) AND (JAK-STAT pathway[Title])", "(SOCS1[Title]) OR (PTPN11[Title]) AND (kinase domain[Title])", "(SOCS1[Title/Abstract]) OR (PTPN11[Title/Abstract]) AND (negative regulation[Title/Abstract])", "(SOCS1[Title/Abstract]) OR (PTPN11[Title/Abstract]) AND (JAK-STAT pathway[Title/Abstract])", "(SOCS1[Title/Abstract]) OR (PTPN11[Title/Abstract]) AND (kinase domain[Title/Abstract])"], "references": ["Ahmed, Chulbul M I, Larkin, Joseph, Johnson, Howard M. \"SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function.\" Frontiers in immunology, 2015, pp. 183.", "Zhang, Wenjun, Chan, Rebecca J, Chen, Hanying, Yang, Zhenyun, He, Yantao, Zhang, Xian, Luo, Yong, Yin, Fuqing, Moh, Akira, Miller, Lucy C, Payne, R Mark, Zhang, Zhong-Yin, Fu, Xin-Yuan, Shou, Weinian. \"Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.\" The Journal of biological chemistry, 2009, pp. 22353-22363.", "Nakagawa, Reiko, Naka, Tetsuji, Tsutsui, Hiroko, Fujimoto, Minoru, Kimura, Akihiro, Abe, Tatsuo, Seki, Ekihiro, Sato, Shintaro, Takeuchi, Osamu, Takeda, Kiyoshi, Akira, Shizuo, Yamanishi, Koichi, Kawase, Ichirou, Nakanishi, Kenji, Kishimoto, Tadamitsu. \"SOCS-1 participates in negative regulation of LPS responses.\" Immunity, 2002, pp. 677-87."]}, "5. Cross-talk with other pathways: IRS1 and IRS2 are adaptor proteins that link the JAK-STAT pathway to the PI3K-Akt signaling pathway. PIK3R1, a regulatory subunit of PI3K, is involved in this cross-talk, which can modulate cellular processes such as growth, survival, and metabolism.": {"keywords": ["(IRS1[Title]) OR (IRS2[Title]) OR (PIK3R1[Title]) AND (PI3K-Akt signaling[Title])", "(IRS1[Title]) OR (IRS2[Title]) OR (PIK3R1[Title]) AND (cellular processes[Title])", "(IRS1[Title]) OR (IRS2[Title]) OR (PIK3R1[Title]) AND (cross-talk[Title])", "(IRS1[Title/Abstract]) OR (IRS2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) AND (PI3K-Akt signaling[Title/Abstract])", "(IRS1[Title/Abstract]) OR (IRS2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) AND (cellular processes[Title/Abstract])", "(IRS1[Title/Abstract]) OR (IRS2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) AND (cross-talk[Title/Abstract])"], "references": ["Belizaire, Roger, Koochaki, Sebastian H J, Udeshi, Namrata D, Vedder, Alexis, Sun, Lei, Svinkina, Tanya, Hartigan, Christina, McConkey, Marie, Kovalcik, Veronica, Bizuayehu, Amanuel, Stanclift, Caroline, Schenone, Monica, Carr, Steven A, Padron, Eric, Ebert, Benjamin L. \"CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.\" Blood, 2021, pp. 2209-2220.", "Guo, Xuan, Sun, Wen, Luo, Guangbin, Wu, Lili, Xu, Guangyuan, Hou, Dan, Hou, Yi, Guo, Xiangyu, Mu, Xiaohong, Qin, Lingling, Liu, Tonghua. \"Panax notoginseng saponins alleviate skeletal muscle insulin resistance by regulating the IRS1-PI3K-AKT signaling pathway and GLUT4 expression.\" FEBS open bio, 2019, pp. 1008-1019.", "Zhou, Jinyi, Shi, Yingying, Yang, Chen, Lu, Shuai, Zhao, Lishuang, Liu, Xianli, Zhou, Da, Luo, Lan, Yin, Zhimin. \"\u03b3-glutamylcysteine alleviates insulin resistance and hepatic steatosis by regulating adenylate cyclase and IGF-1R/IRS1/PI3K/Akt signaling pathways.\" The Journal of nutritional biochemistry, 2023, pp. 109404."]}, "In conclusion, the JAK-STAT signaling pathway is the central biological process performed by this system of interacting proteins. This pathway is essential for transmitting extracellular signals to the nucleus, leading to gene expression regulation. The pathway is tightly regulated by both positive and negative modulators, ensuring proper cellular responses to external stimuli.": {"keywords": [], "references": []}, "The most prominent biological process performed by this system of interacting proteins is DNA damage response and repair. This process is crucial for maintaining genomic stability and preventing the accumulation of mutations that can lead to diseases such as cancer.": {"keywords": [], "references": []}, "1. DNA repair proteins: Several proteins in this system are directly involved in DNA repair pathways, including ATM, ATR, ATRX, BARD1, BRCA1, BRCA2, CHEK2, ERCC2, ERCC3, ERCC5, ERCC6, FANCD2, PALB2, RAD21, RAD50, and XRCC1. These proteins function in various repair mechanisms such as homologous recombination, non-homologous end joining, nucleotide excision repair, and base excision repair.": {"keywords": ["(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK2[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (RAD21[Title]) OR (RAD50[Title]) OR (XRCC1[Title]) AND (DNA repair[Title])", "(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK2[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (RAD21[Title]) OR (RAD50[Title]) OR (XRCC1[Title]) AND (homologous recombination[Title])", "(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (CHEK2[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (RAD21[Title]) OR (RAD50[Title]) OR (XRCC1[Title]) AND (nucleotide excision repair[Title])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (homologous recombination[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (nucleotide excision repair[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Jin, Mei Hua, Oh, Do-Youn. \"ATM in DNA repair in cancer.\" Pharmacology & therapeutics, 2019, pp. 107391.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299."]}, "2. Chromatin remodeling proteins: Proteins such as ARID1A, ARID1B, ARID2, CHD2, CHD4, SMARCA1, SMARCA4, SMARCB1, and SMARCE1 are involved in chromatin remodeling, which is essential for the accessibility of DNA repair machinery to damaged sites.": {"keywords": ["(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (chromatin remodeling[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (DNA repair[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (protein[Title])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (protein[Title/Abstract])"], "references": ["Mardinian, Kristina, Adashek, Jacob J, Botta, Gregory P, Kato, Shumei, Kurzrock, Razelle. \"<i>SMARCA4</i>: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.\" Molecular cancer therapeutics, 2021, pp. 2341-2351.", "Zhang, Shanshan, Zhou, Yu-Feng, Cao, Jian, Burley, Stephen K, Wang, Hui-Yun, Zheng, X F Steven. \"mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.\" Cancer research, 2021, pp. 5652-5665.", "Jiang, Hao, Cao, Hui-Jun, Ma, Ning, Bao, Wen-Dai, Wang, Jing-Jing, Chen, Tian-Wei, Zhang, Er-Bin, Yuan, Yan-Mei, Ni, Qian-Zhi, Zhang, Feng-Kun, Ding, Xu-Fen, Zheng, Qian-Wen, Wang, Yi-Kang, Zhu, Min, Wang, Xiang, Feng, Jing, Zhang, Xue-Li, Cheng, Shu-Qun, Ma, Dan-Jun, Qiu, Lin, Li, Jing-Jing, Xie, Dong. \"Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 4770-4780."]}, "3. Histone modification proteins: Histone modifications play a crucial role in the regulation of DNA repair processes. Proteins such as EZH2, KMT2A, KMT2B, KMT2C, KMT2D, SETD2, and YEATS4 are involved in histone methylation, while HDAC1, HDAC2, HDAC3, HDAC4, and HDAC5 are involved in histone deacetylation.": {"keywords": ["(EZH2[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SETD2[Title]) OR (YEATS4[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) AND (histone modification[Title])", "(EZH2[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SETD2[Title]) OR (YEATS4[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) AND (DNA repair[Title])", "(EZH2[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SETD2[Title]) OR (YEATS4[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC4[Title]) OR (HDAC5[Title]) AND (methylation[Title])", "(EZH2[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SETD2[Title/Abstract]) OR (YEATS4[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) AND (histone modification[Title/Abstract])", "(EZH2[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SETD2[Title/Abstract]) OR (YEATS4[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(EZH2[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SETD2[Title/Abstract]) OR (YEATS4[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC4[Title/Abstract]) OR (HDAC5[Title/Abstract]) AND (methylation[Title/Abstract])"], "references": ["Chen, Jiying, Zhu, Zhiying, Xu, Shi, Li, Jing, Huang, Lilan, Tan, Wenqing, Zhang, Yonggang, Zhao, Yanli. \"HDAC1 participates in polycystic ovary syndrome through histone modification by regulating H19/miR-29a-3p/NLRP3-mediated granulosa cell pyroptosis.\" Molecular and cellular endocrinology, 2023, pp. 111950.", "Cho, Yong Jin, Kim, Soo Hee, Kim, Eun Kyung, Han, Jung Woo, Shin, Kyoo-Ho, Hu, Hyuk, Kim, Kyung Sik, Choi, Young Deuk, Kim, Sunghoon, Lee, Young Han, Suh, Jin-Suck, Ahn, Joong Bae, Chung, Hyun Cheol, Noh, Sung Hoon, Rha, Sun Young, Jung, Sung-Taek, Kim, Hyo Song. \"Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.\" BMC cancer, 2018, pp. 158.", "Gherardi, Samuele, Ripoche, Doriane, Mikaelian, Ivan, Chanal, Marie, Teinturier, Romain, Goehrig, Delphine, Cordier-Bussat, Martine, Zhang, Chang X, Hennino, Ana, Bertolino, Philippe. \"Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.\" Biochimica et biophysica acta. Gene regulatory mechanisms, 2017, pp. 427-437."]}, "4. Transcription factors and co-factors: Several transcription factors and co-factors in this system, such as E2F1, E2F6, MYC, NCOR1, NCOR2, RB1, and TP53, regulate the expression of genes involved in DNA repair and cell cycle control, ensuring proper response to DNA damage.": {"keywords": ["(E2F1[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RB1[Title]) OR (TP53[Title]) AND (transcription factors[Title])", "(E2F1[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RB1[Title]) OR (TP53[Title]) AND (DNA repair[Title])", "(E2F1[Title]) OR (E2F6[Title]) OR (MYC[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (RB1[Title]) OR (TP53[Title]) AND (cell cycle[Title])", "(E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RB1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RB1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (MYC[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (RB1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle[Title/Abstract])"], "references": ["Wilde, Blake R, Ayer, Donald E. \"Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis.\" British journal of cancer, 2015, pp. 1529-33.", "Skoudy, Anouchka, Hern\u00e1ndez-Mu\u00f1oz, Inmaculada, Navarro, Pilar. \"Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.\" Journal of gastrointestinal cancer, 2011, pp. 76-84.", "V\u00e9lez-Cruz, Renier, Johnson, David G. \"E2F1 and p53 transcription factors as accessory factors for nucleotide excision repair.\" International journal of molecular sciences, 2012, pp. 13554-68."]}, "5. DNA damage signaling proteins: Proteins such as MDM2, MDM4, PRKDC, and TOP2A are involved in the signaling pathways that detect DNA damage and initiate the appropriate repair response.": {"keywords": ["(MDM2[Title]) OR (MDM4[Title]) OR (PRKDC[Title]) OR (TOP2A[Title]) AND (DNA damage[Title])", "(MDM2[Title]) OR (MDM4[Title]) OR (PRKDC[Title]) OR (TOP2A[Title]) AND (signaling pathways[Title])", "(MDM2[Title]) OR (MDM4[Title]) OR (PRKDC[Title]) OR (TOP2A[Title]) AND (repair response[Title])", "(MDM2[Title/Abstract]) OR (MDM4[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (DNA damage[Title/Abstract])", "(MDM2[Title/Abstract]) OR (MDM4[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (signaling pathways[Title/Abstract])", "(MDM2[Title/Abstract]) OR (MDM4[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (repair response[Title/Abstract])"], "references": ["Lehman, Jason A, Mayo, Lindsey D. \"Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis.\" International journal of molecular sciences, 2012, pp. 16373-86.", "Li, Jiaqi, Kurokawa, Manabu. \"Regulation of MDM2 Stability After DNA Damage.\" Journal of cellular physiology, 2015, pp. 2318-27.", "Saiki, Anne Y, Caenepeel, Sean, Yu, Dongyin, Lofgren, Julie A, Osgood, Tao, Robertson, Rebecca, Canon, Jude, Su, Cheng, Jones, Adrie, Zhao, Xiaoning, Deshpande, Chetan, Payton, Marc, Ledell, Jebediah, Hughes, Paul E, Oliner, Jonathan D. \"MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.\" Oncotarget, 2014, pp. 2030-43."]}, "6. Splicing and RNA processing proteins: Proper splicing and RNA processing are essential for the expression of functional DNA repair proteins. Proteins such as SF3B1, U2AF1, and ZRSR2 are involved in these processes.": {"keywords": ["(SF3B1[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (splicing[Title])", "(SF3B1[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (RNA processing[Title])", "(SF3B1[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (DNA repair[Title])", "(SF3B1[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (splicing[Title/Abstract])", "(SF3B1[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (RNA processing[Title/Abstract])", "(SF3B1[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (DNA repair[Title/Abstract])"], "references": ["Hluch\u00fd, Milan, Gajdu\u0161kov\u00e1, Pavla, Ruiz de Los Mozos, Igor, R\u00e1jeck\u00fd, Michal, Kluge, Michael, Berger, Benedict-Tilman, Slab\u00e1, Zuzana, Pot\u011b\u0161il, David, Wei\u00df, Elena, Ule, Jernej, Zdr\u00e1hal, Zbyn\u011bk, Knapp, Stefan, Paruch, Kamil, Friedel, Caroline C, Blazek, Dalibor. \"CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1.\" Nature, 2022, pp. 829-834.", "L\u00f3pez-C\u00e1novas, Juan L, Del Rio-Moreno, Mercedes, Garc\u00eda-Fernandez, Helena, Jim\u00e9nez-Vacas, Juan M, Moreno-Montilla, M Trinidad, S\u00e1nchez-Frias, Marina E, Amado, V\u00edctor, L-L\u00f3pez, Fernando, Fondevila, Marcos F, Ciria, Rub\u00e9n, G\u00f3mez-Luque, Irene, Brice\u00f1o, Javier, Nogueiras, Rub\u00e9n, de la Mata, Manuel, Casta\u00f1o, Justo P, Rodriguez-Per\u00e1lvarez, Manuel, Luque, Ra\u00fal M, Gahete, Manuel D. \"Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.\" Cancer letters, 2021, pp. 72-83.", "Guo, Jing, Li, Chuzhong, Fang, Qiuyue, Liu, Yulou, Wang, Dawei, Chen, Yiyuan, Xie, Weiyan, Zhang, Yazhuo. \"The SF3B1<sup>R625H</sup> mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1.\" Journal of experimental & clinical cancer research : CR, 2022, pp. 26."]}, "In conclusion, this system of interacting proteins plays a critical role in the DNA damage response and repair process, ensuring the maintenance of genomic stability and preventing the accumulation of harmful mutations.": {"keywords": [], "references": []}, "1. Cell cycle regulation: Several proteins in the system are involved in the regulation of the cell cycle. For example, CDK8 is a cyclin-dependent kinase that plays a role in transcriptional regulation and cell cycle progression. CHEK2 is a checkpoint kinase that participates in cell cycle arrest in response to DNA damage. PPP2CA and PPP2CB are catalytic subunits of protein phosphatase 2A (PP2A), which is involved in the regulation of various cellular processes, including cell cycle progression.": {"keywords": ["(CDK8[Title]) OR (CHEK2[Title]) OR (PPP2CA[Title]) OR (PPP2CB[Title]) AND (cell cycle regulation[Title])", "(CDK8[Title]) OR (CHEK2[Title]) OR (PPP2CA[Title]) OR (PPP2CB[Title]) AND (transcriptional regulation[Title])", "(CDK8[Title]) OR (CHEK2[Title]) OR (PPP2CA[Title]) OR (PPP2CB[Title]) AND (DNA damage[Title])", "(CDK8[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (PPP2CA[Title/Abstract]) OR (PPP2CB[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CDK8[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (PPP2CA[Title/Abstract]) OR (PPP2CB[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(CDK8[Title/Abstract]) OR (CHEK2[Title/Abstract]) OR (PPP2CA[Title/Abstract]) OR (PPP2CB[Title/Abstract]) AND (DNA damage[Title/Abstract])"], "references": ["Roeb, Wendy, Higgins, Jake, King, Mary-Claire. \"Response to DNA damage of CHEK2 missense mutations in familial breast cancer.\" Human molecular genetics, 2012, pp. 2738-44.", "Mustofa, Md Kawsar, Tanoue, Yuki, Tateishi, Chie, Vaziri, Cyrus, Tateishi, Satoshi. \"Roles of Chk2/CHEK2 in guarding against environmentally induced DNA damage and replication-stress.\" Environmental and molecular mutagenesis, 2020, pp. 730-735.", "Hung, Yin P, Dong, Fei, Torre, Matthew, Crum, Christopher P, Bueno, Raphael, Chirieac, Lucian R. \"Molecular characterization of diffuse malignant peritoneal mesothelioma.\" Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020, pp. 2269-2279."]}, "2. DNA repair: Some proteins in the system are involved in DNA repair mechanisms. For example, XPC is a component of the nucleotide excision repair (NER) pathway, which is responsible for repairing DNA damage caused by ultraviolet (UV) radiation and other sources. TOP2A is a DNA topoisomerase that plays a role in the repair of DNA double-strand breaks.": {"keywords": ["(XPC[Title]) OR (TOP2A[Title]) AND (DNA repair[Title])", "(XPC[Title]) OR (TOP2A[Title]) AND (nucleotide excision repair[Title])", "(XPC[Title]) OR (TOP2A[Title]) AND (DNA topoisomerase[Title])", "(XPC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(XPC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (nucleotide excision repair[Title/Abstract])", "(XPC[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (DNA topoisomerase[Title/Abstract])"], "references": ["Wu, Cheng-Nan, Chang, Wen-Shin, Shih, Liang-Chun, Wang, Yun-Chi, Lee, Hsu-Tung, Yu, Chien-Chih, Wang, Zhi-Hong, Mong, Mei-Chin, Hsia, Te-Chun, Tsai, Chia-Wen, Bau, DA-Tian. \"Interaction of DNA Repair Gene XPC With Smoking and Betel Quid Chewing Behaviors of Oral Cancer.\" Cancer genomics & proteomics, 2021, pp. 441-449.", "Zhang, Elisa T, He, Yuan, Grob, Patricia, Fong, Yick W, Nogales, Eva, Tjian, Robert. \"Architecture of the human XPC DNA repair and stem cell coactivator complex.\" Proceedings of the National Academy of Sciences of the United States of America, 2015, pp. 14817-22.", "Sugasawa, Kaoru. \"UV-induced ubiquitylation of XPC complex, the UV-DDB-ubiquitin ligase complex, and DNA repair.\" Journal of molecular histology, 2006, pp. 189-202."]}, "3. Transcriptional regulation: Several proteins in the system are involved in the regulation of gene expression. For example, CTCF is a transcription factor that plays a role in chromatin organization and gene regulation. HDAC1 is a histone deacetylase that modulates chromatin structure and gene expression. SF3B1 is a component of the spliceosome, which is involved in pre-mRNA splicing and the regulation of alternative splicing.": {"keywords": ["(CTCF[Title]) OR (HDAC1[Title]) OR (SF3B1[Title]) AND (transcriptional regulation[Title])", "(CTCF[Title]) OR (HDAC1[Title]) OR (SF3B1[Title]) AND (chromatin organization[Title])", "(CTCF[Title]) OR (HDAC1[Title]) OR (SF3B1[Title]) AND (alternative splicing[Title])", "(CTCF[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (SF3B1[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(CTCF[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (SF3B1[Title/Abstract]) AND (chromatin organization[Title/Abstract])", "(CTCF[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (SF3B1[Title/Abstract]) AND (alternative splicing[Title/Abstract])"], "references": ["Chen, Yingchun, He, Rongquan, Han, Zhiqiang, Wu, Yanyan, Wang, Qiuyan, Zhu, Xiujuan, Huang, Zhiguang, Ye, Juan, Tang, Yao, Huang, Hongbin, Chen, Jianxu, Shan, Hong, Xiao, Fei. \"Cooperation of ATF4 and CTCF promotes adipogenesis through transcriptional regulation.\" Cell biology and toxicology, 2022, pp. 741-763.", "Marina-Z\u00e1rate, Ester, Rodr\u00edguez-Ronchel, Ana, G\u00f3mez, Manuel J, S\u00e1nchez-Cabo, F\u00e1tima, Ramiro, Almudena R. \"Low-affinity CTCF binding drives transcriptional regulation whereas high-affinity binding encompasses architectural functions.\" iScience, 2023, pp. 106106.", "Hyle, Judith, Djekidel, Mohamed Nadhir, Williams, Justin, Wright, Shaela, Shao, Ying, Xu, Beisi, Li, Chunliang. \"Auxin-inducible degron 2 system deciphers functions of CTCF domains in transcriptional regulation.\" Genome biology, 2023, pp. 14."]}, "4. Ribosome biogenesis and protein synthesis: Some proteins in the system are involved in ribosome biogenesis and protein synthesis. For example, RPL5 and RPS15 are ribosomal proteins that are components of the large and small ribosomal subunits, respectively. NPM1 is a nucleolar protein that is involved in ribosome biogenesis and the assembly of ribosomal subunits.": {"keywords": ["(RPL5[Title]) OR (RPS15[Title]) OR (NPM1[Title]) AND (ribosome biogenesis[Title])", "(RPL5[Title]) OR (RPS15[Title]) OR (NPM1[Title]) AND (protein synthesis[Title])", "(RPL5[Title]) OR (RPS15[Title]) OR (NPM1[Title]) AND (nucleolar protein[Title])", "(RPL5[Title/Abstract]) OR (RPS15[Title/Abstract]) OR (NPM1[Title/Abstract]) AND (ribosome biogenesis[Title/Abstract])", "(RPL5[Title/Abstract]) OR (RPS15[Title/Abstract]) OR (NPM1[Title/Abstract]) AND (protein synthesis[Title/Abstract])", "(RPL5[Title/Abstract]) OR (RPS15[Title/Abstract]) OR (NPM1[Title/Abstract]) AND (nucleolar protein[Title/Abstract])"], "references": ["Lindstr\u00f6m, Mikael S. \"NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling.\" Biochemistry research international, 2011, pp. 195209.", "Turi, Zsofia, Senkyrikova, Marketa, Mistrik, Martin, Bartek, Jiri, Moudry, Pavel. \"Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells.\" Cell cycle (Georgetown, Tex.), 2018, pp. 92-101.", "Bretones, Gabriel, \u00c1lvarez, Miguel G, Arango, Javier R, Rodr\u00edguez, David, Nadeu, Ferran, Prado, Miguel A, Vald\u00e9s-Mas, Rafael, Puente, Diana A, Paulo, Joao A, Delgado, Julio, Villamor, Neus, L\u00f3pez-Guillermo, Armando, Finley, Daniel J, Gygi, Steven P, Campo, El\u00edas, Quesada, V\u00edctor, L\u00f3pez-Ot\u00edn, Carlos. \"Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.\" Blood, 2018, pp. 2375-2388."]}, "5. Protein-protein interactions and signaling: Several proteins in the system are involved in protein-protein interactions and cellular signaling. For example, HRAS is a small GTPase that is involved in signal transduction and the regulation of cell growth and differentiation. RHOA is another small GTPase that is involved in the regulation of actin cytoskeleton organization and cell migration.": {"keywords": ["(HRAS[Title]) OR (RHOA[Title]) AND (protein-protein interactions[Title])", "(HRAS[Title]) OR (RHOA[Title]) AND (cellular signaling[Title])", "(HRAS[Title]) OR (RHOA[Title]) AND (cell growth[Title])", "(HRAS[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (protein-protein interactions[Title/Abstract])", "(HRAS[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (cellular signaling[Title/Abstract])", "(HRAS[Title/Abstract]) OR (RHOA[Title/Abstract]) AND (cell growth[Title/Abstract])"], "references": ["Joshi, Rakesh, Qin, Lyugao, Cao, Xuan, Zhong, Shanshan, Voss, Courtney, Min, Weiping, Li, Shawn S C. \"DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.\" The Journal of biological chemistry, 2020, pp. 645-656.", "Walker-Gray, Ryan, Pallien, Tamara, Miller, Duncan C, Oder, Andreas, Neuenschwander, Martin, von Kries, Jens Peter, Diecke, Sebastian, Klussmann, Enno. \"Disruptors of AKAP-Dependent Protein-Protein Interactions.\" Methods in molecular biology (Clifton, N.J.), 2022, pp. 117-139.", "Messina, Samantha, De Simone, Giovanna, Ascenzi, Paolo. \"Cysteine-based regulation of redox-sensitive Ras small GTPases.\" Redox biology, 2019, pp. 101282."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is cell cycle regulation and DNA repair, with additional roles in transcriptional regulation, ribosome biogenesis, protein synthesis, and cellular signaling.": {"keywords": [], "references": []}, "The interacting proteins in this system are primarily involved in DNA damage response, chromatin remodeling, and transcription regulation. ": {"keywords": [], "references": []}, "1. DNA Damage Response: Several proteins in this system are involved in the detection and repair of DNA damage. Key proteins include ATM, ATR, ATRX, BARD1, BRCA1, ERCC2, ERCC3, ERCC5, ERCC6, FANCD2, PALB2, PARP1, PRKDC, RAD21, TP53, XPA, and XRCC1. These proteins play roles in various DNA repair pathways, such as homologous recombination, non-homologous end joining, and nucleotide excision repair.": {"keywords": ["(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (RAD21[Title]) OR (TP53[Title]) OR (XPA[Title]) OR (XRCC1[Title]) AND (DNA damage[Title])", "(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (RAD21[Title]) OR (TP53[Title]) OR (XPA[Title]) OR (XRCC1[Title]) AND (repair pathways[Title])", "(ATM[Title]) OR (ATR[Title]) OR (ATRX[Title]) OR (BARD1[Title]) OR (BRCA1[Title]) OR (ERCC2[Title]) OR (ERCC3[Title]) OR (ERCC5[Title]) OR (ERCC6[Title]) OR (FANCD2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (RAD21[Title]) OR (TP53[Title]) OR (XPA[Title]) OR (XRCC1[Title]) AND (homologous recombination[Title])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XPA[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (DNA damage[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XPA[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (repair pathways[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (ATRX[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (ERCC2[Title/Abstract]) OR (ERCC3[Title/Abstract]) OR (ERCC5[Title/Abstract]) OR (ERCC6[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (RAD21[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XPA[Title/Abstract]) OR (XRCC1[Title/Abstract]) AND (homologous recombination[Title/Abstract])"], "references": ["Smith, Joanne, Tho, Lye Mun, Xu, Naihan, Gillespie, David A. \"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.\" Advances in cancer research, 2010, pp. 73-112.", "Blackford, Andrew N, Jackson, Stephen P. \"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.\" Molecular cell, 2017, pp. 801-817.", "Aasland, Dorthe, G\u00f6tzinger, Laura, Hauck, Laura, Berte, Nancy, Meyer, Jessica, Effenberger, Melanie, Schneider, Simon, Reuber, Emelie E, Roos, Wynand P, Tomicic, Maja T, Kaina, Bernd, Christmann, Markus. \"Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-\u03baB.\" Cancer research, 2019, pp. 99-113."]}, "2. Chromatin Remodeling: Chromatin remodeling proteins alter the structure of chromatin to regulate gene expression. Key proteins in this system include ARID1A, ARID1B, ARID2, ASXL1, ASXL2, CHD2, CHD4, CREBBP, EP300, EZH2, HDAC1, HDAC2, HDAC3, HDAC5, KAT6A, KDM5A, KDM6A, KMT2A, KMT2B, KMT2C, KMT2D, SMARCA1, SMARCA4, SMARCB1, and SMARCE1. These proteins are involved in histone modification, nucleosome positioning, and chromatin accessibility.": {"keywords": ["(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC5[Title]) OR (KAT6A[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (chromatin remodeling[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC5[Title]) OR (KAT6A[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (gene expression[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (ASXL1[Title]) OR (ASXL2[Title]) OR (CHD2[Title]) OR (CHD4[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (EZH2[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) OR (HDAC5[Title]) OR (KAT6A[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (histone modification[Title])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KAT6A[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KAT6A[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (gene expression[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (ASXL1[Title/Abstract]) OR (ASXL2[Title/Abstract]) OR (CHD2[Title/Abstract]) OR (CHD4[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (EZH2[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (KAT6A[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (histone modification[Title/Abstract])"], "references": ["Mardinian, Kristina, Adashek, Jacob J, Botta, Gregory P, Kato, Shumei, Kurzrock, Razelle. \"<i>SMARCA4</i>: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.\" Molecular cancer therapeutics, 2021, pp. 2341-2351.", "Jiang, Hao, Cao, Hui-Jun, Ma, Ning, Bao, Wen-Dai, Wang, Jing-Jing, Chen, Tian-Wei, Zhang, Er-Bin, Yuan, Yan-Mei, Ni, Qian-Zhi, Zhang, Feng-Kun, Ding, Xu-Fen, Zheng, Qian-Wen, Wang, Yi-Kang, Zhu, Min, Wang, Xiang, Feng, Jing, Zhang, Xue-Li, Cheng, Shu-Qun, Ma, Dan-Jun, Qiu, Lin, Li, Jing-Jing, Xie, Dong. \"Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 4770-4780.", "Zhang, Shanshan, Zhou, Yu-Feng, Cao, Jian, Burley, Stephen K, Wang, Hui-Yun, Zheng, X F Steven. \"mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.\" Cancer research, 2021, pp. 5652-5665."]}, "3. Transcription Regulation: Many proteins in this system are involved in the regulation of transcription, either as transcription factors or as components of transcriptional complexes. Key proteins include AR, BCL6, CTCF, CTNNB1, E2F1, E2F6, GATA1, GATA3, MAX, MDM2, MED1, MED12, MYB, MYC, MYCL, MYCN, NCOR1, NF1, NPM1, PBRM1, PRDM1, RB1, RBL1, REL, RUNX1, SF1, SF3B1, SMAD2, SOX2, SPEN, SRSF2, TAF1, TBL1XR1, TFDP1, TNF, TOP1, TOP2A, U2AF1, UPF1, WT1, XPO1, and ZRSR2. These proteins are involved in various aspects of transcription regulation, such as initiation, elongation, and termination, as well as mRNA splicing and export.": {"keywords": ["(AR[Title]) OR (BCL6[Title]) OR (CTCF[Title]) OR (CTNNB1[Title]) OR (E2F1[Title]) OR (E2F6[Title]) OR (GATA1[Title]) OR (GATA3[Title]) OR (MAX[Title]) OR (MDM2[Title]) OR (MED1[Title]) OR (MED12[Title]) OR (MYB[Title]) OR (MYC[Title]) OR (MYCL[Title]) OR (MYCN[Title]) OR (NCOR1[Title]) OR (NF1[Title]) OR (NPM1[Title]) OR (PBRM1[Title]) OR (PRDM1[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (REL[Title]) OR (RUNX1[Title]) OR (SF1[Title]) OR (SF3B1[Title]) OR (SMAD2[Title]) OR (SOX2[Title]) OR (SPEN[Title]) OR (SRSF2[Title]) OR (TAF1[Title]) OR (TBL1XR1[Title]) OR (TFDP1[Title]) OR (TNF[Title]) OR (TOP1[Title]) OR (TOP2A[Title]) OR (U2AF1[Title]) OR (UPF1[Title]) OR (WT1[Title]) OR (XPO1[Title]) OR (ZRSR2[Title]) AND (transcription regulation[Title])", "(AR[Title]) OR (BCL6[Title]) OR (CTCF[Title]) OR (CTNNB1[Title]) OR (E2F1[Title]) OR (E2F6[Title]) OR (GATA1[Title]) OR (GATA3[Title]) OR (MAX[Title]) OR (MDM2[Title]) OR (MED1[Title]) OR (MED12[Title]) OR (MYB[Title]) OR (MYC[Title]) OR (MYCL[Title]) OR (MYCN[Title]) OR (NCOR1[Title]) OR (NF1[Title]) OR (NPM1[Title]) OR (PBRM1[Title]) OR (PRDM1[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (REL[Title]) OR (RUNX1[Title]) OR (SF1[Title]) OR (SF3B1[Title]) OR (SMAD2[Title]) OR (SOX2[Title]) OR (SPEN[Title]) OR (SRSF2[Title]) OR (TAF1[Title]) OR (TBL1XR1[Title]) OR (TFDP1[Title]) OR (TNF[Title]) OR (TOP1[Title]) OR (TOP2A[Title]) OR (U2AF1[Title]) OR (UPF1[Title]) OR (WT1[Title]) OR (XPO1[Title]) OR (ZRSR2[Title]) AND (transcription factors[Title])", "(AR[Title]) OR (BCL6[Title]) OR (CTCF[Title]) OR (CTNNB1[Title]) OR (E2F1[Title]) OR (E2F6[Title]) OR (GATA1[Title]) OR (GATA3[Title]) OR (MAX[Title]) OR (MDM2[Title]) OR (MED1[Title]) OR (MED12[Title]) OR (MYB[Title]) OR (MYC[Title]) OR (MYCL[Title]) OR (MYCN[Title]) OR (NCOR1[Title]) OR (NF1[Title]) OR (NPM1[Title]) OR (PBRM1[Title]) OR (PRDM1[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (REL[Title]) OR (RUNX1[Title]) OR (SF1[Title]) OR (SF3B1[Title]) OR (SMAD2[Title]) OR (SOX2[Title]) OR (SPEN[Title]) OR (SRSF2[Title]) OR (TAF1[Title]) OR (TBL1XR1[Title]) OR (TFDP1[Title]) OR (TNF[Title]) OR (TOP1[Title]) OR (TOP2A[Title]) OR (U2AF1[Title]) OR (UPF1[Title]) OR (WT1[Title]) OR (XPO1[Title]) OR (ZRSR2[Title]) AND (mRNA splicing[Title])", "(AR[Title/Abstract]) OR (BCL6[Title/Abstract]) OR (CTCF[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (GATA1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MAX[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (MED1[Title/Abstract]) OR (MED12[Title/Abstract]) OR (MYB[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCL[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NF1[Title/Abstract]) OR (NPM1[Title/Abstract]) OR (PBRM1[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (REL[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SMAD2[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (SPEN[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (TAF1[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) OR (TFDP1[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TOP1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (UPF1[Title/Abstract]) OR (WT1[Title/Abstract]) OR (XPO1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (transcription regulation[Title/Abstract])", "(AR[Title/Abstract]) OR (BCL6[Title/Abstract]) OR (CTCF[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (GATA1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MAX[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (MED1[Title/Abstract]) OR (MED12[Title/Abstract]) OR (MYB[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCL[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NF1[Title/Abstract]) OR (NPM1[Title/Abstract]) OR (PBRM1[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (REL[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SMAD2[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (SPEN[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (TAF1[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) OR (TFDP1[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TOP1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (UPF1[Title/Abstract]) OR (WT1[Title/Abstract]) OR (XPO1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(AR[Title/Abstract]) OR (BCL6[Title/Abstract]) OR (CTCF[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F6[Title/Abstract]) OR (GATA1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MAX[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (MED1[Title/Abstract]) OR (MED12[Title/Abstract]) OR (MYB[Title/Abstract]) OR (MYC[Title/Abstract]) OR (MYCL[Title/Abstract]) OR (MYCN[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NF1[Title/Abstract]) OR (NPM1[Title/Abstract]) OR (PBRM1[Title/Abstract]) OR (PRDM1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (REL[Title/Abstract]) OR (RUNX1[Title/Abstract]) OR (SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SMAD2[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (SPEN[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (TAF1[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) OR (TFDP1[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TOP1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (UPF1[Title/Abstract]) OR (WT1[Title/Abstract]) OR (XPO1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (mRNA splicing[Title/Abstract])"], "references": ["Braccioli, Luca, de Wit, Elzo. \"CTCF: a Swiss-army knife for genome organization and transcription regulation.\" Essays in biochemistry, 2019, pp. 157-165.", "Mitra, Partha. \"Transcription regulation of <i>MYB</i>: a potential and novel therapeutic target in cancer.\" Annals of translational medicine, 2018, pp. 443.", "Watson, R J, Robinson, C, Lam, E W. \"Transcription regulation by murine B-myb is distinct from that by c-myb.\" Nucleic acids research, 1993, pp. 267-72."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is the DNA damage response, with significant involvement in chromatin remodeling and transcription regulation. These processes are critical for maintaining genomic integrity and regulating gene expression in response to cellular signals and environmental stressors.": {"keywords": [], "references": []}, "The system of interacting proteins AKT1, AR, CDKN1B, CREBBP, EP300, FOXO3, RARA, SMAD4, SMARCB1, and VHL plays a crucial role in cell cycle regulation and transcriptional control. ": {"keywords": ["(AKT1[Title]) OR (AR[Title]) OR (CDKN1B[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (FOXO3[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) OR (VHL[Title]) AND (cell cycle regulation[Title])", "(AKT1[Title]) OR (AR[Title]) OR (CDKN1B[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (FOXO3[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) OR (VHL[Title]) AND (transcriptional control[Title])", "(AKT1[Title]) OR (AR[Title]) OR (CDKN1B[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (FOXO3[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) OR (VHL[Title]) AND (interacting proteins[Title])", "(AKT1[Title/Abstract]) OR (AR[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (FOXO3[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (VHL[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(AKT1[Title/Abstract]) OR (AR[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (FOXO3[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (VHL[Title/Abstract]) AND (transcriptional control[Title/Abstract])", "(AKT1[Title/Abstract]) OR (AR[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (FOXO3[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (VHL[Title/Abstract]) AND (interacting proteins[Title/Abstract])"], "references": ["Perez, Monika W, Sias-Garcia, Oscar, Daramola, Alfred, Wei, Helen, Terrell, Maci, Rashid, Raushan, Park, Woojun D, Duong, Kevin, Horton, Terzah M, Li, Feng, Cherayil, Nikitha, Koren, Jost Vrabic, Gant, Vincent U, Junco, Jacob J, Curry, Choladda V, Stevens, Alexandra M, Lin, Charles Y, Yi, Joanna S. \"Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.\" Blood advances, 2021, pp. 4864-4876.", "Di-Po\u00ef, Nicolas, Tan, Nguan Soon, Michalik, Liliane, Wahli, Walter, Desvergne, B\u00e9atrice. \"Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway.\" Molecular cell, 2002, pp. 721-33.", "Foley, Christopher, Mitsiades, Nicholas. \"Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.\" Hormones & cancer, 2016, pp. 84-103."]}, "1. Cell Cycle Regulation: CDKN1B, AKT1, FOXO3, and VHL are key players in cell cycle regulation.": {"keywords": ["(CDKN1B[Title]) OR (AKT1[Title]) OR (FOXO3[Title]) OR (VHL[Title]) AND (cell cycle regulation[Title])", "(CDKN1B[Title]) OR (AKT1[Title]) OR (FOXO3[Title]) OR (VHL[Title]) AND (key players[Title])", "(CDKN1B[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (FOXO3[Title/Abstract]) OR (VHL[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CDKN1B[Title/Abstract]) OR (AKT1[Title/Abstract]) OR (FOXO3[Title/Abstract]) OR (VHL[Title/Abstract]) AND (key players[Title/Abstract])"], "references": ["Donlon, Timothy A, Curb, J David, He, Qimei, Grove, John S, Masaki, Kamal H, Rodriguez, Beatriz, Elliott, Ayako, Willcox, D Craig, Willcox, Bradley J. \"FOXO3 gene variants and human aging: coding variants may not be key players.\" The journals of gerontology. Series A, Biological sciences and medical sciences, 2012, pp. 1132-9.", "Morris, Brian J, Willcox, Donald Craig, Donlon, Timothy A, Willcox, Bradley J. \"FOXO3: A Major Gene for Human Longevity--A Mini-Review.\" Gerontology, 2015, pp. 515-25.", "Wu, Chia-Ling, Satomi, Yoshinori, Walsh, Kenneth. \"RNA-seq and metabolomic analyses of Akt1-mediated muscle growth reveals regulation of regenerative pathways and changes in the muscle secretome.\" BMC genomics, 2017, pp. 181."]}, "- CDKN1B (p27) is a cyclin-dependent kinase inhibitor that regulates cell cycle progression by inhibiting the activity of cyclin-CDK complexes, thus preventing cell cycle progression from G1 to S phase.": {"keywords": ["(CDKN1B[Title]) AND (cell cycle progression[Title])", "(CDKN1B[Title]) AND (cyclin-dependent kinase inhibitor[Title])", "(CDKN1B[Title]) AND (G1 to S phase[Title])", "(CDKN1B[Title/Abstract]) AND (cell cycle progression[Title/Abstract])", "(CDKN1B[Title/Abstract]) AND (cyclin-dependent kinase inhibitor[Title/Abstract])", "(CDKN1B[Title/Abstract]) AND (G1 to S phase[Title/Abstract])"], "references": ["Ma, Junli, Zeng, Shan, Zhang, Yan, Deng, Ganlu, Qu, Yanling, Guo, Cao, Yin, Ling, Han, Ying, Shen, Hong. \"BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling.\" Molecular carcinogenesis, 2017, pp. 2279-2289.", "Ren, Chaoqi, Yu, Mengmeng, Zhang, Yao, Fan, Minghui, Chang, Fangfang, Xing, Lixiao, Liu, Yongzhen, Wang, Yongqiang, Qi, Xiaole, Liu, Changjun, Zhang, Yanping, Cui, Hongyu, Li, Kai, Gao, Li, Pan, Qing, Wang, Xiaomei, Gao, Yulong. \"Avian leukosis virus subgroup J promotes cell proliferation and cell cycle progression through miR-221 by targeting CDKN1B.\" Virology, 2018, pp. 121-130.", "Tichomirowa, Maria A, Lee, Misu, Barlier, Anne, Daly, Adrian F, Marinoni, Ilaria, Jaffrain-Rea, Marie-Lise, Naves, Luciana A, Rodien, Patrice, Rohmer, Vincent, Faucz, Fabio Rueda, Caron, Philippe, Estour, Bruno, Lecomte, Pierre, Borson-Chazot, Fran\u00e7oise, Penfornis, Alfred, Yaneva, Maria, Guitelman, Mirtha, Castermans, Emily, Verhaege, Catherine, W\u00e9meau, Jean-Louis, Tabarin, Antoine, Fajardo Monta\u00f1ana, Carmen, Delemer, Brigitte, Kerlan, Veronique, Sadoul, Jean-Louis, Cortet Rudelli, Christine, Archambeaud, Fran\u00e7oise, Zacharieva, Sabine, Theodoropoulou, Marily, Brue, Thierry, Enjalbert, Alain, Bours, Vincent, Pellegata, Natalia S, Beckers, Albert. \"Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.\" Endocrine-related cancer, 2012, pp. 233-41."]}, "- AKT1 is a serine/threonine kinase that promotes cell survival and growth by inhibiting pro-apoptotic proteins, including FOXO3.": {"keywords": ["(AKT1[Title]) OR (FOXO3[Title]) AND (cell survival[Title])", "(AKT1[Title]) OR (FOXO3[Title]) AND (serine/threonine kinase[Title])", "(AKT1[Title]) OR (FOXO3[Title]) AND (pro-apoptotic proteins[Title])", "(AKT1[Title/Abstract]) OR (FOXO3[Title/Abstract]) AND (cell survival[Title/Abstract])", "(AKT1[Title/Abstract]) OR (FOXO3[Title/Abstract]) AND (serine/threonine kinase[Title/Abstract])", "(AKT1[Title/Abstract]) OR (FOXO3[Title/Abstract]) AND (pro-apoptotic proteins[Title/Abstract])"], "references": ["Sun, Gongping, Ding, Xun Austin, Argaw, Yewubdar, Guo, Xiaoran, Montell, Denise J. \"Akt1 and dCIZ1 promote cell survival from apoptotic caspase activation during regeneration and oncogenic overgrowth.\" Nature communications, 2020, pp. 5726.", "Rahmani, Anahita, Kheradmand, Danial, Keyhanvar, Peyman, Shoae-Hassani, Alireza, Darbandi-Azar, Amir. \"Neurogenesis and increase in differentiated neural cell survival via phosphorylation of Akt1 after fluoxetine treatment of stem cells.\" BioMed research international, 2013, pp. 582526.", "Zhong, Sheng, Zhang, Zhiyun, Guo, Zhen, Yang, Wenzhuo, Dou, Gaojing, Lv, Xiaye, Wang, Xinhui, Ge, Junliang, Wu, Bo, Pan, Xuefeng, Wang, Hongyu, Mou, Yonggao. \"Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.\" Bioengineered, 2022, pp. 12003-12020."]}, "- FOXO3 is a transcription factor that regulates cell cycle arrest and apoptosis in response to cellular stress. AKT1 phosphorylates FOXO3, leading to its inactivation and promoting cell survival.": {"keywords": ["(FOXO3[Title]) OR (AKT1[Title]) AND (transcription factor[Title])", "(FOXO3[Title]) OR (AKT1[Title]) AND (cell cycle[Title])", "(FOXO3[Title]) OR (AKT1[Title]) AND (apoptosis[Title])", "(FOXO3[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(FOXO3[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(FOXO3[Title/Abstract]) OR (AKT1[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Fusi, Lorenza, Paudel, Rupesh, Meder, Katharina, Schlosser, Andreas, Schrama, David, Goebeler, Matthias, Schmidt, Marc. \"Interaction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis.\" The Journal of biological chemistry, 2022, pp. 101714.", "Loebel, Madlen, Holzhauser, Luise, Hartwig, Jelka A, Shukla, Praphulla C, Savvatis, Konstantinos, Jenke, Alexander, Gast, Martina, Escher, Felicitas, Becker, Sonya C, Bauer, Sandra, Stroux, Andrea, Beling, Antje, Kespohl, Meike, Pinkert, Sandra, Fechner, Henry, Kuehl, Uwe, Lassner, Dirk, Poller, Wolfgang, Schultheiss, Heinz-Peter, Zeller, Tanja, Blankenberg, Stefan, Papageorgiou, Anna-Pia, Heymans, Stephane, Landmesser, Ulf, Scheibenbogen, Carmen, Skurk, Carsten. \"The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis.\" European heart journal, 2018, pp. 876-887.", "Deng, Aiqing, Ma, Limin, Zhou, Xueli, Wang, Xin, Wang, Shouyan, Chen, Xia. \"FoxO3 transcription factor promotes autophagy after oxidative stress injury in HT22 cells.\" Canadian journal of physiology and pharmacology, 2021, pp. 627-634."]}, "- VHL is a tumor suppressor protein that targets hypoxia-inducible factor (HIF) for degradation, preventing uncontrolled cell proliferation and angiogenesis.": {"keywords": ["(HIF[Title]) OR (VHL[Title]) AND (tumor suppressor[Title])", "(HIF[Title]) OR (VHL[Title]) AND (angiogenesis[Title])", "(HIF[Title]) OR (VHL[Title]) AND (cell proliferation[Title])", "(HIF[Title/Abstract]) OR (VHL[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(HIF[Title/Abstract]) OR (VHL[Title/Abstract]) AND (angiogenesis[Title/Abstract])", "(HIF[Title/Abstract]) OR (VHL[Title/Abstract]) AND (cell proliferation[Title/Abstract])"], "references": ["Xiao, Yiren, Thakkar, Kaushik N, Zhao, Hongjuan, Broughton, James, Li, Yang, Seoane, Jose A, Diep, Anh N, Metzner, Thomas J, von Eyben, Rie, Dill, David L, Brooks, James D, Curtis, Christina, Leppert, John T, Ye, Jiangbin, Peehl, Donna M, Giaccia, Amato J, Sinha, Subarna, Rankin, Erinn B. \"The m<sup>6</sup>A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 21441-21449.", "Kapitsinou, P P, Haase, V H. \"The VHL tumor suppressor and HIF: insights from genetic studies in mice.\" Cell death and differentiation, 2008, pp. 650-9.", "Wang, Ying, Chen, Wanyuan, Lian, Jiayan, Zhang, Haibo, Yu, Bo, Zhang, Minjun, Wei, Fangqiang, Wu, Jianhui, Jiang, Jiaxiang, Jia, Yongshi, Mo, Fan, Zhang, Shirong, Liang, Xiaodong, Mou, Xiaozhou, Tang, Jianming. \"The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1\u03b1.\" Cell death and differentiation, 2020, pp. 695-710."]}, "2. Transcriptional Control: AR, CREBBP, EP300, RARA, SMAD4, and SMARCB1 are involved in transcriptional regulation.": {"keywords": ["(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) AND (transcriptional regulation[Title])", "(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) AND (control[Title])", "(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) OR (RARA[Title]) OR (SMAD4[Title]) OR (SMARCB1[Title]) AND (involved[Title])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) AND (control[Title/Abstract])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) OR (RARA[Title/Abstract]) OR (SMAD4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) AND (involved[Title/Abstract])"], "references": ["Rawat, Laxminarayan, Nayak, Vijayashree. \"Piperlongumine induces ROS mediated apoptosis by transcriptional regulation of SMAD4/P21/P53 genes and synergizes with doxorubicin in osteosarcoma cells.\" Chemico-biological interactions, 2022, pp. 109832.", "Meng, Xiao-Ming, Huang, Xiao Ru, Xiao, Jun, Chung, Arthur C K, Qin, Wei, Chen, Hai-yong, Lan, Hui Yao. \"Disruption of Smad4 impairs TGF-\u03b2/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro.\" Kidney international, 2012, pp. 266-79.", "Alaeddini, Mojgan, Etemad-Moghadam, Shahroo. \"Are Ski and SnoN Involved in the Tumorigenesis of Oral Squamous Cell Carcinoma Through Smad4?\" Applied immunohistochemistry & molecular morphology : AIMM, 2019, pp. 626-630."]}, "- AR (androgen receptor) is a nuclear receptor that, upon binding to androgens, regulates the expression of target genes involved in cell growth and differentiation.": {"keywords": ["(AR[Title]) AND (androgen receptor[Title])", "(AR[Title]) AND (cell growth[Title])", "(AR[Title]) AND (differentiation[Title])", "(AR[Title/Abstract]) AND (androgen receptor[Title/Abstract])", "(AR[Title/Abstract]) AND (cell growth[Title/Abstract])", "(AR[Title/Abstract]) AND (differentiation[Title/Abstract])"], "references": ["Jamroze, Anmbreen, Chatta, Gurkamal, Tang, Dean G. \"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.\" Cancer letters, 2021, pp. 1-9.", "Narayanan, Ramesh. \"Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.\" Asian journal of urology, 2020, pp. 271-283.", "Zhang, Tian, Karsh, Lawrence I, Nissenblatt, Michael J, Canfield, Steven E. \"Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.\" Clinical genitourinary cancer, 2020, pp. 1-10."]}, "- CREBBP and EP300 are histone acetyltransferases that modulate chromatin structure and facilitate the binding of transcription factors to DNA, thus promoting gene expression.": {"keywords": ["(CREBBP[Title]) OR (EP300[Title]) AND (histone acetyltransferases[Title])", "(CREBBP[Title]) OR (EP300[Title]) AND (chromatin structure[Title])", "(CREBBP[Title]) OR (EP300[Title]) AND (gene expression[Title])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (histone acetyltransferases[Title/Abstract])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (chromatin structure[Title/Abstract])", "(CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Furlan, Tobias, Kirchmair, Alexander, Sampson, Natalie, Puhr, Martin, Gruber, Martina, Trajanoski, Zlatko, Santer, Fr\u00e9d\u00e9ric R, Parson, Walther, Handle, Florian, Culig, Zoran. \"MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.\" The American journal of pathology, 2021, pp. 1094-1107.", "He, Dong-Mei, Wu, Hong, Wu, Xiu-Li, Ding, Li, Xu, Ling, Li, Yang-Qiu. \"The gene expression patterns of BMPR2, EP300, TGF\u03b22, and TNFAIP3 in B-Lymphoma cells.\" Cancer biology & medicine, 2014, pp. 202-7.", "Ohayon, Shay, Yitzhaky, Assif, Hertzberg, Libi. \"Gene expression meta-analysis reveals the up-regulation of CREB1 and CREBBP in Brodmann Area 10 of patients with schizophrenia.\" Psychiatry research, 2020, pp. 113311."]}, "- RARA (retinoic acid receptor alpha) is a nuclear receptor that, upon binding to retinoic acid, forms a heterodimer with retinoid X receptor (RXR) and regulates the expression of target genes involved in cell differentiation and apoptosis.": {"keywords": ["(RARA[Title]) OR (RXR[Title]) AND (retinoic acid receptor[Title])", "(RARA[Title]) OR (RXR[Title]) AND (cell differentiation[Title])", "(RARA[Title]) OR (RXR[Title]) AND (apoptosis[Title])", "(RARA[Title/Abstract]) OR (RXR[Title/Abstract]) AND (retinoic acid receptor[Title/Abstract])", "(RARA[Title/Abstract]) OR (RXR[Title/Abstract]) AND (cell differentiation[Title/Abstract])", "(RARA[Title/Abstract]) OR (RXR[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Veerappan, S, Sch\u00e4che, M, Pertile, K K, Islam, F M A, Chen, C Y, Mitchell, P, Dirani, M, Baird, P N. \"The retinoic acid receptor alpha (RARA) gene is not associated with myopia, hypermetropia, and ocular biometric measures.\" Molecular vision, 2009, pp. 1390-7.", "Doi, Ayano, Ishikawa, Kosuke, Shibata, Nao, Ito, Emi, Fujimoto, Jiro, Yamamoto, Mizuki, Shiga, Hatsuki, Mochizuki, Hiromi, Kawamura, Yoshifumi, Goshima, Naoki, Semba, Kentaro, Watanabe, Shinya. \"Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures.\" Molecular oncology, 2015, pp. 355-64.", "Chen, Zhen-Hua, Wang, Wen-Tao, Huang, Wei, Fang, Ke, Sun, Yu-Meng, Liu, Shu-Rong, Luo, Xue-Qun, Chen, Yue-Qin. \"The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway.\" Cell death and differentiation, 2017, pp. 212-224."]}, "- SMAD4 is a transcription factor that mediates TGF-\u03b2 signaling, regulating gene expression involved in cell growth, differentiation, and apoptosis.": {"keywords": ["(SMAD4[Title]) AND (TGF-\u03b2 signaling[Title])", "(SMAD4[Title]) AND (transcription factor[Title])", "(SMAD4[Title]) AND (cell growth[Title])", "(SMAD4[Title/Abstract]) AND (TGF-\u03b2 signaling[Title/Abstract])", "(SMAD4[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(SMAD4[Title/Abstract]) AND (cell growth[Title/Abstract])"], "references": ["Liu, Anyi, Yu, Chengxin, Qiu, Cheng, Wu, Qi, Huang, Changsheng, Li, Xun, She, Xiaowei, Wan, Kairui, Liu, Lang, Li, Mao, Wang, Zhihong, Chen, Yaqi, Hu, Fuqing, Song, Da, Li, Kangdi, Zhao, Chongchong, Deng, Haiteng, Sun, Xuling, Xu, Feng, Lai, Senyan, Luo, Xuelai, Hu, Junbo, Wang, Guihua. \"PRMT5 methylating SMAD4 activates TGF-\u03b2 signaling and promotes colorectal cancer metastasis.\" Oncogene, 2023, pp. 1572-1584.", "Park, Dong-Seok, Yoon, Gang-Ho, Kim, Eun-Young, Lee, Taehyeong, Kim, Kyuhee, Lee, Peter Cw, Chang, Eun-Ju, Choi, Sun-Cheol. \"Wip1 regulates Smad4 phosphorylation and inhibits TGF-\u03b2 signaling.\" EMBO reports, 2020, pp. e48693.", "Moskowitz, Ivan P, Wang, Jun, Peterson, Michael A, Pu, William T, Mackinnon, Alexander C, Oxburgh, Leif, Chu, Gerald C, Sarkar, Molly, Berul, Charles, Smoot, Leslie, Robertson, Elizabeth J, Schwartz, Robert, Seidman, Jonathan G, Seidman, Christine E. \"Transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac valve development. [corrected].\" Proceedings of the National Academy of Sciences of the United States of America, 2011, pp. 4006-11."]}, "- SMARCB1 is a component of the SWI/SNF chromatin remodeling complex, which modulates chromatin structure and facilitates the binding of transcription factors to DNA, thus regulating gene expression.": {"keywords": ["(SMARCB1[Title]) AND (chromatin remodeling[Title])", "(SMARCB1[Title]) AND (transcription factors[Title])", "(SMARCB1[Title]) AND (gene expression[Title])", "(SMARCB1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(SMARCB1[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(SMARCB1[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Holsten, Till, Bens, Susanne, Oyen, Florian, Nemes, Karolina, Hasselblatt, Martin, Kordes, Uwe, Siebert, Reiner, Fr\u00fchwald, Michael C, Schneppenheim, Reinhard, Sch\u00fcller, Ulrich. \"Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.\" European journal of human genetics : EJHG, 2018, pp. 1083-1093.", "Valencia, Alfredo M, Collings, Clayton K, Dao, Hai T, St Pierre, Roodolph, Cheng, Yung-Chih, Huang, Junwei, Sun, Zhen-Yu, Seo, Hyuk-Soo, Mashtalir, Nazar, Comstock, Dawn E, Bolonduro, Olubusayo, Vangos, Nicholas E, Yeoh, Zoe C, Dornon, Mary Kate, Hermawan, Crystal, Barrett, Lee, Dhe-Paganon, Sirano, Woolf, Clifford J, Muir, Tom W, Kadoch, Cigall. \"Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling.\" Cell, 2019, pp. 1342-1356.e23.", "Chatterjee, Shankha Subhra, Biswas, Mayukh, Boila, Liberalis Debraj, Banerjee, Debasis, Sengupta, Amitava. \"SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia.\" Molecular cancer research : MCR, 2018, pp. 791-804."]}, "In conclusion, this system of interacting proteins plays a prominent role in cell cycle regulation and transcriptional control, ensuring proper cell growth, differentiation, and apoptosis.": {"keywords": [], "references": []}, "The system of interacting proteins primarily performs transcriptional regulation, which involves modulating the rate of gene transcription into mRNA. This process is crucial for controlling gene expression and ensuring proper cellular function.": {"keywords": [], "references": []}, "1. Transcription factors and co-regulators: Several proteins in the system, such as BCL6, CEBPA, ESR2, PGR, RARA, and RXRA, are transcription factors that bind to specific DNA sequences and regulate gene expression. Additionally, proteins like ANKRD11, CREBBP, NCOA3, NCOR1, NCOR2, and NRIP1 act as co-regulators, modulating the activity of transcription factors.": {"keywords": ["(BCL6[Title]) OR (CEBPA[Title]) OR (ESR2[Title]) OR (PGR[Title]) OR (RARA[Title]) OR (RXRA[Title]) OR (ANKRD11[Title]) OR (CREBBP[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (NRIP1[Title]) AND (transcription factors[Title])", "(BCL6[Title]) OR (CEBPA[Title]) OR (ESR2[Title]) OR (PGR[Title]) OR (RARA[Title]) OR (RXRA[Title]) OR (ANKRD11[Title]) OR (CREBBP[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (NRIP1[Title]) AND (co-regulators[Title])", "(BCL6[Title]) OR (CEBPA[Title]) OR (ESR2[Title]) OR (PGR[Title]) OR (RARA[Title]) OR (RXRA[Title]) OR (ANKRD11[Title]) OR (CREBBP[Title]) OR (NCOA3[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (NRIP1[Title]) AND (gene expression[Title])", "(BCL6[Title/Abstract]) OR (CEBPA[Title/Abstract]) OR (ESR2[Title/Abstract]) OR (PGR[Title/Abstract]) OR (RARA[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (ANKRD11[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (NRIP1[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(BCL6[Title/Abstract]) OR (CEBPA[Title/Abstract]) OR (ESR2[Title/Abstract]) OR (PGR[Title/Abstract]) OR (RARA[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (ANKRD11[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (NRIP1[Title/Abstract]) AND (co-regulators[Title/Abstract])", "(BCL6[Title/Abstract]) OR (CEBPA[Title/Abstract]) OR (ESR2[Title/Abstract]) OR (PGR[Title/Abstract]) OR (RARA[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (ANKRD11[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (NCOA3[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (NRIP1[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Gorbacheva, Alisa M, Uvarova, Aksinya N, Ustiugova, Alina S, Bhattacharyya, Arindam, Korneev, Kirill V, Kuprash, Dmitry V, Mitkin, Nikita A. \"EGR1 and RXRA transcription factors link TGF-\u03b2 pathway and CCL2 expression in triple negative breast cancer cells.\" Scientific reports, 2021, pp. 14120.", "Ismail, Sawsan, Elshimali, Yahya, Daoud, Ali, Alshehabi, Zuheir. \"Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.\" Annals of medicine and surgery (2012), 2022, pp. 103786.", "Wang, Hongsheng, Jain, Shweta, Li, Peng, Lin, Jian-Xin, Oh, Jangsuk, Qi, Chenfeng, Gao, Yuanyuan, Sun, Jiafang, Sakai, Tomomi, Naghashfar, Zohreh, Abbasi, Sadia, Kovalchuk, Alexander L, Bolland, Silvia, Nutt, Stephen L, Leonard, Warren J, Morse, Herbert C. \"Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses.\" Proceedings of the National Academy of Sciences of the United States of America, 2019, pp. 9511-9520."]}, "Reasoning: Transcription factors and co-regulators are essential for controlling gene expression, and their interactions can either activate or repress transcription.": {"keywords": [], "references": []}, "2. Chromatin remodeling: Proteins like HDAC3 and HDAC5 are histone deacetylases, which remove acetyl groups from histones, leading to chromatin condensation and transcriptional repression. In contrast, CREBBP is a histone acetyltransferase that adds acetyl groups to histones, promoting chromatin relaxation and transcriptional activation.": {"keywords": ["(HDAC3[Title]) OR (HDAC5[Title]) OR (CREBBP[Title]) AND (chromatin remodeling[Title])", "(HDAC3[Title]) OR (HDAC5[Title]) OR (CREBBP[Title]) AND (histone deacetylases[Title])", "(HDAC3[Title]) OR (HDAC5[Title]) OR (CREBBP[Title]) AND (histone acetyltransferase[Title])", "(HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (histone deacetylases[Title/Abstract])", "(HDAC3[Title/Abstract]) OR (HDAC5[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (histone acetyltransferase[Title/Abstract])"], "references": ["Shu, Guanhua, Kram\u00e1r, Enik\u00f6 A, L\u00f3pez, Alberto J, Huynh, Grace, Wood, Marcelo A, Kwapis, Janine L. \"Deleting HDAC3 rescues long-term memory impairments induced by disruption of the neuron-specific chromatin remodeling subunit BAF53b.\" Learning & memory (Cold Spring Harbor, N.Y.), 2018, pp. 109-114.", "Seo, Jinwon, Min, Soo Kee, Park, Hye-Rim, Kim, Dong Hoon, Kwon, Mi Jung, Kim, Lee Su, Ju, Young-Su. \"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.\" Journal of breast cancer, 2014, pp. 323-31.", "Elmezayen, Ammar D, Yelek\u00e7i, Kemal. \"Homology modeling and <i>in silico</i> design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes.\" Journal of biomolecular structure & dynamics, 2021, pp. 6396-6414."]}, "Reasoning: Chromatin remodeling is a critical aspect of transcriptional regulation, as it determines the accessibility of DNA to transcription factors and other regulatory proteins.": {"keywords": [], "references": []}, "3. Corepressor and coactivator complexes: Several proteins in the system, such as GPS2, NCOR1, NCOR2, and TBL1XR1, are components of corepressor or coactivator complexes. These complexes interact with transcription factors to either repress or activate gene transcription.": {"keywords": ["(GPS2[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (TBL1XR1[Title]) AND (corepressor complexes[Title])", "(GPS2[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (TBL1XR1[Title]) AND (coactivator complexes[Title])", "(GPS2[Title]) OR (NCOR1[Title]) OR (NCOR2[Title]) OR (TBL1XR1[Title]) AND (gene transcription[Title])", "(GPS2[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (corepressor complexes[Title/Abstract])", "(GPS2[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (coactivator complexes[Title/Abstract])", "(GPS2[Title/Abstract]) OR (NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (gene transcription[Title/Abstract])"], "references": ["Oppi, Sara, Nusser-Stein, Stefanie, Blyszczuk, Przemyslaw, Wang, Xu, Jomard, Anne, Marzolla, Vincenzo, Yang, Kangmin, Velagapudi, Srividya, Ward, Liam J, Yuan, Xi-Ming, Geiger, Martin A, Guillaumon, Ana T, Othman, Alaa, Hornemann, Thorsten, Rancic, Zoran, Ryu, Dongryeol, Oosterveer, Maaike H, Osto, Elena, L\u00fcscher, Thomas F, Stein, Sokrates. \"Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR\u03b3 signature.\" European heart journal, 2020, pp. 995-1005.", "M\u00fcller, Lena, Hainberger, Daniela, Stolz, Valentina, Ellmeier, Wilfried. \"NCOR1-a new player on the field of T\u00a0cell development.\" Journal of leukocyte biology, 2018, pp. 1061-1068.", "Wong, Madeline M, Guo, Chun, Zhang, Jinsong. \"Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.\" American journal of clinical and experimental urology, 2014, pp. 169-87."]}, "Reasoning: Corepressor and coactivator complexes play a crucial role in modulating the activity of transcription factors, thereby influencing gene expression.": {"keywords": [], "references": []}, "4. Protein-protein interactions: The proteins in this system interact with each other to form functional complexes, such as the NCoR/SMRT-HDAC3 complex, which includes NCOR1, NCOR2, HDAC3, and TBL1XR1. These interactions are essential for the proper functioning of the transcriptional regulation process.": {"keywords": ["(NCOR1[Title]) OR (NCOR2[Title]) OR (HDAC3[Title]) OR (TBL1XR1[Title]) AND (protein-protein interactions[Title])", "(NCOR1[Title]) OR (NCOR2[Title]) OR (HDAC3[Title]) OR (TBL1XR1[Title]) AND (functional complexes[Title])", "(NCOR1[Title]) OR (NCOR2[Title]) OR (HDAC3[Title]) OR (TBL1XR1[Title]) AND (transcriptional regulation[Title])", "(NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (protein-protein interactions[Title/Abstract])", "(NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (functional complexes[Title/Abstract])", "(NCOR1[Title/Abstract]) OR (NCOR2[Title/Abstract]) OR (HDAC3[Title/Abstract]) OR (TBL1XR1[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])"], "references": ["Yin, Huiqi, Kang, Zhenlong, Zhang, Yingwen, Gong, Yingyun, Liu, Mengrou, Xue, Yanfeng, He, Wenxiu, Wang, Yanfeng, Zhang, Shuya, Xu, Qiushi, Fu, Kaiqiang, Zheng, Bangjin, Xie, Jie, Zhang, Jinwen, Wang, Yuanyuan, Lin, Mingyan, Zhang, Yihan, Feng, Hua, Xin, Changpeng, Guan, Yichun, Huang, Chaoyang, Guo, Xuejiang, Wang, P Jeremy, Baur, Joseph A, Zheng, Ke, Sun, Zheng, Ye, Lan. \"HDAC3 controls male fertility through enzyme-independent transcriptional regulation at the meiotic exit of spermatogenesis.\" Nucleic acids research, 2021, pp. 5106-5123.", "Thatikonda, Sowjanya, Pooladanda, Venkatesh, Sigalapalli, Dilep Kumar, Godugu, Chandraiah. \"Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation.\" Cell death & disease, 2020, pp. 21.", "Nanou, Aikaterini, Toumpeki, Chrisavgi, Lavigne, Matthieu D, Lazou, Vassiliki, Demmers, Jeroen, Paparountas, Triantafillos, Thanos, Dimitris, Katsantoni, Eleni. \"The dual role of LSD1 and HDAC3 in STAT5-dependent transcription is determined by protein interactions, binding affinities, motifs and genomic positions.\" Nucleic acids research, 2017, pp. 142-154."]}, "Reasoning: Protein-protein interactions are critical for the formation of functional complexes that regulate gene transcription.": {"keywords": [], "references": []}, "5. Involvement in cellular processes: The transcriptional regulation performed by this system of interacting proteins is involved in various cellular processes, such as cell differentiation (RUNX1T1), lipid metabolism (RXRA), and immune response (CEBPA).": {"keywords": ["(RUNX1T1[Title]) OR (RXRA[Title]) OR (CEBPA[Title]) AND (transcriptional regulation[Title])", "(RUNX1T1[Title]) OR (RXRA[Title]) OR (CEBPA[Title]) AND (cell differentiation[Title])", "(RUNX1T1[Title]) OR (RXRA[Title]) OR (CEBPA[Title]) AND (lipid metabolism[Title])", "(RUNX1T1[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (CEBPA[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(RUNX1T1[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (CEBPA[Title/Abstract]) AND (cell differentiation[Title/Abstract])", "(RUNX1T1[Title/Abstract]) OR (RXRA[Title/Abstract]) OR (CEBPA[Title/Abstract]) AND (lipid metabolism[Title/Abstract])"], "references": ["Sierra, Beatriz, Triska, Petr, Soares, Pedro, Garcia, Gissel, Perez, Ana B, Aguirre, Eglys, Oliveira, Marisa, Cavadas, Bruno, Regnault, B\u00e9atrice, Alvarez, Mayling, Ruiz, Didye, Samuels, David C, Sakuntabhai, Anavaj, Pereira, Luisa, Guzman, Maria G. \"OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans.\" PLoS pathogens, 2017, pp. e1006220.", "Cui, Ming, Xiao, Zelin, Wang, Yue, Zheng, Minying, Song, Tianqiang, Cai, Xiaoli, Sun, Baodi, Ye, Lihong, Zhang, Xiaodong. \"Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway.\" Cancer research, 2015, pp. 846-57.", "Xu, Jianze, Gao, Jianing, Liu, Junyan, Huang, Xue, Zhang, Huan, Ma, Ao, Ye, Jingwei, Zhang, Xingxia, Li, Yang, Yang, Gang, Yin, Hao, Khan, Ranjha, Li, Tao, Fan, Suixing, Jiang, Xiaohua, Zhang, Yuanwei, Jiang, Hanwei, Ma, Hui, Shi, Qinghua. \"ZFP541 maintains the repression of pre-pachytene transcriptional programs and promotes male meiosis progression.\" Cell reports, 2022, pp. 110540."]}, "Reasoning: The regulation of gene transcription is essential for controlling various cellular processes, ensuring proper cellular function and response to environmental stimuli.": {"keywords": [], "references": []}, "Proteins: ARFRP1, CALR, EGFR, SEC23B, TRAF3, TUSC3": {"keywords": [], "references": []}, "1. EGFR as the central component:": {"keywords": ["(EGFR[Title]) AND (EGFR[Title])", "(EGFR[Title]) AND (central component[Title])", "(EGFR[Title]) AND (Unknown[Title])", "(EGFR[Title/Abstract]) AND (EGFR[Title/Abstract])", "(EGFR[Title/Abstract]) AND (central component[Title/Abstract])", "(EGFR[Title/Abstract]) AND (Unknown[Title/Abstract])"], "references": ["Sabbah, Dima A, Hajjo, Rima, Sweidan, Kamal. \"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.\" Current topics in medicinal chemistry, 2020, pp. 815-834.", "da Cunha Santos, Gilda, Shepherd, Frances A, Tsao, Ming Sound. \"EGFR mutations and lung cancer.\" Annual review of pathology, 2011, pp. 49-69.", "Remon, J, Steuer, C E, Ramalingam, S S, Felip, E. \"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.\" Annals of oncology : official journal of the European Society for Medical Oncology, 2018, pp. i20-i27."]}, "EGFR (Epidermal Growth Factor Receptor) is a receptor tyrosine kinase involved in cell growth, differentiation, and survival. It is the central component of this system, as it interacts with the other proteins and initiates downstream signaling pathways.": {"keywords": ["(EGFR[Title]) AND (cell growth[Title])", "(EGFR[Title]) AND (differentiation[Title])", "(EGFR[Title]) AND (survival[Title])", "(EGFR[Title/Abstract]) AND (cell growth[Title/Abstract])", "(EGFR[Title/Abstract]) AND (differentiation[Title/Abstract])", "(EGFR[Title/Abstract]) AND (survival[Title/Abstract])"], "references": ["Zhu, Cuicui, Zhu, Qingyi, Wu, Zhaomeng, Yin, Yingying, Kang, Dan, Lu, Shan, Liu, Ping. \"Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.\" Journal of cellular physiology, 2018, pp. 1104-1119.", "Roy, Suyasha, Rizvi, Zaigham Abbas, Clarke, Alexander J, Macdonald, Felicity, Pandey, Abhaydeep, Zaiss, Dietmar Martin Werner, Simon, Anna Kathrina, Awasthi, Amit. \"EGFR-HIF1\u03b1 signaling positively regulates the differentiation of IL-9 producing T helper cells.\" Nature communications, 2021, pp. 3182.", "Jiang, Runqiu, Tang, Junwei, Chen, Yun, Deng, Lei, Ji, Jie, Xie, Yu, Wang, Ke, Jia, Wei, Chu, Wen-Ming, Sun, Beicheng. \"The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion.\" Nature communications, 2017, pp. 15129."]}, "2. ARFRP1 and CALR in protein trafficking:": {"keywords": ["(ARFRP1[Title]) OR (CALR[Title]) AND (protein trafficking[Title])", "(ARFRP1[Title]) OR (CALR[Title]) AND (ARFRP1[Title])", "(ARFRP1[Title]) OR (CALR[Title]) AND (CALR[Title])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) AND (protein trafficking[Title/Abstract])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) AND (ARFRP1[Title/Abstract])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) AND (CALR[Title/Abstract])"], "references": ["Yang, Feng, Li, Tiantian, Peng, Ziqing, Liu, Yang, Guo, Yusong. \"The amphipathic helices of Arfrp1 and Arl14 are sufficient to determine subcellular localizations.\" The Journal of biological chemistry, 2020, pp. 16643-16654.", "Wilhelmi, Ilka, Grunwald, Stephan, Gimber, Niclas, Popp, Oliver, Dittmar, Gunnar, Arumughan, Anup, Wanker, Erich E, Laeger, Thomas, Schmoranzer, Jan, Daumke, Oliver, Sch\u00fcrmann, Annette. \"The ARFRP1-dependent Golgi scaffolding protein GOPC is required for insulin secretion from pancreatic \u03b2-cells.\" Molecular metabolism, 2021, pp. 101151.", "Jaschke, Alexander, Chung, Bomee, Hesse, Deike, Kluge, Reinhart, Zahn, Claudia, Moser, Markus, Petzke, Klaus-J\u00fcrgen, Brigelius-Floh\u00e9, Regina, Puchkov, Dmytro, Koepsell, Hermann, Heeren, Joerg, Joost, Hans-Georg, Sch\u00fcrmann, Annette. \"The GTPase ARFRP1 controls the lipidation of chylomicrons in the Golgi of the intestinal epithelium.\" Human molecular genetics, 2012, pp. 3128-42."]}, "ARFRP1 (ADP-ribosylation factor-related protein 1) is a small GTPase involved in vesicular trafficking. CALR (Calreticulin) is a chaperone protein that assists in protein folding and quality control in the endoplasmic reticulum (ER). Both proteins are involved in the trafficking and maturation of EGFR, ensuring its proper localization and function.": {"keywords": ["(ARFRP1[Title]) OR (CALR[Title]) OR (EGFR[Title]) AND (vesicular trafficking[Title])", "(ARFRP1[Title]) OR (CALR[Title]) OR (EGFR[Title]) AND (protein folding[Title])", "(ARFRP1[Title]) OR (CALR[Title]) OR (EGFR[Title]) AND (endoplasmic reticulum[Title])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (vesicular trafficking[Title/Abstract])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (protein folding[Title/Abstract])", "(ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (endoplasmic reticulum[Title/Abstract])"], "references": ["Xie, Sijie, Jiang, Xiaoxue, Qin, Rushi, Song, Shuting, Lu, Yanan, Wang, Liyan, Chen, Yingjie, Lu, Dongdong. \"miR-1307 promotes hepatocarcinogenesis by CALR-OSTC-endoplasmic reticulum protein folding pathway.\" iScience, 2021, pp. 103271.", "Xu, Zheng, Zhao, Yunjie, Zhong, Peng, Wang, Jingying, Weng, Qiaoyou, Qian, Yuanyuan, Han, Jibo, Zou, Chunpeng, Liang, Guang. \"EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress.\" Oncotarget, 2017, pp. 32655-32667.", "Fucikova, Jitka, Spisek, Radek, Kroemer, Guido, Galluzzi, Lorenzo. \"Calreticulin and cancer.\" Cell research, 2021, pp. 5-16."]}, "SEC23B (Sec23 homolog B) is a component of the COPII complex, which is responsible for the transport of proteins from the ER to the Golgi apparatus. It plays a role in the trafficking of EGFR, ensuring its proper transport and processing.": {"keywords": ["(SEC23B[Title]) OR (EGFR[Title]) AND (COPII complex[Title])", "(SEC23B[Title]) OR (EGFR[Title]) AND (protein transport[Title])", "(SEC23B[Title]) OR (EGFR[Title]) AND (Golgi apparatus[Title])", "(SEC23B[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (COPII complex[Title/Abstract])", "(SEC23B[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (protein transport[Title/Abstract])", "(SEC23B[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (Golgi apparatus[Title/Abstract])"], "references": ["Ohashi, Yoshimi, Okamura, Mutsumi, Katayama, Ryohei, Fang, Siyang, Tsutsui, Saki, Akatsuka, Akinobu, Shan, Mingde, Choi, Hyeong-Wook, Fujita, Naoya, Yoshimatsu, Kentaro, Shiina, Isamu, Yamori, Takao, Dan, Shingo. \"Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.\" Oncotarget, 2018, pp. 1641-1655.", "Tang, B L, Kausalya, J, Low, D Y, Lock, M L, Hong, W. \"A family of mammalian proteins homologous to yeast Sec24p.\" Biochemical and biophysical research communications, 1999, pp. 679-84.", "Lang, Michael R, Lapierre, Lynne A, Frotscher, Michael, Goldenring, James R, Knapik, Ela W. \"Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation.\" Nature genetics, 2006, pp. 1198-203."]}, "TRAF3 (TNF Receptor-Associated Factor 3) is an adaptor protein that mediates signal transduction from various receptors, including EGFR. It plays a role in the activation of downstream signaling pathways, such as the NF-\u03baB and MAPK pathways, which regulate cell growth, differentiation, and survival.": {"keywords": ["(TRAF3[Title]) OR (EGFR[Title]) OR (NF-\u03baB[Title]) OR (MAPK[Title]) AND (signal transduction[Title])", "(TRAF3[Title]) OR (EGFR[Title]) OR (NF-\u03baB[Title]) OR (MAPK[Title]) AND (activation[Title])", "(TRAF3[Title]) OR (EGFR[Title]) OR (NF-\u03baB[Title]) OR (MAPK[Title]) AND (pathways[Title])", "(TRAF3[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (NF-\u03baB[Title/Abstract]) OR (MAPK[Title/Abstract]) AND (signal transduction[Title/Abstract])", "(TRAF3[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (NF-\u03baB[Title/Abstract]) OR (MAPK[Title/Abstract]) AND (activation[Title/Abstract])", "(TRAF3[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (NF-\u03baB[Title/Abstract]) OR (MAPK[Title/Abstract]) AND (pathways[Title/Abstract])"], "references": ["Gandhi, Manav, Nair, Sujit. \"New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.\" Life sciences, 2020, pp. 118123.", "Jin, Haojie, Shi, Yaoping, Lv, Yuanyuan, Yuan, Shengxian, Ramirez, Christel F A, Lieftink, Cor, Wang, Liqin, Wang, Siying, Wang, Cun, Dias, Matheus Henrique, Jochems, Fleur, Yang, Yuan, Bosma, Astrid, Hijmans, E Marielle, de Groot, Marnix H P, Vegna, Serena, Cui, Dan, Zhou, Yangyang, Ling, Jing, Wang, Hui, Guo, Yuchen, Zheng, Xingling, Isima, Nikita, Wu, Haiqiu, Sun, Chong, Beijersbergen, Roderick L, Akkari, Leila, Zhou, Weiping, Zhai, Bo, Qin, Wenxin, Bernards, Ren\u00e9. \"EGFR activation limits the response of liver cancer to lenvatinib.\" Nature, 2021, pp. 730-734.", "Zhao, Weiming, Ma, Li, Cai, Cheng, Gong, Xiaohui. \"Caffeine Inhibits NLRP3 Inflammasome Activation by Suppressing MAPK/NF-\u03baB and A2aR Signaling in LPS-Induced THP-1 Macrophages.\" International journal of biological sciences, 2019, pp. 1571-1581."]}, "TUSC3 (Tumor Suppressor Candidate 3) is a subunit of the oligosaccharyltransferase (OST) complex, which is involved in the N-linked glycosylation of proteins. It plays a role in the glycosylation of EGFR, which is essential for its proper folding, stability, and function.": {"keywords": ["(TUSC3[Title]) OR (EGFR[Title]) AND (glycosylation[Title])", "(TUSC3[Title]) OR (EGFR[Title]) AND (oligosaccharyltransferase[Title])", "(TUSC3[Title]) OR (EGFR[Title]) AND (EGFR[Title])", "(TUSC3[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (glycosylation[Title/Abstract])", "(TUSC3[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (oligosaccharyltransferase[Title/Abstract])", "(TUSC3[Title/Abstract]) OR (EGFR[Title/Abstract]) AND (EGFR[Title/Abstract])"], "references": ["Mohorko, Elisabeth, Owen, Robin L, Maloj\u010di\u0107, Goran, Brozzo, Maurice S, Aebi, Markus, Glockshuber, Rudi. \"Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation.\" Structure (London, England : 1993), 2014, pp. 590-601.", "Lopez Sambrooks, Cecilia, Baro, Marta, Quijano, Amanda, Narayan, Azeet, Cui, Wei, Greninger, Patricia, Egan, Regina, Patel, Abhijit, Benes, Cyril H, Saltzman, W Mark, Contessa, Joseph N. \"Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.\" Cancer research, 2018, pp. 5094-5106.", "Sabbah, Dima A, Hajjo, Rima, Sweidan, Kamal. \"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.\" Current topics in medicinal chemistry, 2020, pp. 815-834."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is EGFR-mediated signaling. The proteins ARFRP1, CALR, SEC23B, and TUSC3 are involved in the trafficking, maturation, and glycosylation of EGFR, ensuring its proper function. TRAF3 mediates signal transduction from EGFR, leading to the activation of downstream signaling pathways that regulate various cellular processes.": {"keywords": ["(EGFR[Title]) OR (ARFRP1[Title]) OR (CALR[Title]) OR (SEC23B[Title]) OR (TUSC3[Title]) OR (TRAF3[Title]) AND (EGFR-mediated signaling[Title])", "(EGFR[Title]) OR (ARFRP1[Title]) OR (CALR[Title]) OR (SEC23B[Title]) OR (TUSC3[Title]) OR (TRAF3[Title]) AND (protein trafficking[Title])", "(EGFR[Title]) OR (ARFRP1[Title]) OR (CALR[Title]) OR (SEC23B[Title]) OR (TUSC3[Title]) OR (TRAF3[Title]) AND (signal transduction[Title])", "(EGFR[Title/Abstract]) OR (ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (SEC23B[Title/Abstract]) OR (TUSC3[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (EGFR-mediated signaling[Title/Abstract])", "(EGFR[Title/Abstract]) OR (ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (SEC23B[Title/Abstract]) OR (TUSC3[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (protein trafficking[Title/Abstract])", "(EGFR[Title/Abstract]) OR (ARFRP1[Title/Abstract]) OR (CALR[Title/Abstract]) OR (SEC23B[Title/Abstract]) OR (TUSC3[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (signal transduction[Title/Abstract])"], "references": ["Liu, Xiaojing, Li, Qing, Huang, Ping, Tong, Dongdong, Wu, Haitao, Zhang, Fenghe. \"EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.\" Journal of cellular biochemistry, 2018, pp. 8368-8377.", "Pines, Gur, K\u00f6stler, Wolfgang J, Yarden, Yosef. \"Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.\" FEBS letters, 2010, pp. 2699-706.", "Lo, Hui-Wen, Hsu, Sheng-Chieh, Hung, Mien-Chie. \"EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.\" Breast cancer research and treatment, 2006, pp. 211-8."]}, "The most prominent biological process performed by this system of interacting proteins is receptor tyrosine kinase (RTK) signaling. This process is crucial for cellular communication, growth, and differentiation.": {"keywords": [], "references": []}, "1. RTK activation: The presence of EGF, EGFR, ERBB2, ERBB3, ERBB4, PDGFRA, and RET indicates that this system involves multiple RTKs. EGF activates EGFR, while ERBB2, ERBB3, and ERBB4 are members of the same family. PDGFRA and RET are also RTKs. Activation of these receptors occurs upon ligand binding, leading to receptor dimerization and autophosphorylation of tyrosine residues.": {"keywords": ["(EGF[Title]) OR (EGFR[Title]) OR (ERBB2[Title]) OR (ERBB3[Title]) OR (ERBB4[Title]) OR (PDGFRA[Title]) OR (RET[Title]) AND (RTK activation[Title])", "(EGF[Title]) OR (EGFR[Title]) OR (ERBB2[Title]) OR (ERBB3[Title]) OR (ERBB4[Title]) OR (PDGFRA[Title]) OR (RET[Title]) AND (ligand binding[Title])", "(EGF[Title]) OR (EGFR[Title]) OR (ERBB2[Title]) OR (ERBB3[Title]) OR (ERBB4[Title]) OR (PDGFRA[Title]) OR (RET[Title]) AND (receptor dimerization[Title])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (ERBB2[Title/Abstract]) OR (ERBB3[Title/Abstract]) OR (ERBB4[Title/Abstract]) OR (PDGFRA[Title/Abstract]) OR (RET[Title/Abstract]) AND (RTK activation[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (ERBB2[Title/Abstract]) OR (ERBB3[Title/Abstract]) OR (ERBB4[Title/Abstract]) OR (PDGFRA[Title/Abstract]) OR (RET[Title/Abstract]) AND (ligand binding[Title/Abstract])", "(EGF[Title/Abstract]) OR (EGFR[Title/Abstract]) OR (ERBB2[Title/Abstract]) OR (ERBB3[Title/Abstract]) OR (ERBB4[Title/Abstract]) OR (PDGFRA[Title/Abstract]) OR (RET[Title/Abstract]) AND (receptor dimerization[Title/Abstract])"], "references": ["Shao, Qiang, Zhu, Weiliang. \"Ligand binding effects on the activation of the EGFR extracellular domain.\" Physical chemistry chemical physics : PCCP, 2019, pp. 8141-8151.", "Azimzadeh Irani, Maryam, Kannan, Srinivasaraghavan, Verma, Chandra. \"Role of N-glycosylation in EGFR ectodomain ligand binding.\" Proteins, 2017, pp. 1529-1549.", "Cho, Jeonghee. \"Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective.\" BMB reports, 2020, pp. 133-141."]}, "2. Downstream signaling: The proteins FRS2, INPPL1, IRS1, JAK1, JAK2, PIK3R1, PLCG2, PTPN11, STAT3, and STAT5A are involved in downstream signaling pathways. FRS2, INPPL1, and IRS1 act as adaptor proteins, linking RTKs to downstream effectors. JAK1 and JAK2 are non-receptor tyrosine kinases that can be activated by RTKs, leading to the activation of STAT3 and STAT5A, which are transcription factors. PIK3R1 is a regulatory subunit of PI3K, which is involved in the PI3K/AKT pathway. PLCG2 is a phospholipase that generates second messengers, leading to the activation of protein kinase C (PKC) and calcium signaling. PTPN11 is a protein tyrosine phosphatase that can both positively and negatively regulate RTK signaling.": {"keywords": ["(FRS2[Title]) OR (INPPL1[Title]) OR (IRS1[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (PIK3R1[Title]) OR (PLCG2[Title]) OR (PTPN11[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) AND (downstream signaling[Title])", "(FRS2[Title]) OR (INPPL1[Title]) OR (IRS1[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (PIK3R1[Title]) OR (PLCG2[Title]) OR (PTPN11[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) AND (adaptor proteins[Title])", "(FRS2[Title]) OR (INPPL1[Title]) OR (IRS1[Title]) OR (JAK1[Title]) OR (JAK2[Title]) OR (PIK3R1[Title]) OR (PLCG2[Title]) OR (PTPN11[Title]) OR (STAT3[Title]) OR (STAT5A[Title]) AND (transcription factors[Title])", "(FRS2[Title/Abstract]) OR (INPPL1[Title/Abstract]) OR (IRS1[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) OR (PLCG2[Title/Abstract]) OR (PTPN11[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) AND (downstream signaling[Title/Abstract])", "(FRS2[Title/Abstract]) OR (INPPL1[Title/Abstract]) OR (IRS1[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) OR (PLCG2[Title/Abstract]) OR (PTPN11[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) AND (adaptor proteins[Title/Abstract])", "(FRS2[Title/Abstract]) OR (INPPL1[Title/Abstract]) OR (IRS1[Title/Abstract]) OR (JAK1[Title/Abstract]) OR (JAK2[Title/Abstract]) OR (PIK3R1[Title/Abstract]) OR (PLCG2[Title/Abstract]) OR (PTPN11[Title/Abstract]) OR (STAT3[Title/Abstract]) OR (STAT5A[Title/Abstract]) AND (transcription factors[Title/Abstract])"], "references": ["Tong, Wei, Zhang, Jing, Lodish, Harvey F. \"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.\" Blood, 2005, pp. 4604-12.", "Yamauchi, K, Pessin, J E. \"Insulin receptor substrate-1 (IRS1) and Shc compete for a limited pool of Grb2 in mediating insulin downstream signaling.\" The Journal of biological chemistry, 1994, pp. 31107-14.", "Sato, Takuya, Gotoh, Noriko. \"The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.\" Expert opinion on therapeutic targets, 2009, pp. 689-700."]}, "3. Negative regulation: The proteins BCR, CBL, and CBLB are involved in the negative regulation of RTK signaling. BCR is a negative regulator of the JAK/STAT pathway. CBL and CBLB are E3 ubiquitin ligases that target activated RTKs for degradation, thus attenuating the signaling.": {"keywords": ["(BCR[Title]) OR (CBL[Title]) OR (CBLB[Title]) OR (RTK[Title]) OR (JAK/STAT[Title]) AND (negative regulation[Title])", "(BCR[Title]) OR (CBL[Title]) OR (CBLB[Title]) OR (RTK[Title]) OR (JAK/STAT[Title]) AND (RTK signaling[Title])", "(BCR[Title]) OR (CBL[Title]) OR (CBLB[Title]) OR (RTK[Title]) OR (JAK/STAT[Title]) AND (E3 ubiquitin[Title])", "(BCR[Title/Abstract]) OR (CBL[Title/Abstract]) OR (CBLB[Title/Abstract]) OR (RTK[Title/Abstract]) OR (JAK/STAT[Title/Abstract]) AND (negative regulation[Title/Abstract])", "(BCR[Title/Abstract]) OR (CBL[Title/Abstract]) OR (CBLB[Title/Abstract]) OR (RTK[Title/Abstract]) OR (JAK/STAT[Title/Abstract]) AND (RTK signaling[Title/Abstract])", "(BCR[Title/Abstract]) OR (CBL[Title/Abstract]) OR (CBLB[Title/Abstract]) OR (RTK[Title/Abstract]) OR (JAK/STAT[Title/Abstract]) AND (E3 ubiquitin[Title/Abstract])"], "references": ["Tang, Rong, Langdon, Wallace Y, Zhang, Jian. \"Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases.\" Frontiers in endocrinology, 2022, pp. 971162.", "Huang, Fang, Gu, Hua. \"Negative regulation of lymphocyte development and function by the Cbl family of proteins.\" Immunological reviews, 2008, pp. 229-38.", "Thien, Christine B F, Langdon, Wallace Y. \"c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.\" The Biochemical journal, 2005, pp. 153-66."]}, "4. CSF3R involvement: CSF3R is a receptor for colony-stimulating factor 3 (CSF3), which is involved in the regulation of granulocyte production and function. Although not an RTK, its presence in this system suggests a potential crosstalk between RTK signaling and CSF3R-mediated processes.": {"keywords": ["(CSF3R[Title]) OR (CSF3[Title]) AND (CSF3R[Title])", "(CSF3R[Title]) OR (CSF3[Title]) AND (granulocyte production[Title])", "(CSF3R[Title]) OR (CSF3[Title]) AND (RTK signaling[Title])", "(CSF3R[Title/Abstract]) OR (CSF3[Title/Abstract]) AND (CSF3R[Title/Abstract])", "(CSF3R[Title/Abstract]) OR (CSF3[Title/Abstract]) AND (granulocyte production[Title/Abstract])", "(CSF3R[Title/Abstract]) OR (CSF3[Title/Abstract]) AND (RTK signaling[Title/Abstract])"], "references": ["Maxson, Julia E, Gotlib, Jason, Pollyea, Daniel A, Fleischman, Angela G, Agarwal, Anupriya, Eide, Christopher A, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K, Tognon, Cristina E, Pond, J Blake, Collins, Robert H, Goueli, Basem, Oh, Stephen T, Deininger, Michael W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, Tyner, Jeffrey W. \"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.\" The New England journal of medicine, 2013, pp. 1781-90.", "Tefferi, A, Thiele, J, Vannucchi, A M, Barbui, T. \"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.\" Leukemia, 2014, pp. 1407-13.", "Wang, Biao, Wen, Lijun, Wang, Zheng, Chen, Suning, Qiu, Huiying. \"Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.\" Clinical lymphoma, myeloma & leukemia, 2022, pp. 393-404."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is receptor tyrosine kinase signaling, which plays a critical role in cellular communication, growth, and differentiation. The system includes proteins involved in RTK activation, downstream signaling, and negative regulation, as well as potential crosstalk with other signaling pathways.": {"keywords": [], "references": []}, "The primary biological process performed by this system of interacting proteins is the ubiquitin-proteasome system, which is responsible for the degradation of proteins in the cell. This process is essential for maintaining cellular homeostasis and regulating various cellular processes.": {"keywords": [], "references": []}, "1. CUL3: Cullin-3 (CUL3) is a scaffold protein that forms the core of the Cullin-RING E3 ubiquitin ligase complex. This complex is responsible for the ubiquitination of target proteins, marking them for degradation by the proteasome. CUL3's role as a scaffold protein is crucial for the assembly and function of the E3 ligase complex.": {"keywords": ["(CUL3[Title]) AND (scaffold protein[Title])", "(CUL3[Title]) AND (ubiquitination[Title])", "(CUL3[Title]) AND (proteasome[Title])", "(CUL3[Title/Abstract]) AND (scaffold protein[Title/Abstract])", "(CUL3[Title/Abstract]) AND (ubiquitination[Title/Abstract])", "(CUL3[Title/Abstract]) AND (proteasome[Title/Abstract])"], "references": ["Li, Xuan, Yang, Kai-Bin, Chen, Wei, Mai, Jia, Wu, Xiao-Qi, Sun, Ting, Wu, Rui-Yan, Jiao, Lin, Li, Dan-Dan, Ji, Jiao, Zhang, Hai-Liang, Yu, Yan, Chen, Yu-Hong, Feng, Gong-Kan, Deng, Rong, Li, Jun-Dong, Zhu, Xiao-Feng. \"CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression.\" Autophagy, 2021, pp. 4323-4340.", "Zhai, Fengguang, Li, Jingyun, Ye, Meng, Jin, Xiaofeng. \"The functions and effects of CUL3-E3 ligases mediated non-degradative ubiquitination.\" Gene, 2022, pp. 146562.", "Saritas, Turgay, Cuevas, Catherina A, Ferdaus, Mohammed Z, Kuppe, Christoph, Kramann, Rafael, Moeller, Marcus J, Floege, J\u00fcrgen, Singer, Jeffrey D, McCormick, James A. \"Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis.\" Scientific reports, 2019, pp. 4596."]}, "2. ELOC: Elongin C (ELOC) is a subunit of the Elongin BC complex, which acts as an adaptor protein for Cullin-RING E3 ubiquitin ligases. ELOC's interaction with CUL3 and other proteins in the complex is essential for the proper functioning of the ubiquitin-proteasome system.": {"keywords": ["(ELOC[Title]) OR (CUL3[Title]) AND (Elongin BC complex[Title])", "(ELOC[Title]) OR (CUL3[Title]) AND (Cullin-RING E3 ubiquitin ligases[Title])", "(ELOC[Title]) OR (CUL3[Title]) AND (ubiquitin-proteasome system[Title])", "(ELOC[Title/Abstract]) OR (CUL3[Title/Abstract]) AND (Elongin BC complex[Title/Abstract])", "(ELOC[Title/Abstract]) OR (CUL3[Title/Abstract]) AND (Cullin-RING E3 ubiquitin ligases[Title/Abstract])", "(ELOC[Title/Abstract]) OR (CUL3[Title/Abstract]) AND (ubiquitin-proteasome system[Title/Abstract])"], "references": ["Schieven, Sebastiaan M, Traets, Joleen J H, Vliet, Alex V, Baalen, Martijn V, Song, Ji-Ying, Guimaraes, Marcos Da Silva, Kuilman, Thomas, Peeper, Daniel S. \"The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma.\" Molecular cancer research : MCR, 2023, pp. 428-443.", "Cardote, Teresa A F, Ciulli, Alessio. \"Structure-Guided Design of Peptides as Tools to Probe the Protein-Protein Interaction between Cullin-2 and Elongin\u2005BC Substrate Adaptor in Cullin RING E3 Ubiquitin Ligases.\" ChemMedChem, 2017, pp. 1491-1496.", "Xing, Hongyan, Hong, Yiling, Sarge, Kevin D. \"PEST sequences mediate heat shock factor 2 turnover by interacting with the Cul3 subunit of the Cul3-RING ubiquitin ligase.\" Cell stress & chaperones, 2010, pp. 301-8."]}, "3. FBXW7: F-box and WD repeat domain-containing 7 (FBXW7) is a substrate recognition component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex. FBXW7 binds to specific target proteins, allowing the E3 ligase complex to ubiquitinate them for degradation.": {"keywords": ["(FBXW7[Title]) OR (SCF[Title]) OR (SKP1[Title]) OR (CUL1[Title]) AND (ubiquitin ligase[Title])", "(FBXW7[Title]) OR (SCF[Title]) OR (SKP1[Title]) OR (CUL1[Title]) AND (substrate recognition[Title])", "(FBXW7[Title]) OR (SCF[Title]) OR (SKP1[Title]) OR (CUL1[Title]) AND (protein degradation[Title])", "(FBXW7[Title/Abstract]) OR (SCF[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(FBXW7[Title/Abstract]) OR (SCF[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) AND (substrate recognition[Title/Abstract])", "(FBXW7[Title/Abstract]) OR (SCF[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) AND (protein degradation[Title/Abstract])"], "references": ["Baek, Kheewoong, Scott, Daniel C, Henneberg, Lukas T, King, Moeko T, Mann, Matthias, Schulman, Brenda A. \"Systemwide disassembly and assembly of SCF ubiquitin ligase complexes.\" Cell, 2023, pp. 1895-1911.e21.", "Zheng, Ning, Schulman, Brenda A, Song, Langzhou, Miller, Julie J, Jeffrey, Philip D, Wang, Ping, Chu, Claire, Koepp, Deanna M, Elledge, Stephen J, Pagano, Michele, Conaway, Ronald C, Conaway, Joan W, Harper, J Wade, Pavletich, Nikola P. \"Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.\" Nature, 2002, pp. 703-9.", "Orlicky, Stephen, Tang, Xiaojing, Neduva, Victor, Elowe, Nadine, Brown, Eric D, Sicheri, Frank, Tyers, Mike. \"An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase.\" Nature biotechnology, 2010, pp. 733-7."]}, "4. HSP90AA1: Heat shock protein 90 alpha family class A member 1 (HSP90AA1) is a molecular chaperone that assists in the folding and stabilization of client proteins. HSP90AA1 can interact with the ubiquitin-proteasome system to regulate the degradation of its client proteins, ensuring proper protein homeostasis.": {"keywords": ["(HSP90AA1[Title]) AND (molecular chaperone[Title])", "(HSP90AA1[Title]) AND (protein homeostasis[Title])", "(HSP90AA1[Title]) AND (ubiquitin-proteasome[Title])", "(HSP90AA1[Title/Abstract]) AND (molecular chaperone[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (protein homeostasis[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (ubiquitin-proteasome[Title/Abstract])"], "references": ["Zuehlke, Abbey D, Beebe, Kristin, Neckers, Len, Prince, Thomas. \"Regulation and function of the human HSP90AA1 gene.\" Gene, 2015, pp. 8-16.", "Yang, Cai-Xia, Chen, Lu, Mou, Qiao, Yang, Yu-Wei, Wang, Yi, Yin, Zongjun, Du, Zhi-Qiang. \"HSP90AA1 promotes viability and lactate production but inhibits hormone secretion of porcine immature Sertoli cells.\" Theriogenology, 2022, pp. 64-74.", "Badri, T M, Chen, K L, Alsiddig, M A, Li, Lian, Cai, Yafei, Wang, G L. \"Genetic polymorphism in Hsp90AA1 gene is associated with the thermotolerance in Chinese Holstein cows.\" Cell stress & chaperones, 2018, pp. 639-651."]}, "5. PARK2: Parkin RBR E3 ubiquitin-protein ligase (PARK2) is an E3 ubiquitin ligase involved in the ubiquitination and degradation of proteins associated with mitochondrial quality control. PARK2's role in the ubiquitin-proteasome system is essential for maintaining mitochondrial function and preventing cellular damage.": {"keywords": ["(PARK2[Title]) AND (ubiquitin ligase[Title])", "(PARK2[Title]) AND (mitochondrial quality control[Title])", "(PARK2[Title]) AND (cellular damage[Title])", "(PARK2[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(PARK2[Title/Abstract]) AND (mitochondrial quality control[Title/Abstract])", "(PARK2[Title/Abstract]) AND (cellular damage[Title/Abstract])"], "references": ["Zhou, Xiaofeng, Li, Yajie, Wang, Weilong, Wang, Sujie, Hou, Jinghan, Zhang, Aijia, Lv, Benjie, Gao, Can, Yan, Ziyi, Pang, Dan, Lu, Kui, Ahmad, Nor Hazwani, Wang, Lidong, Zhu, Jian, Zhang, Lichen, Zhuang, Ting, Li, Xiumin. \"Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.\" Theranostics, 2020, pp. 9443-9457.", "Montagnani, Valentina, Maresca, Luisa, Apollo, Alessandro, Pepe, Sara, Carr, Ryan M, Fernandez-Zapico, Martin E, Stecca, Barbara. \"E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.\" The Journal of biological chemistry, 2020, pp. 16058-16071.", "Bingol, Baris, Tea, Joy S, Phu, Lilian, Reichelt, Mike, Bakalarski, Corey E, Song, Qinghua, Foreman, Oded, Kirkpatrick, Donald S, Sheng, Morgan. \"The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.\" Nature, 2014, pp. 370-5."]}, "6. SKP1: S-phase kinase-associated protein 1 (SKP1) is an adaptor protein that forms part of the SCF E3 ubiquitin ligase complex. SKP1 interacts with F-box proteins, such as FBXW7, to facilitate the ubiquitination of target proteins.": {"keywords": ["(SKP1[Title]) OR (FBXW7[Title]) AND (ubiquitin ligase[Title])", "(SKP1[Title]) OR (FBXW7[Title]) AND (adaptor protein[Title])", "(SKP1[Title]) OR (FBXW7[Title]) AND (F-box proteins[Title])", "(SKP1[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(SKP1[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (adaptor protein[Title/Abstract])", "(SKP1[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (F-box proteins[Title/Abstract])"], "references": ["Zheng, Ning, Schulman, Brenda A, Song, Langzhou, Miller, Julie J, Jeffrey, Philip D, Wang, Ping, Chu, Claire, Koepp, Deanna M, Elledge, Stephen J, Pagano, Michele, Conaway, Ronald C, Conaway, Joan W, Harper, J Wade, Pavletich, Nikola P. \"Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.\" Nature, 2002, pp. 703-9.", "Kourtis, Nikos, Strikoudis, Alexandros, Aifantis, Iannis. \"Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond.\" Current opinion in cell biology, 2015, pp. 28-34.", "Li, Rongbo, Zhang, Yan, Garg, Ankur, Sui, Pengfei, Sun, Xin. \"E3 ubiquitin ligase FBXW7 balances airway cell fates.\" Developmental biology, 2022, pp. 89-97."]}, "7. STK11: Serine/threonine kinase 11 (STK11) is a tumor suppressor protein that regulates cell growth and polarity. STK11 can be ubiquitinated and degraded by the ubiquitin-proteasome system, highlighting the importance of this system in regulating cellular processes.": {"keywords": ["(STK11[Title]) AND (tumor suppressor[Title])", "(STK11[Title]) AND (cell growth[Title])", "(STK11[Title]) AND (ubiquitin-proteasome[Title])", "(STK11[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(STK11[Title/Abstract]) AND (cell growth[Title/Abstract])", "(STK11[Title/Abstract]) AND (ubiquitin-proteasome[Title/Abstract])"], "references": ["Marinaccio, Christian, Suraneni, Praveen, Celik, Hamza, Volk, Andrew, Wen, Qiang Jeremy, Ling, Te, Bulic, Marinka, Lasho, Terra, Koche, Richard P, Famulare, Christopher A, Farnoud, Noushin, Stein, Brady, Schieber, Michael, Gurbuxani, Sandeep, Root, David E, Younger, Scott T, Hoffman, Ronald, Gangat, Naseema, Ntziachristos, Panagiotis, Chandel, Navdeep S, Levine, Ross L, Rampal, Raajit K, Challen, Grant A, Tefferi, Ayalew, Crispino, John D. \"LKB1/<i>STK11</i> Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms.\" Cancer discovery, 2021, pp. 1398-1410.", "Rho, Seung Bae, Byun, Hyun Jung, Kim, Boh-Ram, Lee, Chang Hoon. \"LKB1/STK11 Tumor Suppressor Reduces Angiogenesis by Directly Interacting with VEGFR2 in Tumorigenesis.\" Biomolecules & therapeutics, 2023, pp. 456-465.", "Wagner, Tracy M, Mullally, James E, Fitzpatrick, F A. \"Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation.\" The Journal of biological chemistry, 2006, pp. 2598-604."]}, "8. VHL: Von Hippel-Lindau tumor suppressor (VHL) is a component of the VCB-CUL2 E3 ubiquitin ligase complex, which targets hypoxia-inducible factor (HIF) for degradation. VHL's role in the ubiquitin-proteasome system is crucial for maintaining cellular oxygen homeostasis and preventing tumor formation.": {"keywords": ["(VHL[Title]) OR (HIF[Title]) AND (ubiquitin ligase[Title])", "(VHL[Title]) OR (HIF[Title]) AND (oxygen homeostasis[Title])", "(VHL[Title]) OR (HIF[Title]) AND (tumor suppressor[Title])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (oxygen homeostasis[Title/Abstract])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (tumor suppressor[Title/Abstract])"], "references": ["Buckley, Dennis L, Van Molle, Inge, Gareiss, Peter C, Tae, Hyun Seop, Michel, Julien, Noblin, Devin J, Jorgensen, William L, Ciulli, Alessio, Crews, Craig M. \"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1\u03b1 interaction.\" Journal of the American Chemical Society, 2012, pp. 4465-8.", "Di Gregorio, Jacopo, Cilenti, Lucia, Ambivero, Camilla T, Andl, Thomas, Liao, Ronglih, Zervos, Antonis S. \"UBXN7 cofactor of CRL3<sup>KEAP1</sup> and CRL2<sup>VHL</sup> ubiquitin ligase complexes mediates reciprocal regulation of NRF2 and HIF-1\u03b1 proteins.\" Biochimica et biophysica acta. Molecular cell research, 2021, pp. 118963.", "Zhang, Bichao, Kirn, Lauren A, Burke, Richard. \"The Vhl E3 ubiquitin ligase complex regulates melanisation via sima, cnc and the copper import protein Ctr1A.\" Biochimica et biophysica acta. Molecular cell research, 2021, pp. 119022."]}, "In conclusion, the primary biological process performed by this system of interacting proteins is the ubiquitin-proteasome system, which is essential for maintaining cellular homeostasis and regulating various cellular processes. The proteins CUL3, ELOC, FBXW7, HSP90AA1, PARK2, SKP1, STK11, and VHL all play crucial roles in this system, either as components of E3 ubiquitin ligase complexes or as regulators of protein degradation.": {"keywords": ["(CUL3[Title]) OR (ELOC[Title]) OR (FBXW7[Title]) OR (HSP90AA1[Title]) OR (PARK2[Title]) OR (SKP1[Title]) OR (STK11[Title]) OR (VHL[Title]) AND (ubiquitin-proteasome system[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (FBXW7[Title]) OR (HSP90AA1[Title]) OR (PARK2[Title]) OR (SKP1[Title]) OR (STK11[Title]) OR (VHL[Title]) AND (cellular homeostasis[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (FBXW7[Title]) OR (HSP90AA1[Title]) OR (PARK2[Title]) OR (SKP1[Title]) OR (STK11[Title]) OR (VHL[Title]) AND (protein degradation[Title])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXW7[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) OR (PARK2[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (STK11[Title/Abstract]) OR (VHL[Title/Abstract]) AND (ubiquitin-proteasome system[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXW7[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) OR (PARK2[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (STK11[Title/Abstract]) OR (VHL[Title/Abstract]) AND (cellular homeostasis[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXW7[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) OR (PARK2[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (STK11[Title/Abstract]) OR (VHL[Title/Abstract]) AND (protein degradation[Title/Abstract])"], "references": ["Rhodes, Shannon L, Fitzmaurice, Arthur G, Cockburn, Myles, Bronstein, Jeff M, Sinsheimer, Janet S, Ritz, Beate. \"Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson\u05f3s disease.\" Environmental research, 2013, pp. 1-8.", "Bharadwaj, Nandita, Barthakur, Sharmistha, Biswas, Akash Deep, Kumar Das, Monoj, Kour, Manpreet, Ramteke, Anand, Gogoi, Nirmali. \"Transcript expression profiling in two contrasting cultivars and molecular cloning of a SKP-1 like gene, a component of SCF-ubiquitin proteasome system from mungbean Vigna radiate L.\" Scientific reports, 2019, pp. 8103.", "Pozzebon, Maria Elena, Varadaraj, Archana, Mattoscio, Domenico, Jaffray, Ellis G, Miccolo, Claudia, Galimberti, Viviana, Tommasino, Massimo, Hay, Ronald T, Chiocca, Susanna. \"BC-box protein domain-related mechanism for VHL protein degradation.\" Proceedings of the National Academy of Sciences of the United States of America, 2013, pp. 18168-73."]}, "The primary biological process performed by this system of interacting proteins is apoptosis and cell signaling. Apoptosis is a form of programmed cell death that plays a crucial role in maintaining cellular homeostasis and eliminating damaged or unwanted cells. Cell signaling is the process by which cells communicate with each other to coordinate their activities and respond to their environment.": {"keywords": [], "references": []}, "1. Apoptosis regulation: Several proteins in this system are directly involved in the regulation of apoptosis. CASP8 (caspase-8) is an initiator caspase that activates downstream effector caspases, leading to cell death. FAS and TNF (tumor necrosis factor) are both death receptors that can initiate apoptosis upon binding to their respective ligands. TP53 (p53) is a tumor suppressor protein that can induce apoptosis in response to DNA damage or other cellular stresses.": {"keywords": ["(CASP8[Title]) OR (FAS[Title]) OR (TNF[Title]) OR (TP53[Title]) AND (apoptosis regulation[Title])", "(CASP8[Title]) OR (FAS[Title]) OR (TNF[Title]) OR (TP53[Title]) AND (cell death[Title])", "(CASP8[Title]) OR (FAS[Title]) OR (TNF[Title]) OR (TP53[Title]) AND (tumor suppressor[Title])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis regulation[Title/Abstract])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell death[Title/Abstract])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (tumor suppressor[Title/Abstract])"], "references": ["Seeberger, H, Kn\u00f6rr, C, M\u00fcller-Hermelink, H K, Greiner, A. \"[Impaired CD95-(Fas,APO-1-)apoptosis regulation is a progression factor in early MALT-type lymphoma genesis].\" Medizinische Klinik (Munich, Germany : 1983), 2001, pp. 9-14.", "Taft, Justin, Markson, Michael, Legarda, Diana, Patel, Roosheel, Chan, Mark, Malle, Louise, Richardson, Ashley, Gruber, Conor, Mart\u00edn-Fern\u00e1ndez, Marta, Mancini, Grazia M S, van Laar, Jan A M, van Pelt, Philomine, Buta, Sofija, Wokke, Beatrijs H A, Sabli, Ira K D, Sancho-Shimizu, Vanessa, Chavan, Pallavi Pimpale, Schnappauf, Oskar, Khubchandani, Raju, C\u00fcceo\u011flu, M\u00fc\u015ferref Kasap, \u00d6zen, Seza, Kastner, Daniel L, Ting, Adrian T, Aksentijevich, Ivona, Hollink, Iris H I M, Bogunovic, Dusan. \"Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death.\" Cell, 2021, pp. 4447-4463.e20.", "Lafont, Elodie, Draber, Peter, Rieser, Eva, Reichert, Matthias, Kupka, Sebastian, de Miguel, Diego, Draberova, Helena, von M\u00e4ssenhausen, Anne, Bhamra, Amandeep, Henderson, Stephen, Wojdyla, Katarzyna, Chalk, Avigayil, Surinova, Silvia, Linkermann, Andreas, Walczak, Henning. \"TBK1 and IKK\u03b5 prevent TNF-induced cell death by RIPK1 phosphorylation.\" Nature cell biology, 2018, pp. 1389-1399."]}, "2. Inhibition of apoptosis: BIRC3 (cIAP2) is an inhibitor of apoptosis protein that can prevent cell death by inhibiting caspases and promoting the degradation of pro-apoptotic proteins. TNFAIP3 (A20) is a negative regulator of TNF-induced apoptosis, acting by inhibiting the activation of NF-\u03baB, a transcription factor that promotes cell survival.": {"keywords": ["(BIRC3[Title]) OR (TNFAIP3[Title]) AND (apoptosis inhibition[Title])", "(BIRC3[Title]) OR (TNFAIP3[Title]) AND (caspases[Title])", "(BIRC3[Title]) OR (TNFAIP3[Title]) AND (NF-\u03baB[Title])", "(BIRC3[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (apoptosis inhibition[Title/Abstract])", "(BIRC3[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (caspases[Title/Abstract])", "(BIRC3[Title/Abstract]) OR (TNFAIP3[Title/Abstract]) AND (NF-\u03baB[Title/Abstract])"], "references": ["Asslaber, Daniela, Wacht, Nathalie, Leisch, Michael, Qi, Yuan, Maeding, Nicole, Hufnagl, Clemens, Jansko, Bettina, Zaborsky, Nadja, Villunger, Andreas, Hartmann, Tanja N, Greil, Richard, Egle, Alexander. \"BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-\u03baB Nuclear Translocation.\" Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, pp. 1901-1912.", "Cao, Jia, Qiu, Jing, Wang, Xi, Lu, ZhenHui, Wang, Danni, Feng, HuiMin, Li, XiaoHan, Liu, QiaoQiao, Pan, HuaZheng, Han, XueBo, Wei, Jun, Liu, ShiHai, Wang, LiBin. \"Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-\u03baB pathway.\" Journal of Cancer, 2018, pp. 3006-3015.", "Grabinger, Thomas, Bode, Konstantin J, Demgenski, Janine, Seitz, Carina, Delgado, M Eugenia, Kostadinova, Feodora, Reinhold, Cindy, Etemadi, Nima, Wilhelm, Sabine, Schweinlin, Matthias, H\u00e4nggi, Kay, Knop, Janin, Hauck, Christof, Walles, Heike, Silke, John, Wajant, Harald, Nachbur, Ueli, W Wei-Lynn, Wong, Brunner, Thomas. \"Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.\" Gastroenterology, 2017, pp. 867-879."]}, "3. Signal transduction: Several proteins in this system are involved in signal transduction pathways that regulate cell survival, proliferation, and differentiation. MAP3K7 (TAK1) is a kinase that activates the NF-\u03baB and MAPK signaling pathways in response to various stimuli, including TNF and CD40. TRAF2 and TRAF3 are adaptor proteins that mediate signaling from TNF receptors and CD40, respectively.": {"keywords": ["(MAP3K7[Title]) OR (TRAF2[Title]) OR (TRAF3[Title]) AND (signal transduction[Title])", "(MAP3K7[Title]) OR (TRAF2[Title]) OR (TRAF3[Title]) AND (cell survival[Title])", "(MAP3K7[Title]) OR (TRAF2[Title]) OR (TRAF3[Title]) AND (kinase[Title])", "(MAP3K7[Title/Abstract]) OR (TRAF2[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (signal transduction[Title/Abstract])", "(MAP3K7[Title/Abstract]) OR (TRAF2[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (cell survival[Title/Abstract])", "(MAP3K7[Title/Abstract]) OR (TRAF2[Title/Abstract]) OR (TRAF3[Title/Abstract]) AND (kinase[Title/Abstract])"], "references": ["Davies, Clare C, Mak, Tak W, Young, Lawrence S, Eliopoulos, Aristides G. \"TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells.\" Molecular and cellular biology, 2005, pp. 9806-19.", "Hsu, H, Shu, H B, Pan, M G, Goeddel, D V. \"TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.\" Cell, 1996, pp. 299-308.", "Yoneda, T, Imaizumi, K, Maeda, M, Yui, D, Manabe, T, Katayama, T, Sato, N, Gomi, F, Morihara, T, Mori, Y, Miyoshi, K, Hitomi, J, Ugawa, S, Yamada, S, Okabe, M, Tohyama, M. \"Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein.\" The Journal of biological chemistry, 2000, pp. 11114-20."]}, "4. DNA repair and cell cycle regulation: PARP1 (poly(ADP-ribose) polymerase 1) is involved in DNA repair and the regulation of the cell cycle. It can also modulate the activity of TP53, linking DNA damage response to apoptosis.": {"keywords": ["(PARP1[Title]) OR (TP53[Title]) AND (DNA repair[Title])", "(PARP1[Title]) OR (TP53[Title]) AND (cell cycle regulation[Title])", "(PARP1[Title]) OR (TP53[Title]) AND (apoptosis[Title])", "(PARP1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(PARP1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(PARP1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Ray Chaudhuri, Arnab, Nussenzweig, Andr\u00e9. \"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.\" Nature reviews. Molecular cell biology, 2017, pp. 610-621.", "Patterson-Fortin, Jeffrey, Bose, Arindam, Tsai, Wei-Chih, Grochala, Carter, Nguyen, Huy, Zhou, Jia, Parmar, Kalindi, Lazaro, Jean-Bernard, Liu, Joyce, McQueen, Kelsey, Shapiro, Geoffrey I, Kozono, David, D'Andrea, Alan D. \"Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.\" Cancer research, 2022, pp. 3815-3829.", "Zada, David, Sela, Yaniv, Matosevich, Noa, Monsonego, Adir, Lerer-Goldshtein, Tali, Nir, Yuval, Appelbaum, Lior. \"Parp1 promotes sleep, which enhances DNA repair in neurons.\" Molecular cell, 2021, pp. 4979-4993.e7."]}, "5. Immune response: CD40 and TNFRSF9 (4-1BB) are both members of the TNF receptor superfamily and play important roles in the activation and regulation of immune cells. CD40 is expressed on B cells, dendritic cells, and macrophages, while TNFRSF9 is primarily expressed on activated T cells.": {"keywords": ["(CD40[Title]) OR (TNFRSF9[Title]) AND (immune cells[Title])", "(CD40[Title]) OR (TNFRSF9[Title]) AND (activation[Title])", "(CD40[Title]) OR (TNFRSF9[Title]) AND (regulation[Title])", "(CD40[Title/Abstract]) OR (TNFRSF9[Title/Abstract]) AND (immune cells[Title/Abstract])", "(CD40[Title/Abstract]) OR (TNFRSF9[Title/Abstract]) AND (activation[Title/Abstract])", "(CD40[Title/Abstract]) OR (TNFRSF9[Title/Abstract]) AND (regulation[Title/Abstract])"], "references": ["Diggs, Laurence P, Ruf, Benjamin, Ma, Chi, Heinrich, Bernd, Cui, Linda, Zhang, Qianfei, McVey, John C, Wabitsch, Simon, Heinrich, Sophia, Rosato, Umberto, Lai, Walter, Subramanyam, Varun, Longerich, Thomas, Loosen, Sven H, Luedde, Tom, Neumann, Ulf Peter, Desar, Sabina, Kleiner, David, Gores, Gregory, Wang, Xin Wei, Greten, Tim F. \"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.\" Journal of hepatology, 2021, pp. 1145-1154.", "Sum, Eva, Rapp, Moritz, Fr\u00f6bel, Philipp, Le Clech, Marine, D\u00fcrr, Harald, Giusti, Anna Maria, Perro, Mario, Speziale, Dario, Kunz, Leo, Menietti, Elena, Br\u00fcnker, Peter, Hopfer, Ulrike, Lechmann, Martin, Sobieniecki, Andrzej, Appelt, Birte, Adelfio, Roberto, Nicolini, Valeria, Freimoser-Grundschober, Anne, Jordaan, Whitney, Labiano, Sara, Weber, Felix, Emrich, Thomas, Christen, Fran\u00e7ois, Essig, Birgit, Romero, Pedro, Trumpfheller, Christine, Uma\u00f1a, Pablo. \"Fibroblast Activation Protein \u03b1-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.\" Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, pp. 4036-4053.", "Valencia, Julio C, Erwin-Cohen, Rebecca A, Clavijo, Paul E, Allen, Clint, Sanford, Michael E, Day, Chi-Ping, Hess, Megan M, Johnson, Morgan, Yin, Jie, Fenimore, John M, Bettencourt, Ian A, Tsuneyama, Koichi, Romero, Maria E, Klarmann, Kimberly D, Jiang, Peng, Bae, Heekyong R, McVicar, Daniel W, Merlino, Glenn, Edmondson, Elijah F, Anandasabapathy, Niroshana, Young, Howard A. \"Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.\" Cancer research, 2021, pp. 5977-5990."]}, "In conclusion, this system of interacting proteins is primarily involved in the regulation of apoptosis and cell signaling, with additional roles in DNA repair, cell cycle regulation, and immune response. These proteins work together to maintain cellular homeostasis and respond to various cellular stresses and environmental cues.": {"keywords": [], "references": []}, "The system of interacting proteins ARAF, BRAF, HRAS, KRAS, MAP2K1, MAPK1, and RAF1 primarily participate in the Mitogen-Activated Protein Kinase/Extracellular signal-Regulated Kinase (MAPK/ERK) signaling pathway. This pathway is crucial for regulating cell proliferation, differentiation, and survival.": {"keywords": ["(ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (MAP2K1[Title]) OR (MAPK1[Title]) OR (RAF1[Title]) AND (MAPK/ERK pathway[Title])", "(ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (MAP2K1[Title]) OR (MAPK1[Title]) OR (RAF1[Title]) AND (cell proliferation[Title])", "(ARAF[Title]) OR (BRAF[Title]) OR (HRAS[Title]) OR (KRAS[Title]) OR (MAP2K1[Title]) OR (MAPK1[Title]) OR (RAF1[Title]) AND (differentiation[Title])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) OR (RAF1[Title/Abstract]) AND (MAPK/ERK pathway[Title/Abstract])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) OR (RAF1[Title/Abstract]) AND (cell proliferation[Title/Abstract])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) OR (MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) OR (RAF1[Title/Abstract]) AND (differentiation[Title/Abstract])"], "references": ["Bologna-Molina, Ronell, Ogawa, Ikuko, Mosqueda-Taylor, Adalberto, Takata, Takashi, S\u00e1nchez-Romero, Celeste, Villarroel-Dorrego, Mariana, Takeda, Yasunori, Mikami, Toshinari. \"Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.\" Oral diseases, 2019, pp. 481-487.", "Yang, Kege, Li, Yaqing, Lian, Guoda, Lin, Haoming, Shang, Changzhen, Zeng, Linjuan, Chen, Shaojie, Li, Jiajia, Huang, Chumei, Huang, Kaihong, Chen, Yinting. \"KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.\" International journal of cancer, 2018, pp. 2323-2334.", "Fujii, Shinsuke, Ishibashi, Takuma, Kokura, Megumi, Fujimoto, Tatsufumi, Matsumoto, Shinji, Shidara, Satsuki, Kurppa, Kari J, Pape, Judith, Caton, Javier, Morgan, Peter R, Heikinheimo, Kristiina, Kikuchi, Akira, Jimi, Eijiro, Kiyoshima, Tamotsu. \"RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation.\" The Journal of pathology, 2022, pp. 119-133."]}, "1. RAS GTPases (HRAS, KRAS): These proteins function as molecular switches, cycling between active GTP-bound and inactive GDP-bound states. They are activated by extracellular signals, such as growth factors, and play a central role in the MAPK/ERK pathway. Their dysregulation can lead to uncontrolled cell growth and cancer.": {"keywords": ["(HRAS[Title]) OR (KRAS[Title]) AND (GTPases[Title])", "(HRAS[Title]) OR (KRAS[Title]) AND (MAPK/ERK pathway[Title])", "(HRAS[Title]) OR (KRAS[Title]) AND (cancer[Title])", "(HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) AND (GTPases[Title/Abstract])", "(HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) AND (MAPK/ERK pathway[Title/Abstract])", "(HRAS[Title/Abstract]) OR (KRAS[Title/Abstract]) AND (cancer[Title/Abstract])"], "references": ["Yin, Guowei, Huang, Jing, Petela, Johnny, Jiang, Hongmei, Zhang, Yuetong, Gong, Siqi, Wu, Jiaxin, Liu, Bei, Shi, Jianyou, Gao, Yijun. \"Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.\" Signal transduction and targeted therapy, 2023, pp. 212.", "Cai, Qixu, Hosokawa, Tomohisa, Zeng, Menglong, Hayashi, Yasunori, Zhang, Mingjie. \"Shank3 Binds to and Stabilizes the Active Form of Rap1 and HRas GTPases via Its NTD-ANK Tandem with Distinct Mechanisms.\" Structure (London, England : 1993), 2020, pp. 290-300.e4.", "Bologna-Molina, Ronell, Ogawa, Ikuko, Mosqueda-Taylor, Adalberto, Takata, Takashi, S\u00e1nchez-Romero, Celeste, Villarroel-Dorrego, Mariana, Takeda, Yasunori, Mikami, Toshinari. \"Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.\" Oral diseases, 2019, pp. 481-487."]}, "2. RAF kinases (ARAF, BRAF, RAF1): These serine/threonine kinases are direct downstream effectors of RAS proteins. Upon activation by RAS, they undergo a conformational change and phosphorylate MAP2K1. Mutations in BRAF, particularly V600E, are frequently observed in various cancers, leading to constitutive activation of the MAPK/ERK pathway.": {"keywords": ["(ARAF[Title]) OR (BRAF[Title]) OR (RAF1[Title]) OR (MAP2K1[Title]) AND (kinases[Title])", "(ARAF[Title]) OR (BRAF[Title]) OR (RAF1[Title]) OR (MAP2K1[Title]) AND (RAS proteins[Title])", "(ARAF[Title]) OR (BRAF[Title]) OR (RAF1[Title]) OR (MAP2K1[Title]) AND (MAPK/ERK pathway[Title])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (kinases[Title/Abstract])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (RAS proteins[Title/Abstract])", "(ARAF[Title/Abstract]) OR (BRAF[Title/Abstract]) OR (RAF1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (MAPK/ERK pathway[Title/Abstract])"], "references": ["Yadav, Vipin, Chen, Shih-Hsun, Yue, Yong Gong, Buchanan, Sean, Beckmann, Richard P, Peng, Sheng-Bin. \"Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.\" Pharmacology & therapeutics, 2015, pp. 139-49.", "Holderfield, Matthew, Deuker, Marian M, McCormick, Frank, McMahon, Martin. \"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.\" Nature reviews. Cancer, 2014, pp. 455-67.", "Zhang, Jianchun, Ji, Tao. \"Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.\" Journal of molecular modeling, 2017, pp. 1."]}, "3. MAP2K1 (MEK1): This dual-specificity kinase is activated by RAF kinases through phosphorylation. Once activated, MAP2K1 phosphorylates and activates MAPK1, propagating the signal downstream.": {"keywords": ["(MAP2K1[Title]) OR (MAPK1[Title]) AND (kinase[Title])", "(MAP2K1[Title]) OR (MAPK1[Title]) AND (phosphorylation[Title])", "(MAP2K1[Title]) OR (MAPK1[Title]) AND (signal[Title])", "(MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) AND (kinase[Title/Abstract])", "(MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) AND (phosphorylation[Title/Abstract])", "(MAP2K1[Title/Abstract]) OR (MAPK1[Title/Abstract]) AND (signal[Title/Abstract])"], "references": ["Zhao, Like, Zhou, Rongwei, Wang, Qian, Cheng, Yongjing, Gao, Ming, Huang, Cibo. \"MicroRNA-320c inhibits articular chondrocytes proliferation and induces apoptosis by targeting mitogen-activated protein kinase 1 (MAPK1).\" International journal of rheumatic diseases, 2021, pp. 402-410.", "Zheng, Yan, Zhou, Chuang, Yu, Xin-Xin, Wu, Chao, Jia, Hu-Liang, Gao, Xiao-Mei, Yang, Ji-Meng, Wang, Chao-Qun, Luo, Qin, Zhu, Ying, Zhang, Yu, Wei, Jin-Wang, Sheng, Yuan-Yuan, Dong, Qiong-Zhu, Qin, Lun-Xiu. \"Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of \u03b2-Catenin.\" Cell death & disease, 2018, pp. 179.", "Tepekoy, Filiz, Akkoyunlu, Gokhan. \"The effect of FSH and activin A on Akt and MAPK1/3 phosphorylation in cultured bovine ovarian cortical strips.\" Journal of ovarian research, 2016, pp. 13."]}, "4. MAPK1 (ERK2): This serine/threonine kinase is the final effector in the MAPK/ERK pathway. Upon activation by MAP2K1, it translocates to the nucleus and phosphorylates various transcription factors, ultimately regulating gene expression and cellular processes.": {"keywords": ["(MAPK1[Title]) OR (MAP2K1[Title]) AND (serine/threonine kinase[Title])", "(MAPK1[Title]) OR (MAP2K1[Title]) AND (MAPK/ERK pathway[Title])", "(MAPK1[Title]) OR (MAP2K1[Title]) AND (gene expression[Title])", "(MAPK1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (serine/threonine kinase[Title/Abstract])", "(MAPK1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (MAPK/ERK pathway[Title/Abstract])", "(MAPK1[Title/Abstract]) OR (MAP2K1[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Yu, T-T, Wang, C-Y, Tong, R. \"ERBB2 gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3 signaling pathway.\" European review for medical and pharmacological sciences, 2020, pp. 5267-5280.", "Gao, Yan, Ren, Jiusheng, Zhang, Liqun, Zhang, Yonghong, Wu, Xinhui, Jiang, Hao, Xu, Fangfang, Yuan, Bao, Yu, Xianfeng, Zhang, Jiabao. \"The effects of demecolcine, alone or in combination with sucrose on bovine oocyte protrusion rate, MAPK1 protein level and c-mos gene expression level.\" Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2014, pp. 1974-82.", "Xie, Baoming, Zhao, Mingqiu, Song, Dan, Wu, Keke, Yi, Lin, Li, Wenhui, Li, Xiaoming, Wang, Kun, Chen, Jinding. \"Induction of autophagy and suppression of type I IFN secretion by CSFV.\" Autophagy, 2021, pp. 925-947."]}, "In summary, the most prominent biological process performed by this system of interacting proteins is the MAPK/ERK signaling pathway, which is essential for cell growth, differentiation, and survival. Dysregulation of this pathway, through mutations or overexpression of its components, can lead to various diseases, including cancer.": {"keywords": [], "references": []}, "Proteins: CUL3, ELOC, FBXW7, HSP90AA1, MDM2, SKP1, STK11, TNF, VHL": {"keywords": [], "references": []}, "1. Cullin-RING ubiquitin ligase complex formation": {"keywords": [], "references": []}, "- CUL3, ELOC, and SKP1 are components of the Cullin-RING ubiquitin ligase complex.": {"keywords": ["(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (Cullin-RING[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (ubiquitin ligase[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (complex[Title])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (Cullin-RING[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (complex[Title/Abstract])"], "references": ["Chen, Hsin-Yi, Liu, Chin-Chih, Chen, Ruey-Hwa. \"Cul3-KLHL20 ubiquitin ligase: physiological functions, stress responses, and disease implications.\" Cell division, 2016, pp. 5.", "Zheng, Ning, Schulman, Brenda A, Song, Langzhou, Miller, Julie J, Jeffrey, Philip D, Wang, Ping, Chu, Claire, Koepp, Deanna M, Elledge, Stephen J, Pagano, Michele, Conaway, Ronald C, Conaway, Joan W, Harper, J Wade, Pavletich, Nikola P. \"Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.\" Nature, 2002, pp. 703-9.", "McGourty, Colleen A, Akopian, David, Walsh, Carolyn, Gorur, Amita, Werner, Achim, Schekman, Randy, Bautista, Diana, Rape, Michael. \"Regulation of the CUL3\u00a0Ubiquitin Ligase by a Calcium-Dependent Co-adaptor.\" Cell, 2016, pp. 525-538.e14."]}, "- CUL3 serves as a scaffold protein, while ELOC and SKP1 act as adaptor proteins.": {"keywords": ["(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (scaffold protein[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (adaptor proteins[Title])", "(CUL3[Title]) OR (ELOC[Title]) OR (SKP1[Title]) AND (CUL3[Title])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (scaffold protein[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (adaptor proteins[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (SKP1[Title/Abstract]) AND (CUL3[Title/Abstract])"], "references": ["Patton, E E, Willems, A R, Sa, D, Kuras, L, Thomas, D, Craig, K L, Tyers, M. \"Cdc53 is a scaffold protein for multiple Cdc34/Skp1/F-box proteincomplexes that regulate cell division and methionine biosynthesis in yeast.\" Genes & development, 1998, pp. 692-705.", "Kato, Kohji, Miya, Fuyuki, Oka, Yasuyoshi, Mizuno, Seiji, Saitoh, Shinji. \"A novel missense variant in CUL3 shows altered binding ability to BTB-adaptor proteins leading to diverse phenotypes of CUL3-related disorders.\" Journal of human genetics, 2021, pp. 491-498.", "Li, Xuan, Yang, Kai-Bin, Chen, Wei, Mai, Jia, Wu, Xiao-Qi, Sun, Ting, Wu, Rui-Yan, Jiao, Lin, Li, Dan-Dan, Ji, Jiao, Zhang, Hai-Liang, Yu, Yan, Chen, Yu-Hong, Feng, Gong-Kan, Deng, Rong, Li, Jun-Dong, Zhu, Xiao-Feng. \"CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression.\" Autophagy, 2021, pp. 4323-4340."]}, "- This complex is involved in the ubiquitination and subsequent degradation of target proteins.": {"keywords": [], "references": []}, "- FBXW7 is an F-box protein that recognizes and binds to phosphorylated substrates.": {"keywords": ["(FBXW7[Title]) AND (F-box protein[Title])", "(FBXW7[Title]) AND (phosphorylated substrates[Title])", "(FBXW7[Title]) AND (recognizes[Title])", "(FBXW7[Title/Abstract]) AND (F-box protein[Title/Abstract])", "(FBXW7[Title/Abstract]) AND (phosphorylated substrates[Title/Abstract])", "(FBXW7[Title/Abstract]) AND (recognizes[Title/Abstract])"], "references": ["Zhao, Jiejie, Xiong, Xuelian, Li, Yao, Liu, Xing, Wang, Tao, Zhang, Hong, Jiao, Yang, Jiang, Jingjing, Zhang, Huijie, Tang, Qiqun, Gao, Xin, Li, Xuejun, Lu, Yan, Liu, Bin, Hu, Cheng, Li, Xiaoying. \"Hepatic F-Box Protein FBXW7 Maintains Glucose Homeostasis Through Degradation of Fetuin-A.\" Diabetes, 2018, pp. 818-830.", "Yumimoto, Kanae, Akiyoshi, Sayuri, Ueo, Hiroki, Sagara, Yasuaki, Onoyama, Ichiro, Ueo, Hiroaki, Ohno, Shinji, Mori, Masaki, Mimori, Koshi, Nakayama, Keiichi I. \"F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner.\" The Journal of clinical investigation, 2015, pp. 621-35.", "Fan, Jingyi, Bellon, Marcia, Ju, Mingyi, Zhao, Lin, Wei, Minjie, Fu, Liwu, Nicot, Christophe. \"Clinical significance of FBXW7 loss of function in human cancers.\" Molecular cancer, 2022, pp. 87."]}, "- It interacts with SKP1, forming the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex.": {"keywords": ["(SKP1[Title]) OR (CUL1[Title]) OR (F-box[Title]) AND (ubiquitin ligase[Title])", "(SKP1[Title]) OR (CUL1[Title]) OR (F-box[Title]) AND (protein complex[Title])", "(SKP1[Title]) OR (CUL1[Title]) OR (F-box[Title]) AND (interaction[Title])", "(SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) OR (F-box[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) OR (F-box[Title/Abstract]) AND (protein complex[Title/Abstract])", "(SKP1[Title/Abstract]) OR (CUL1[Title/Abstract]) OR (F-box[Title/Abstract]) AND (interaction[Title/Abstract])"], "references": ["Harper, J Wade, Schulman, Brenda A. \"Cullin-RING Ubiquitin Ligase Regulatory Circuits: A Quarter Century Beyond the F-Box Hypothesis.\" Annual review of biochemistry, 2021, pp. 403-429.", "Zheng, Ning, Schulman, Brenda A, Song, Langzhou, Miller, Julie J, Jeffrey, Philip D, Wang, Ping, Chu, Claire, Koepp, Deanna M, Elledge, Stephen J, Pagano, Michele, Conaway, Ronald C, Conaway, Joan W, Harper, J Wade, Pavletich, Nikola P. \"Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.\" Nature, 2002, pp. 703-9.", "Burrows, Amy C, Prokop, John, Summers, Matthew K. \"Skp1-Cul1-F-box ubiquitin ligase (SCF(\u03b2TrCP))-mediated destruction of the ubiquitin-specific protease USP37 during G2-phase promotes mitotic entry.\" The Journal of biological chemistry, 2012, pp. 39021-9."]}, "- This complex targets specific proteins for ubiquitination and degradation.": {"keywords": [], "references": []}, "- HSP90AA1 is a molecular chaperone that assists in the folding, stabilization, and degradation of client proteins.": {"keywords": ["(HSP90AA1[Title]) AND (molecular chaperone[Title])", "(HSP90AA1[Title]) AND (protein folding[Title])", "(HSP90AA1[Title]) AND (protein stabilization[Title])", "(HSP90AA1[Title/Abstract]) AND (molecular chaperone[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (protein folding[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (protein stabilization[Title/Abstract])"], "references": ["Zuehlke, Abbey D, Beebe, Kristin, Neckers, Len, Prince, Thomas. \"Regulation and function of the human HSP90AA1 gene.\" Gene, 2015, pp. 8-16.", "Yang, Cai-Xia, Chen, Lu, Mou, Qiao, Yang, Yu-Wei, Wang, Yi, Yin, Zongjun, Du, Zhi-Qiang. \"HSP90AA1 promotes viability and lactate production but inhibits hormone secretion of porcine immature Sertoli cells.\" Theriogenology, 2022, pp. 64-74.", "Badri, T M, Chen, K L, Alsiddig, M A, Li, Lian, Cai, Yafei, Wang, G L. \"Genetic polymorphism in Hsp90AA1 gene is associated with the thermotolerance in Chinese Holstein cows.\" Cell stress & chaperones, 2018, pp. 639-651."]}, "- It interacts with various proteins, including MDM2 and STK11, to regulate their stability and function.": {"keywords": ["(MDM2[Title]) OR (STK11[Title]) AND (protein interaction[Title])", "(MDM2[Title]) OR (STK11[Title]) AND (regulate stability[Title])", "(MDM2[Title]) OR (STK11[Title]) AND (function[Title])", "(MDM2[Title/Abstract]) OR (STK11[Title/Abstract]) AND (protein interaction[Title/Abstract])", "(MDM2[Title/Abstract]) OR (STK11[Title/Abstract]) AND (regulate stability[Title/Abstract])", "(MDM2[Title/Abstract]) OR (STK11[Title/Abstract]) AND (function[Title/Abstract])"], "references": ["Holzer, Philipp. \"Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.\" Chimia, 2017, pp. 716-721.", "Zhou, Jiajia, Kryczek, Ilona, Li, Shasha, Li, Xiong, Aguilar, Angelo, Wei, Shuang, Grove, Sara, Vatan, Linda, Yu, Jiali, Yan, Yijian, Liao, Peng, Lin, Heng, Li, Jing, Li, Gaopeng, Du, Wan, Wang, Weichao, Lang, Xueting, Wang, Weimin, Wang, Shaomeng, Zou, Weiping. \"The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.\" Nature immunology, 2021, pp. 460-470.", "Mu, Hongbei, Cai, Siying, Wang, Xiaofei, Li, Huiying, Zhang, Ling, Li, Huaibiao, Xiang, Wenpei. \"RNA binding protein IGF2BP1 meditates oxidative stress-induced granulosa cell dysfunction by regulating MDM2 mRNA stability in an m<sup>6</sup>A-dependent manner.\" Redox biology, 2022, pp. 102492."]}, "- MDM2 is an E3 ubiquitin ligase that targets the tumor suppressor protein p53 for degradation.": {"keywords": ["(MDM2[Title]) OR (p53[Title]) AND (ubiquitin ligase[Title])", "(MDM2[Title]) OR (p53[Title]) AND (tumor suppressor[Title])", "(MDM2[Title]) OR (p53[Title]) AND (p53 degradation[Title])", "(MDM2[Title/Abstract]) OR (p53[Title/Abstract]) AND (ubiquitin ligase[Title/Abstract])", "(MDM2[Title/Abstract]) OR (p53[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(MDM2[Title/Abstract]) OR (p53[Title/Abstract]) AND (p53 degradation[Title/Abstract])"], "references": ["Zhou, Jiajia, Kryczek, Ilona, Li, Shasha, Li, Xiong, Aguilar, Angelo, Wei, Shuang, Grove, Sara, Vatan, Linda, Yu, Jiali, Yan, Yijian, Liao, Peng, Lin, Heng, Li, Jing, Li, Gaopeng, Du, Wan, Wang, Weichao, Lang, Xueting, Wang, Weimin, Wang, Shaomeng, Zou, Weiping. \"The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.\" Nature immunology, 2021, pp. 460-470.", "Sola, Martina, Rendon-Angel, Azucena, Rojo Martinez, Viviana, Sgrignani, Jacopo, Magrin, Claudia, Piovesana, Ester, Cavalli, Andrea, Paganetti, Paolo, Papin, St\u00e9phanie. \"Tau protein binds to the P53 E3 ubiquitin ligase MDM2.\" Scientific reports, 2023, pp. 10208.", "Liu, Juan, Zhang, Cen, Hu, Wenwei, Feng, Zhaohui. \"Tumor suppressor p53 and metabolism.\" Journal of molecular cell biology, 2019, pp. 284-292."]}, "- It interacts with HSP90AA1, which stabilizes MDM2 and enhances its activity.": {"keywords": ["(HSP90AA1[Title]) OR (MDM2[Title]) AND (HSP90AA1[Title])", "(HSP90AA1[Title]) OR (MDM2[Title]) AND (MDM2[Title])", "(HSP90AA1[Title]) OR (MDM2[Title]) AND (activity[Title])", "(HSP90AA1[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (HSP90AA1[Title/Abstract])", "(HSP90AA1[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (MDM2[Title/Abstract])", "(HSP90AA1[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (activity[Title/Abstract])"], "references": ["Xiao, Xin, Wang, Wei, Li, Yuqian, Yang, Di, Li, Xiaokang, Shen, Chao, Liu, Yan, Ke, Xianzhu, Guo, Shuo, Guo, Zheng. \"HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.\" Journal of experimental & clinical cancer research : CR, 2018, pp. 201.", "Zuehlke, Abbey D, Beebe, Kristin, Neckers, Len, Prince, Thomas. \"Regulation and function of the human HSP90AA1 gene.\" Gene, 2015, pp. 8-16.", "Yang, Shaosong, Nie, Tiejian, She, Hua, Tao, Kai, Lu, Fangfang, Hu, Yiman, Huang, Lu, Zhu, Lin, Feng, Dayun, He, Dan, Qi, Jing, Kukar, Thomas, Ma, Long, Mao, Zixu, Yang, Qian. \"Regulation of TFEB nuclear localization by HSP90AA1 promotes autophagy and longevity.\" Autophagy, 2023, pp. 822-838."]}, "- This interaction plays a crucial role in the regulation of cell cycle and apoptosis.": {"keywords": [], "references": []}, "- STK11 is a serine/threonine kinase that acts as a tumor suppressor.": {"keywords": ["(STK11[Title]) AND (serine/threonine kinase[Title])", "(STK11[Title]) AND (tumor suppressor[Title])", "(STK11[Title]) AND (STK11[Title])", "(STK11[Title/Abstract]) AND (serine/threonine kinase[Title/Abstract])", "(STK11[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(STK11[Title/Abstract]) AND (STK11[Title/Abstract])"], "references": ["Altamish, Mohammad, Dahiya, Rajiv, Singh, Avinash Kumar, Mishra, Anurag, Aljabali, Alaa A A, Satija, Saurabh, Mehta, Meenu, Dureja, Harish, Prasher, Parteek, Negi, Poonam, Kapoor, Deepak N, Goyal, Rohit, Tambuwala, Murtaza M, Chellappan, Dinesh Kumar, Dua, Kamal, Gupta, Gaurav. \"Role of the Serine/Threonine Kinase 11 (STK11) or Liver Kinase B1 (LKB1) Gene in Peutz-Jeghers Syndrome.\" Critical reviews in eukaryotic gene expression, 2020, pp. 245-252.", "Marinaccio, Christian, Suraneni, Praveen, Celik, Hamza, Volk, Andrew, Wen, Qiang Jeremy, Ling, Te, Bulic, Marinka, Lasho, Terra, Koche, Richard P, Famulare, Christopher A, Farnoud, Noushin, Stein, Brady, Schieber, Michael, Gurbuxani, Sandeep, Root, David E, Younger, Scott T, Hoffman, Ronald, Gangat, Naseema, Ntziachristos, Panagiotis, Chandel, Navdeep S, Levine, Ross L, Rampal, Raajit K, Challen, Grant A, Tefferi, Ayalew, Crispino, John D. \"LKB1/<i>STK11</i> Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms.\" Cancer discovery, 2021, pp. 1398-1410.", "Rho, Seung Bae, Byun, Hyun Jung, Kim, Boh-Ram, Lee, Chang Hoon. \"LKB1/STK11 Tumor Suppressor Reduces Angiogenesis by Directly Interacting with VEGFR2 in Tumorigenesis.\" Biomolecules & therapeutics, 2023, pp. 456-465."]}, "- It phosphorylates and activates various downstream targets, including AMPK and p53.": {"keywords": ["(AMPK[Title]) OR (p53[Title]) AND (phosphorylates[Title])", "(AMPK[Title]) OR (p53[Title]) AND (downstream targets[Title])", "(AMPK[Title]) OR (p53[Title]) AND (AMPK[Title])", "(AMPK[Title/Abstract]) OR (p53[Title/Abstract]) AND (phosphorylates[Title/Abstract])", "(AMPK[Title/Abstract]) OR (p53[Title/Abstract]) AND (downstream targets[Title/Abstract])", "(AMPK[Title/Abstract]) OR (p53[Title/Abstract]) AND (AMPK[Title/Abstract])"], "references": ["Zhang, Qian, Liu, Shengduo, Zhang, Chen-Song, Wu, Qirou, Yu, Xinyuan, Zhou, Ruyuan, Meng, Fansen, Wang, Ailian, Zhang, Fei, Chen, Shasha, Wang, Xiaojian, Li, Lei, Huang, Jun, Huang, Yao-Wei, Zou, Jian, Qin, Jun, Liang, Tingbo, Feng, Xin-Hua, Lin, Sheng-Cai, Xu, Pinglong. \"AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity.\" Molecular cell, 2022, pp. 4519-4536.e7.", "Li, Yu, Xu, Shanqin, Mihaylova, Maria M, Zheng, Bin, Hou, Xiuyun, Jiang, Bingbing, Park, Ogyi, Luo, Zhijun, Lefai, Etienne, Shyy, John Y-J, Gao, Bin, Wierzbicki, Michel, Verbeuren, Tony J, Shaw, Reuben J, Cohen, Richard A, Zang, Mengwei. \"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.\" Cell metabolism, 2011, pp. 376-388.", "Sun, Yu, Li, Xin, Yin, Chengqian, Zhang, Judy, Liang, Ershang, Wu, Xianfang, Ni, Ying, Arbesman, Joshua, Goding, Colin R, Chen, Shuyang. \"AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis.\" Cancer research, 2023, pp. 1062-1073."]}, "- STK11 interacts with HSP90AA1, which stabilizes and regulates its activity.": {"keywords": ["(STK11[Title]) OR (HSP90AA1[Title]) AND (STK11[Title])", "(STK11[Title]) OR (HSP90AA1[Title]) AND (HSP90AA1[Title])", "(STK11[Title]) OR (HSP90AA1[Title]) AND (activity[Title])", "(STK11[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) AND (STK11[Title/Abstract])", "(STK11[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) AND (HSP90AA1[Title/Abstract])", "(STK11[Title/Abstract]) OR (HSP90AA1[Title/Abstract]) AND (activity[Title/Abstract])"], "references": ["Xiao, Xin, Wang, Wei, Li, Yuqian, Yang, Di, Li, Xiaokang, Shen, Chao, Liu, Yan, Ke, Xianzhu, Guo, Shuo, Guo, Zheng. \"HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.\" Journal of experimental & clinical cancer research : CR, 2018, pp. 201.", "Zuehlke, Abbey D, Beebe, Kristin, Neckers, Len, Prince, Thomas. \"Regulation and function of the human HSP90AA1 gene.\" Gene, 2015, pp. 8-16.", "Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K, Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C, Masuda, Sayuri, Piel, Brandon P, Sholl, Lynette M, Kirschmeier, Paul T, Paweletz, Cloud P, Watanabe, Hideo, Yajima, Mamiko, Barbie, David A. \"Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.\" Cancer discovery, 2019, pp. 34-45."]}, "- TNF is a pro-inflammatory cytokine that plays a role in inflammation, immune response, and apoptosis.": {"keywords": [], "references": []}, "- It interacts with various proteins, including HSP90AA1, to regulate its stability and function.": {"keywords": ["(HSP90AA1[Title]) AND (protein interaction[Title])", "(HSP90AA1[Title]) AND (stability[Title])", "(HSP90AA1[Title]) AND (function[Title])", "(HSP90AA1[Title/Abstract]) AND (protein interaction[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (stability[Title/Abstract])", "(HSP90AA1[Title/Abstract]) AND (function[Title/Abstract])"], "references": ["Ram\u00f3n, Manuel, Salces-Ortiz, Judit, Gonz\u00e1lez, Carmen, P\u00e9rez-Guzm\u00e1n, M Dolores, Garde, J Juli\u00e1n, Garc\u00eda-\u00c1lvarez, Olga, Maroto-Morales, Alejandro, Calvo, Jorge H, Serrano, M Magdalena. \"Influence of the temperature and the genotype of the HSP90AA1 gene over sperm chromatin stability in Manchega Rams.\" PloS one, 2014, pp. e86107.", "Xu, Yunbin, Liu, Fei, Liu, Juan, Wang, Dandan, Yan, Yan, Ji, Senlin, Zan, Jie, Zhou, Jiyong. \"The co-chaperone Cdc37 regulates the rabies virus phosphoprotein stability by targeting to Hsp90AA1 machinery.\" Scientific reports, 2016, pp. 27123.", "Zuehlke, Abbey D, Beebe, Kristin, Neckers, Len, Prince, Thomas. \"Regulation and function of the human HSP90AA1 gene.\" Gene, 2015, pp. 8-16."]}, "- VHL is an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) for degradation.": {"keywords": ["(VHL[Title]) OR (HIF[Title]) AND (E3 ubiquitin ligase[Title])", "(VHL[Title]) OR (HIF[Title]) AND (hypoxia-inducible factor[Title])", "(VHL[Title]) OR (HIF[Title]) AND (degradation[Title])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (E3 ubiquitin ligase[Title/Abstract])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (hypoxia-inducible factor[Title/Abstract])", "(VHL[Title/Abstract]) OR (HIF[Title/Abstract]) AND (degradation[Title/Abstract])"], "references": ["Buckley, Dennis L, Van Molle, Inge, Gareiss, Peter C, Tae, Hyun Seop, Michel, Julien, Noblin, Devin J, Jorgensen, William L, Ciulli, Alessio, Crews, Craig M. \"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1\u03b1 interaction.\" Journal of the American Chemical Society, 2012, pp. 4465-8.", "Zhang, Bichao, Kirn, Lauren A, Burke, Richard. \"The Vhl E3 ubiquitin ligase complex regulates melanisation via sima, cnc and the copper import protein Ctr1A.\" Biochimica et biophysica acta. Molecular cell research, 2021, pp. 119022.", "Lee, Jee H, Elly, Chris, Park, Yoon, Liu, Yun-Cai. \"E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1\u03b1 to Maintain Regulatory T Cell Stability and Suppressive Capacity.\" Immunity, 2015, pp. 1062-74."]}, "- It interacts with CUL3 and ELOC, forming the VCB (VHL-CUL3-ELOC) complex.": {"keywords": ["(CUL3[Title]) OR (ELOC[Title]) AND (CUL3[Title])", "(CUL3[Title]) OR (ELOC[Title]) AND (ELOC[Title])", "(CUL3[Title]) OR (ELOC[Title]) AND (VCB[Title])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) AND (CUL3[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) AND (ELOC[Title/Abstract])", "(CUL3[Title/Abstract]) OR (ELOC[Title/Abstract]) AND (VCB[Title/Abstract])"], "references": ["Morandell, Jasmin, Schwarz, Lena A, Basilico, Bernadette, Tasciyan, Saren, Dimchev, Georgi, Nicolas, Armel, Sommer, Christoph, Kreuzinger, Caroline, Dotter, Christoph P, Knaus, Lisa S, Dobler, Zoe, Cacci, Emanuele, Schur, Florian K M, Danzl, Johann G, Novarino, Gaia. \"Cul3 regulates cytoskeleton protein homeostasis and cell migration during a critical window of brain development.\" Nature communications, 2021, pp. 3058.", "Wang, Yan, Zhao, Peng, Wang, Lili, Wang, Jigang, Ji, Xiaobin, Li, Yunxia, Shi, Hailei, Li, Yujun, Zhang, Wei, Jiang, Yanxia. \"Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.\" Pathology, research and practice, 2022, pp. 153960.", "Pham, Vinh Ngoc, Kathare, Praveen Kumar, Huq, Enamul. \"Phytochromes and Phytochrome Interacting Factors.\" Plant physiology, 2018, pp. 1025-1038."]}, "- This complex is involved in the regulation of cellular response to hypoxia.": {"keywords": [], "references": []}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is protein degradation and regulation. The proteins are involved in the formation of various E3 ubiquitin ligase complexes, chaperone activity, and regulation of cellular processes such as cell cycle, apoptosis, and response to hypoxia.": {"keywords": [], "references": []}, "The system of interacting proteins primarily involves cell cycle regulation, DNA damage response, and protein degradation. The most prominent biological process performed by this system is cell cycle regulation and DNA damage response.": {"keywords": [], "references": []}, "1. Cell cycle regulation: Several proteins in the system are involved in cell cycle regulation. AURKB (Aurora Kinase B) plays a crucial role in mitosis, ensuring proper chromosome segregation and cytokinesis. CCND1 (Cyclin D1) is a regulatory subunit of CDK4/6, promoting cell cycle progression from G1 to S phase. STK11 (LKB1) is a tumor suppressor and regulates cell cycle arrest in response to cellular stress.": {"keywords": ["(AURKB[Title]) OR (CCND1[Title]) OR (STK11[Title]) AND (cell cycle regulation[Title])", "(AURKB[Title]) OR (CCND1[Title]) OR (STK11[Title]) AND (mitosis[Title])", "(AURKB[Title]) OR (CCND1[Title]) OR (STK11[Title]) AND (cytokinesis[Title])", "(AURKB[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (STK11[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(AURKB[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (STK11[Title/Abstract]) AND (mitosis[Title/Abstract])", "(AURKB[Title/Abstract]) OR (CCND1[Title/Abstract]) OR (STK11[Title/Abstract]) AND (cytokinesis[Title/Abstract])"], "references": ["Wang, Qiong, He, Guopei, Hou, Mengmeng, Chen, Liutao, Chen, Shangwu, Xu, Anlong, Fu, Yonggui. \"Cell Cycle Regulation by Alternative Polyadenylation of CCND1.\" Scientific reports, 2018, pp. 6824.", "Moura, David S, Campillo-Marcos, Ignacio, V\u00e1zquez-Cedeira, Marta, Lazo, Pedro A. \"VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis.\" Cellular and molecular life sciences : CMLS, 2018, pp. 2591-2611.", "Biswas, Leelabati, Tyc, Katarzyna, El Yakoubi, Warif, Morgan, Katie, Xing, Jinchuan, Schindler, Karen. \"Meiosis interrupted: the genetics of female infertility via meiotic failure.\" Reproduction (Cambridge, England), 2021, pp. R13-R35."]}, "2. DNA damage response: DDB2 (Damage-specific DNA binding protein 2) is involved in nucleotide excision repair, recognizing and binding to damaged DNA. TP53 (p53) is a tumor suppressor and transcription factor that regulates cell cycle arrest, apoptosis, and DNA repair in response to DNA damage. MDM2 (Mouse double minute 2 homolog) is an E3 ubiquitin ligase that negatively regulates TP53 by promoting its degradation.": {"keywords": ["(DDB2[Title]) OR (TP53[Title]) OR (MDM2[Title]) AND (DNA damage response[Title])", "(DDB2[Title]) OR (TP53[Title]) OR (MDM2[Title]) AND (nucleotide excision repair[Title])", "(DDB2[Title]) OR (TP53[Title]) OR (MDM2[Title]) AND (cell cycle arrest[Title])", "(DDB2[Title/Abstract]) OR (TP53[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(DDB2[Title/Abstract]) OR (TP53[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (nucleotide excision repair[Title/Abstract])", "(DDB2[Title/Abstract]) OR (TP53[Title/Abstract]) OR (MDM2[Title/Abstract]) AND (cell cycle arrest[Title/Abstract])"], "references": ["Lindemann, A, Takahashi, H, Patel, A A, Osman, A A, Myers, J N. \"Targeting the DNA Damage Response in OSCC with TP53 Mutations.\" Journal of dental research, 2018, pp. 635-644.", "Zhang, Ying, Mandemaker, Imke K, Matsumoto, Syota, Foreman, Oded, Holland, Christopher P, Lloyd, Whitney R, Sugasawa, Kaoru, Vermeulen, Wim, Marteijn, Jurgen A, Galardy, Paul J. \"USP44 Stabilizes DDB2 to Facilitate Nucleotide Excision Repair and Prevent Tumors.\" Frontiers in cell and developmental biology, 2021, pp. 663411.", "Pines, Alex, Vrouwe, Mischa G, Marteijn, Jurgen A, Typas, Dimitris, Luijsterburg, Martijn S, Cansoy, Medine, Hensbergen, Paul, Deelder, Andr\u00e9, de Groot, Anton, Matsumoto, Syota, Sugasawa, Kaoru, Thoma, Nicolas, Vermeulen, Wim, Vrieling, Harry, Mullenders, Leon. \"PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1.\" The Journal of cell biology, 2012, pp. 235-49."]}, "3. Protein degradation: Several proteins in the system are involved in protein degradation through the ubiquitin-proteasome pathway. CUL3 (Cullin 3) and SKP1 (S-phase kinase-associated protein 1) are components of E3 ubiquitin ligase complexes, which target specific substrates for degradation. ELOC (Elongin C) is a component of the Elongin-Cullin-SOCS-box (ECS) complex, which also functions as an E3 ubiquitin ligase. FBXO11 (F-box protein 11) and FBXW7 (F-box and WD repeat domain-containing 7) are F-box proteins that act as substrate recognition components of SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complexes.": {"keywords": ["(CUL3[Title]) OR (SKP1[Title]) OR (ELOC[Title]) OR (FBXO11[Title]) OR (FBXW7[Title]) AND (protein degradation[Title])", "(CUL3[Title]) OR (SKP1[Title]) OR (ELOC[Title]) OR (FBXO11[Title]) OR (FBXW7[Title]) AND (ubiquitin-proteasome pathway[Title])", "(CUL3[Title]) OR (SKP1[Title]) OR (ELOC[Title]) OR (FBXO11[Title]) OR (FBXW7[Title]) AND (E3 ubiquitin ligase[Title])", "(CUL3[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXO11[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (protein degradation[Title/Abstract])", "(CUL3[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXO11[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (ubiquitin-proteasome pathway[Title/Abstract])", "(CUL3[Title/Abstract]) OR (SKP1[Title/Abstract]) OR (ELOC[Title/Abstract]) OR (FBXO11[Title/Abstract]) OR (FBXW7[Title/Abstract]) AND (E3 ubiquitin ligase[Title/Abstract])"], "references": ["van den Heuvel, Sander. \"Protein degradation: CUL-3 and BTB--partners in proteolysis.\" Current biology : CB, 2004, pp. R59-61.", "Ou, Chan-Yen, Lin, Yi-Fan, Chen, Ying-Jiun, Chien, Cheng-Ting. \"Distinct protein degradation mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye development.\" Genes & development, 2002, pp. 2403-14.", "Farrell, Brian M, Gerth, Fabian, Yang, Cheng-Hao R, Yeh, Johannes T-H. \"A synthetic KLHL20 ligand to validate CUL3<sup>KLHL20</sup> as a potent E3 ligase for targeted protein degradation.\" Genes & development, 2022, pp. 1031-1042."]}, "4. Transcriptional regulation: ETV4 (ETS variant 4) and ETV5 (ETS variant 5) are transcription factors that regulate the expression of genes involved in cell proliferation, differentiation, and apoptosis. PRAME (Preferentially expressed antigen in melanoma) is a cancer/testis antigen that functions as a transcriptional repressor.": {"keywords": ["(ETV4[Title]) OR (ETV5[Title]) OR (PRAME[Title]) AND (transcription factors[Title])", "(ETV4[Title]) OR (ETV5[Title]) OR (PRAME[Title]) AND (cell proliferation[Title])", "(ETV4[Title]) OR (ETV5[Title]) OR (PRAME[Title]) AND (apoptosis[Title])", "(ETV4[Title/Abstract]) OR (ETV5[Title/Abstract]) OR (PRAME[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(ETV4[Title/Abstract]) OR (ETV5[Title/Abstract]) OR (PRAME[Title/Abstract]) AND (cell proliferation[Title/Abstract])", "(ETV4[Title/Abstract]) OR (ETV5[Title/Abstract]) OR (PRAME[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Fontanet, Paula Aldana, R\u00edos, Antonella Soledad, Alsina, Fernando Cruz, Paratcha, Gustavo, Ledda, Fernanda. \"Pea3 Transcription Factors, Etv4 and Etv5, Are Required for Proper Hippocampal Dendrite Development and Plasticity.\" Cerebral cortex (New York, N.Y. : 1991), 2018, pp. 236-249.", "Kuure, Satu, Chi, Xuan, Lu, Benson, Costantini, Frank. \"The transcription factors Etv4 and Etv5 mediate formation of the ureteric bud tip domain during kidney development.\" Development (Cambridge, England), 2010, pp. 1975-9.", "Akagi, Tadayuki, Kuure, Satu, Uranishi, Kousuke, Koide, Hiroshi, Costantini, Frank, Yokota, Takashi. \"ETS-related transcription factors ETV4 and ETV5 are involved in proliferation and induction of differentiation-associated genes in embryonic stem (ES) cells.\" The Journal of biological chemistry, 2015, pp. 22460-73."]}, "5. Tumor suppressors and oncogenes: NF2 (Neurofibromin 2) and VHL (Von Hippel-Lindau tumor suppressor) are tumor suppressors involved in the regulation of cell growth and differentiation. RIT1 (Ras-like without CAAX 1) is an oncogene that activates the MAPK/ERK signaling pathway, promoting cell proliferation and survival.": {"keywords": ["(NF2[Title]) OR (VHL[Title]) OR (RIT1[Title]) AND (tumor suppressors[Title])", "(NF2[Title]) OR (VHL[Title]) OR (RIT1[Title]) AND (oncogenes[Title])", "(NF2[Title]) OR (VHL[Title]) OR (RIT1[Title]) AND (cell growth[Title])", "(NF2[Title/Abstract]) OR (VHL[Title/Abstract]) OR (RIT1[Title/Abstract]) AND (tumor suppressors[Title/Abstract])", "(NF2[Title/Abstract]) OR (VHL[Title/Abstract]) OR (RIT1[Title/Abstract]) AND (oncogenes[Title/Abstract])", "(NF2[Title/Abstract]) OR (VHL[Title/Abstract]) OR (RIT1[Title/Abstract]) AND (cell growth[Title/Abstract])"], "references": ["Blagosklonny, M V. \"Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors.\" Oncogene, 2001, pp. 395-8.", "Semenza, Gregg L. \"VHL and p53: tumor suppressors team up to prevent cancer.\" Molecular cell, 2006, pp. 437-9.", "Cai, Qi-Liang, Knight, Jason S, Verma, Suhbash C, Zald, Philip, Robertson, Erle S. \"EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.\" PLoS pathogens, 2006, pp. e116."]}, "6. Cellular stress response: HSP90AA1 (Heat shock protein 90 alpha family class A member 1) is a molecular chaperone that assists in protein folding and stabilization, particularly under stress conditions. TNF (Tumor necrosis factor) is a pro-inflammatory cytokine that mediates cell death and inflammation in response to cellular stress.": {"keywords": ["(HSP90AA1[Title]) OR (TNF[Title]) AND (cellular stress response[Title])", "(HSP90AA1[Title]) OR (TNF[Title]) AND (molecular chaperone[Title])", "(HSP90AA1[Title]) OR (TNF[Title]) AND (inflammation[Title])", "(HSP90AA1[Title/Abstract]) OR (TNF[Title/Abstract]) AND (cellular stress response[Title/Abstract])", "(HSP90AA1[Title/Abstract]) OR (TNF[Title/Abstract]) AND (molecular chaperone[Title/Abstract])", "(HSP90AA1[Title/Abstract]) OR (TNF[Title/Abstract]) AND (inflammation[Title/Abstract])"], "references": ["Zelov\u00e1, Hana, Ho\u0161ek, Jan. \"TNF-\u03b1 signalling and inflammation: interactions between old acquaintances.\" Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013, pp. 641-51.", "Blaser, Heiko, Dostert, Catherine, Mak, Tak W, Brenner, Dirk. \"TNF and ROS Crosstalk in Inflammation.\" Trends in cell biology, 2016, pp. 249-261.", "van Loo, Geert, Bertrand, Mathieu J M. \"Death by TNF: a road to inflammation.\" Nature reviews. Immunology, 2023, pp. 289-303."]}, "7. Epigenetic regulation: TET2 (Tet methylcytosine dioxygenase 2) is involved in DNA demethylation, playing a role in epigenetic regulation of gene expression.": {"keywords": ["(TET2[Title]) AND (epigenetic regulation[Title])", "(TET2[Title]) AND (DNA demethylation[Title])", "(TET2[Title]) AND (gene expression[Title])", "(TET2[Title/Abstract]) AND (epigenetic regulation[Title/Abstract])", "(TET2[Title/Abstract]) AND (DNA demethylation[Title/Abstract])", "(TET2[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Elliott, Esther K, Hopkins, Lloyd N, Hensen, Robert, Sutherland, Heidi G, Haupt, Larisa M, Griffiths, Lyn R. \"Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.\" Frontiers in genetics, 2021, pp. 768913.", "Zhang, Xinyue, Cong, Yan, Chu, Zhaowei, Shi, Linjing, Zheng, Yi, Zhao, Qiang, Geng, Songmei, Guo, Kun. \"Aberrant epigenetic regulation of RAR\u03b2 by TET2 is involved in cutaneous squamous cell carcinoma resistance to retinoic acid.\" The international journal of biochemistry & cell biology, 2022, pp. 106190.", "Okashita, Naoki, Kuroki, Shunsuke, Maeda, Ryo, Tachibana, Makoto. \"TET2 catalyzes active DNA demethylation of the Sry promoter and enhances its expression.\" Scientific reports, 2019, pp. 13462."]}, "8. Protein-protein interactions: PARK2 (Parkin RBR E3 ubiquitin protein ligase) is an E3 ubiquitin ligase that mediates protein-protein interactions and is involved in the regulation of mitophagy.": {"keywords": ["(PARK2[Title]) AND (protein-protein interactions[Title])", "(PARK2[Title]) AND (E3 ubiquitin ligase[Title])", "(PARK2[Title]) AND (mitophagy[Title])", "(PARK2[Title/Abstract]) AND (protein-protein interactions[Title/Abstract])", "(PARK2[Title/Abstract]) AND (E3 ubiquitin ligase[Title/Abstract])", "(PARK2[Title/Abstract]) AND (mitophagy[Title/Abstract])"], "references": ["Zhou, Xiaofeng, Li, Yajie, Wang, Weilong, Wang, Sujie, Hou, Jinghan, Zhang, Aijia, Lv, Benjie, Gao, Can, Yan, Ziyi, Pang, Dan, Lu, Kui, Ahmad, Nor Hazwani, Wang, Lidong, Zhu, Jian, Zhang, Lichen, Zhuang, Ting, Li, Xiumin. \"Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.\" Theranostics, 2020, pp. 9443-9457.", "Montagnani, Valentina, Maresca, Luisa, Apollo, Alessandro, Pepe, Sara, Carr, Ryan M, Fernandez-Zapico, Martin E, Stecca, Barbara. \"E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.\" The Journal of biological chemistry, 2020, pp. 16058-16071.", "Tsubouchi, Kazuya, Araya, Jun, Kuwano, Kazuyoshi. \"PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses.\" Inflammation and regeneration, 2018, pp. 18."]}, "In conclusion, the system of interacting proteins is primarily involved in cell cycle regulation and DNA damage response, with additional roles in protein degradation, transcriptional regulation, tumor suppression, cellular stress response, epigenetic regulation, and protein-protein interactions.": {"keywords": [], "references": []}, "Proteins: BCL2, BCL2L1, BCL2L11, BCL2L2, CASP8, FAS, IFNGR1, MCL1, MS4A1, PARP1, PTPN13, TBX3, TP53.": {"keywords": [], "references": []}, "1. BCL2 family proteins (BCL2, BCL2L1, BCL2L11, BCL2L2, MCL1) are key regulators of apoptosis. They function by controlling mitochondrial outer membrane permeabilization, which leads to the release of cytochrome c and activation of caspases. BCL2 and BCL2L1 are anti-apoptotic, while BCL2L11 is pro-apoptotic. BCL2L2 and MCL1 have both anti- and pro-apoptotic roles depending on cellular context.": {"keywords": ["(BCL2[Title]) OR (BCL2L1[Title]) OR (BCL2L11[Title]) OR (BCL2L2[Title]) OR (MCL1[Title]) AND (apoptosis[Title])", "(BCL2[Title]) OR (BCL2L1[Title]) OR (BCL2L11[Title]) OR (BCL2L2[Title]) OR (MCL1[Title]) AND (mitochondrial membrane[Title])", "(BCL2[Title]) OR (BCL2L1[Title]) OR (BCL2L11[Title]) OR (BCL2L2[Title]) OR (MCL1[Title]) AND (cytochrome c[Title])", "(BCL2[Title/Abstract]) OR (BCL2L1[Title/Abstract]) OR (BCL2L11[Title/Abstract]) OR (BCL2L2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (apoptosis[Title/Abstract])", "(BCL2[Title/Abstract]) OR (BCL2L1[Title/Abstract]) OR (BCL2L11[Title/Abstract]) OR (BCL2L2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (mitochondrial membrane[Title/Abstract])", "(BCL2[Title/Abstract]) OR (BCL2L1[Title/Abstract]) OR (BCL2L11[Title/Abstract]) OR (BCL2L2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (cytochrome c[Title/Abstract])"], "references": ["Edlich, Frank. \"BCL-2 proteins and apoptosis: Recent insights and unknowns.\" Biochemical and biophysical research communications, 2018, pp. 26-34.", "Warren, Chloe F A, Wong-Brown, Michelle W, Bowden, Nikola A. \"BCL-2 family isoforms in apoptosis and cancer.\" Cell death & disease, 2019, pp. 177.", "Liang, Ji, Cao, Ruixiu, Wang, Xiongjun, Zhang, Yajuan, Wang, Pan, Gao, Hong, Li, Chen, Yang, Fan, Zeng, Rong, Wei, Ping, Li, Dawei, Li, Wenfeng, Yang, Weiwei. \"Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2.\" Cell research, 2017, pp. 329-351."]}, "2. CASP8 is an initiator caspase involved in the extrinsic apoptosis pathway. It is activated by FAS, a death receptor, upon binding to its ligand (FASL). Activated CASP8 can cleave and activate downstream effector caspases, leading to apoptosis.": {"keywords": ["(CASP8[Title]) OR (FAS[Title]) OR (FASL[Title]) AND (apoptosis[Title])", "(CASP8[Title]) OR (FAS[Title]) OR (FASL[Title]) AND (CASP8[Title])", "(CASP8[Title]) OR (FAS[Title]) OR (FASL[Title]) AND (extrinsic pathway[Title])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (FASL[Title/Abstract]) AND (apoptosis[Title/Abstract])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (FASL[Title/Abstract]) AND (CASP8[Title/Abstract])", "(CASP8[Title/Abstract]) OR (FAS[Title/Abstract]) OR (FASL[Title/Abstract]) AND (extrinsic pathway[Title/Abstract])"], "references": ["Tan, Siwei, Liu, Xianzhi, Chen, Lingjun, Wu, Xiaoqin, Tao, Li, Pan, Xuemei, Tan, Shuyan, Liu, Huiling, Jiang, Jie, Wu, Bin. \"Fas/FasL mediates NF-\u03baBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis.\" Cell death & disease, 2021, pp. 474.", "Nagata, S. \"Fas-mediated apoptosis.\" Advances in experimental medicine and biology, 1996, pp. 119-24.", "Mao, Ming-Guang, Xu, Jia, Liu, Rui-Ting, Ye, Lin, Wang, Rui, Jiang, Jie-Lan. \"Fas/FasL of pacific cod mediated apoptosis.\" Developmental and comparative immunology, 2021, pp. 104022."]}, "3. IFNGR1 is a receptor for interferon-gamma (IFN-\u03b3), a cytokine with immunomodulatory and pro-apoptotic functions. Binding of IFN-\u03b3 to IFNGR1 can activate downstream signaling pathways, including the JAK-STAT pathway, which can induce apoptosis in certain cell types.": {"keywords": ["(IFNGR1[Title]) OR (IFN-\u03b3[Title]) OR (JAK-STAT[Title]) AND (interferon-gamma[Title])", "(IFNGR1[Title]) OR (IFN-\u03b3[Title]) OR (JAK-STAT[Title]) AND (JAK-STAT pathway[Title])", "(IFNGR1[Title]) OR (IFN-\u03b3[Title]) OR (JAK-STAT[Title]) AND (apoptosis[Title])", "(IFNGR1[Title/Abstract]) OR (IFN-\u03b3[Title/Abstract]) OR (JAK-STAT[Title/Abstract]) AND (interferon-gamma[Title/Abstract])", "(IFNGR1[Title/Abstract]) OR (IFN-\u03b3[Title/Abstract]) OR (JAK-STAT[Title/Abstract]) AND (JAK-STAT pathway[Title/Abstract])", "(IFNGR1[Title/Abstract]) OR (IFN-\u03b3[Title/Abstract]) OR (JAK-STAT[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Kak, Gunjan, Raza, Mohsin, Tiwari, Brijendra K. \"Interferon-gamma (IFN-\u03b3): Exploring its implications in infectious diseases.\" Biomolecular concepts, 2018, pp. 64-79.", "Ding, Huihui, Wang, Gongfu, Yu, Zhen, Sun, Huimin, Wang, Lu. \"Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1/2 (IFN\u03b3R1/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway.\" Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, pp. 113683.", "Singh, Snahlata, Kumar, Sushil, Srivastava, Ratnesh Kumar, Nandi, Ajeya, Thacker, Gatha, Murali, Hemma, Kim, Sabrina, Baldeon, Mary, Tobias, John, Blanco, Mario Andres, Saffie, Rizwan, Zaidi, M Raza, Sinha, Satrajit, Busino, Luca, Fuchs, Serge Y, Chakrabarti, Rumela. \"Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling.\" Nature cell biology, 2020, pp. 591-602."]}, "4. MS4A1 (CD20) is a membrane protein expressed on B cells. It is involved in B cell activation and proliferation. Its role in apoptosis is not well-defined, but it has been suggested that it may modulate BCL2 family protein function.": {"keywords": ["(MS4A1[Title]) OR (CD20[Title]) OR (BCL2[Title]) AND (B cell activation[Title])", "(MS4A1[Title]) OR (CD20[Title]) OR (BCL2[Title]) AND (membrane protein[Title])", "(MS4A1[Title]) OR (CD20[Title]) OR (BCL2[Title]) AND (apoptosis[Title])", "(MS4A1[Title/Abstract]) OR (CD20[Title/Abstract]) OR (BCL2[Title/Abstract]) AND (B cell activation[Title/Abstract])", "(MS4A1[Title/Abstract]) OR (CD20[Title/Abstract]) OR (BCL2[Title/Abstract]) AND (membrane protein[Title/Abstract])", "(MS4A1[Title/Abstract]) OR (CD20[Title/Abstract]) OR (BCL2[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Weber, Martin S, Prod'homme, Thomas, Patarroyo, Juan C, Molnarfi, Nicolas, Karnezis, Tara, Lehmann-Horn, Klaus, Danilenko, Dimitry M, Eastham-Anderson, Jeffrey, Slavin, Anthony J, Linington, Christopher, Bernard, Claude C A, Martin, Flavius, Zamvil, Scott S. \"B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.\" Annals of neurology, 2010, pp. 369-83.", "Jahrsd\u00f6rfer, B, Jox, R, M\u00fchlenhoff, L, Tschoep, K, Krug, A, Rothenfusser, S, Meinhardt, G, Emmerich, B, Endres, S, Hartmann, G. \"Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.\" Journal of leukocyte biology, 2002, pp. 83-92.", "Wilson, B E, Mochon, E, Boxer, L M. \"Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.\" Molecular and cellular biology, 1996, pp. 5546-56."]}, "5. PARP1 is a DNA repair enzyme that detects and repairs DNA strand breaks. In the context of apoptosis, PARP1 can be cleaved and inactivated by caspases, leading to the accumulation of DNA damage and amplification of the apoptotic signal.": {"keywords": ["(PARP1[Title]) OR (caspases[Title]) AND (DNA repair[Title])", "(PARP1[Title]) OR (caspases[Title]) AND (enzyme[Title])", "(PARP1[Title]) OR (caspases[Title]) AND (apoptosis[Title])", "(PARP1[Title/Abstract]) OR (caspases[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(PARP1[Title/Abstract]) OR (caspases[Title/Abstract]) AND (enzyme[Title/Abstract])", "(PARP1[Title/Abstract]) OR (caspases[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Ray Chaudhuri, Arnab, Nussenzweig, Andr\u00e9. \"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.\" Nature reviews. Molecular cell biology, 2017, pp. 610-621.", "Zada, David, Sela, Yaniv, Matosevich, Noa, Monsonego, Adir, Lerer-Goldshtein, Tali, Nir, Yuval, Appelbaum, Lior. \"Parp1 promotes sleep, which enhances DNA repair in neurons.\" Molecular cell, 2021, pp. 4979-4993.e7.", "Mao, Zhiyong, Hine, Christopher, Tian, Xiao, Van Meter, Michael, Au, Matthew, Vaidya, Amita, Seluanov, Andrei, Gorbunova, Vera. \"SIRT6 promotes DNA repair under stress by activating PARP1.\" Science (New York, N.Y.), 2011, pp. 1443-6."]}, "6. PTPN13 is a protein tyrosine phosphatase involved in the regulation of various signaling pathways. It has been reported to interact with FAS and modulate FAS-mediated apoptosis, although its precise role in this process is not fully understood.": {"keywords": ["(PTPN13[Title]) OR (FAS[Title]) AND (protein tyrosine phosphatase[Title])", "(PTPN13[Title]) OR (FAS[Title]) AND (signaling pathways[Title])", "(PTPN13[Title]) OR (FAS[Title]) AND (apoptosis[Title])", "(PTPN13[Title/Abstract]) OR (FAS[Title/Abstract]) AND (protein tyrosine phosphatase[Title/Abstract])", "(PTPN13[Title/Abstract]) OR (FAS[Title/Abstract]) AND (signaling pathways[Title/Abstract])", "(PTPN13[Title/Abstract]) OR (FAS[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Inazawa, J, Ariyama, T, Abe, T, Druck, T, Ohta, M, Huebner, K, Yanagisawa, J, Reed, J C, Sato, T. \"PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.\" Genomics, 1996, pp. 240-2.", "Zhu, J-H, Chen, R, Yi, W, Cantin, G T, Fearns, C, Yang, Y, Yates, J R, Lee, J-D. \"Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.\" Oncogene, 2008, pp. 2525-31.", "van den Maagdenberg, A M, Olde Weghuis, D, Rijss, J, Merkx, G F, Wieringa, B, Geurts van Kessel, A, Hendriks, W J. \"The gene (PTPN13) encoding the protein tyrosine phosphatase PTP-BL/PTP-BAS is located in mouse chromosome region 5E/F and human chromosome region 4q21.\" Cytogenetics and cell genetics, 1996, pp. 153-5."]}, "7. TBX3 is a transcription factor involved in development and cell fate determination. It has been implicated in the regulation of apoptosis through the repression of pro-apoptotic genes, such as BCL2L11.": {"keywords": ["(TBX3[Title]) OR (BCL2L11[Title]) AND (transcription factor[Title])", "(TBX3[Title]) OR (BCL2L11[Title]) AND (development[Title])", "(TBX3[Title]) OR (BCL2L11[Title]) AND (apoptosis[Title])", "(TBX3[Title/Abstract]) OR (BCL2L11[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(TBX3[Title/Abstract]) OR (BCL2L11[Title/Abstract]) AND (development[Title/Abstract])", "(TBX3[Title/Abstract]) OR (BCL2L11[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Feng, Xianguang, Yao, Wenhuan, Zhang, Zengzhen, Yuan, Fangshui, Liang, Li, Zhou, Jingqiang, Liu, Shuang, Song, Jiqing. \"T-box Transcription Factor Tbx3 Contributes to Human Hepatocellular Carcinoma Cell Migration and Invasion by Repressing E-Cadherin Expression.\" Oncology research, 2018, pp. 959-966.", "Aliwaini, Saeb, Lubbad, Abdel Monem, Shourfa, Ahmed, Hamada, Hosam A A, Ayesh, Basim, Abu Tayem, Husam Eddeen M, Abu Mustafa, Ayman, Abu Rouk, Fayek, Redwan, Moen M, Al-Najjar, Mohamed. \"Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer.\" Molecular and clinical oncology, 2019, pp. 105-112.", "Peres, Jade, Prince, Sharon. \"The T-box transcription factor, TBX3, is sufficient to promote melanoma formation and invasion.\" Molecular cancer, 2013, pp. 117."]}, "8. TP53 (p53) is a tumor suppressor protein that plays a central role in the cellular response to DNA damage and other stress signals. It can induce apoptosis by transcriptionally activating pro-apoptotic genes, such as BCL2L11 and PUMA, and repressing anti-apoptotic genes, such as BCL2 and MCL1.": {"keywords": ["(BCL2L11[Title]) OR (PUMA[Title]) OR (BCL2[Title]) OR (MCL1[Title]) AND (tumor suppressor[Title])", "(BCL2L11[Title]) OR (PUMA[Title]) OR (BCL2[Title]) OR (MCL1[Title]) AND (DNA damage[Title])", "(BCL2L11[Title]) OR (PUMA[Title]) OR (BCL2[Title]) OR (MCL1[Title]) AND (apoptosis[Title])", "(BCL2L11[Title/Abstract]) OR (PUMA[Title/Abstract]) OR (BCL2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(BCL2L11[Title/Abstract]) OR (PUMA[Title/Abstract]) OR (BCL2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (DNA damage[Title/Abstract])", "(BCL2L11[Title/Abstract]) OR (PUMA[Title/Abstract]) OR (BCL2[Title/Abstract]) OR (MCL1[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Park, So Young, Jeong, Mi Suk, Jang, Se Bok. \"In vitro binding properties of tumor suppressor p53 with PUMA and NOXA.\" Biochemical and biophysical research communications, 2012, pp. 350-6.", "Lin, Yi-Chia, Lin, Ji-Fan, Tsai, Te-Fu, Chou, Kuang-Yu, Chen, Hung-En, Hwang, Thomas I-Sheng. \"Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells.\" Asian journal of surgery, 2017, pp. 396-406.", "Widden, Hayley, Kaczmarczyk, Aneta, Subedi, Ashok, Whitaker, Robert H, Placzek, William J. \"MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73.\" Cell death & disease, 2020, pp. 946."]}, "Proteins: BARD1, BLM, BRCA1, BRCA2, BUB1B, CHEK1, FANCD2, RAD51, RAD51C, TOP2A, TP53, WRN.": {"keywords": [], "references": []}, "- BRCA1, BRCA2, RAD51, and RAD51C are key components of HRR, a process that repairs double-strand breaks in DNA.": {"keywords": ["(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) AND (HRR[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) AND (double-strand breaks[Title])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) AND (HRR[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) AND (double-strand breaks[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Kwon, Youngho, R\u00f6sner, Heike, Zhao, Weixing, Selemenakis, Platon, He, Zhuoling, Kawale, Ajinkya S, Katz, Jeffrey N, Rogers, Cody M, Neal, Francisco E, Badamchi Shabestari, Aida, Petrosius, Valdemaras, Singh, Akhilesh K, Joel, Marina Z, Lu, Lucy, Holloway, Stephen P, Burma, Sandeep, Mukherjee, Bipasha, Hromas, Robert, Mazin, Alexander, Wiese, Claudia, S\u00f8rensen, Claus S, Sung, Patrick. \"DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation.\" Nature communications, 2023, pp. 432."]}, "- BRCA1 and BARD1 form a complex that plays a role in DNA damage response and repair.": {"keywords": ["(BRCA1[Title]) OR (BARD1[Title]) AND (DNA damage response[Title])", "(BRCA1[Title]) OR (BARD1[Title]) AND (repair[Title])", "(BRCA1[Title]) OR (BARD1[Title]) AND (complex[Title])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) AND (repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) AND (complex[Title/Abstract])"], "references": ["Foo, Tzeh Keong, Xia, Bing. \"BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.\" Cancer research, 2022, pp. 3191-3197.", "Mirza-Aghazadeh-Attari, Mohammad, Recio, Maria Jos\u00e9, Darband, Saber Ghazizadeh, Kaviani, Mojtaba, Safa, Amin, Mihanfar, Ainaz, Sadighparvar, Shirin, Karimian, Ansar, Alemi, Forough, Majidinia, Maryam, Yousefi, Bahman. \"DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.\" DNA repair, 2021, pp. 103032.", "Macchini, Marina, Centonze, Federico, Peretti, Umberto, Orsi, Giulia, Militello, Anna Maria, Valente, Maria Maddalena, Cascinu, Stefano, Reni, Michele. \"Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.\" Cancer treatment reviews, 2022, pp. 102357."]}, "- BRCA2 and RAD51C facilitate RAD51 loading onto single-stranded DNA, promoting strand invasion and exchange.": {"keywords": ["(BRCA2[Title]) OR (RAD51C[Title]) OR (RAD51[Title]) AND (RAD51 loading[Title])", "(BRCA2[Title]) OR (RAD51C[Title]) OR (RAD51[Title]) AND (strand invasion[Title])", "(BRCA2[Title]) OR (RAD51C[Title]) OR (RAD51[Title]) AND (DNA[Title])", "(BRCA2[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (RAD51 loading[Title/Abstract])", "(BRCA2[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (strand invasion[Title/Abstract])", "(BRCA2[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (DNA[Title/Abstract])"], "references": ["Park, Pyoung Hwa, Yamamoto, Tomomi M, Li, Hua, Alcivar, Allen L, Xia, Bing, Wang, Yifan, Bernhardy, Andrea J, Turner, Kristen M, Kossenkov, Andrew V, Watson, Zachary L, Behbakht, Kian, Casadei, Silvia, Swisher, Elizabeth M, Mischel, Paul S, Johnson, Neil, Bitler, Benjamin G. \"Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.\" Molecular cancer therapeutics, 2020, pp. 602-613.", "Zhang, Hongshan, Schaub, Jeffrey M, Finkelstein, Ilya J. \"RADX condenses single-stranded DNA to antagonize RAD51 loading.\" Nucleic acids research, 2020, pp. 7834-7843.", "Lahiri, Sudipta, Jensen, Ryan B. \"DNA Strand Exchange to Monitor Human RAD51-Mediated Strand Invasion and Pairing.\" Methods in molecular biology (Clifton, N.J.), 2021, pp. 101-113."]}, "- FANCD2 is involved in the Fanconi anemia pathway, which repairs interstrand crosslinks in DNA.": {"keywords": ["(FANCD2[Title]) AND (Fanconi anemia pathway[Title])", "(FANCD2[Title]) AND (DNA repair[Title])", "(FANCD2[Title]) AND (interstrand crosslinks[Title])", "(FANCD2[Title/Abstract]) AND (Fanconi anemia pathway[Title/Abstract])", "(FANCD2[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(FANCD2[Title/Abstract]) AND (interstrand crosslinks[Title/Abstract])"], "references": ["Kupculak, Marian, Bai, Fengxiang, Luo, Qiang, Yoshikawa, Yasunaga, Lopez-Martinez, David, Xu, Hannan, Uphoff, Stephan, Cohn, Martin A. \"Phosphorylation by ATR triggers FANCD2 chromatin loading and activates the Fanconi anemia pathway.\" Cell reports, 2023, pp. 112721.", "Rego, Meghan A, Kolling, Frederick W, Vuono, Elizabeth A, Mauro, Maurizio, Howlett, Niall G. \"Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein.\" Blood, 2012, pp. 2109-17.", "Chang, Lixian, Gao, Xingjie, Wang, Yuxia, Huang, Chunmin, Gao, Min, Wang, Xiaomin, Liu, Chao, Wu, Wenqi, An, Wenbin, Wan, Yang, Zhang, Aoli, Zhang, Yingchi, Yuan, Weiping, Zhu, Xiaofan. \"DNAH2 facilitates the homologous recombination repair of Fanconi anemia pathway through modulating FANCD2 ubiquitination.\" Blood science (Baltimore, Md.), 2021, pp. 71-77."]}, "- BRCA1, BRCA2, and RAD51 also participate in this pathway, highlighting the interconnectivity of DNA repair processes.": {"keywords": ["(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) AND (interconnectivity[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) AND (BRCA1[Title])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (interconnectivity[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) AND (BRCA1[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Kwon, Youngho, R\u00f6sner, Heike, Zhao, Weixing, Selemenakis, Platon, He, Zhuoling, Kawale, Ajinkya S, Katz, Jeffrey N, Rogers, Cody M, Neal, Francisco E, Badamchi Shabestari, Aida, Petrosius, Valdemaras, Singh, Akhilesh K, Joel, Marina Z, Lu, Lucy, Holloway, Stephen P, Burma, Sandeep, Mukherjee, Bipasha, Hromas, Robert, Mazin, Alexander, Wiese, Claudia, S\u00f8rensen, Claus S, Sung, Patrick. \"DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation.\" Nature communications, 2023, pp. 432."]}, "- BLM and WRN are RecQ helicases that unwind DNA, playing a role in DNA replication, repair, and recombination.": {"keywords": ["(BLM[Title]) OR (WRN[Title]) AND (DNA replication[Title])", "(BLM[Title]) OR (WRN[Title]) AND (RecQ helicases[Title])", "(BLM[Title]) OR (WRN[Title]) AND (DNA repair[Title])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (DNA replication[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (RecQ helicases[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (DNA repair[Title/Abstract])"], "references": ["Manthei, Kelly A, Keck, James L. \"The BLM dissolvasome in DNA replication and repair.\" Cellular and molecular life sciences : CMLS, 2013, pp. 4067-84.", "de Renty, Christelle, Pond, Kelvin W, Yagle, Mary K, Ellis, Nathan A. \"BLM Sumoylation Is Required for Replication Stability and Normal Fork Velocity During DNA Replication.\" Frontiers in molecular biosciences, 2022, pp. 875102.", "Lozada, Enerlyn, Yi, Jingjie, Luo, Jianyuan, Orren, David K. \"Acetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.\" Biogerontology, 2014, pp. 347-66."]}, "- Mutations in BLM and WRN are associated with Bloom syndrome and Werner syndrome, respectively, both characterized by genomic instability.": {"keywords": ["(BLM[Title]) OR (WRN[Title]) AND (mutations[Title])", "(BLM[Title]) OR (WRN[Title]) AND (genomic instability[Title])", "(BLM[Title]) OR (WRN[Title]) AND (Bloom syndrome[Title])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (mutations[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (genomic instability[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (Bloom syndrome[Title/Abstract])"], "references": ["Ledet, Elisa M, Antonarakis, Emmanuel S, Isaacs, William B, Lotan, Tamara L, Pritchard, Colin, Sartor, A Oliver. \"Germline BLM mutations and metastatic prostate cancer.\" The Prostate, 2020, pp. 235-237.", "Bononi, Angela, Goto, Keisuke, Ak, Guntulu, Yoshikawa, Yoshie, Emi, Mitsuru, Pastorino, Sandra, Carparelli, Lorenzo, Ferro, Angelica, Nasu, Masaki, Kim, Jin-Hee, Suarez, Joelle S, Xu, Ronghui, Tanji, Mika, Takinishi, Yasutaka, Minaai, Michael, Novelli, Flavia, Pagano, Ian, Gaudino, Giovanni, Pass, Harvey I, Groden, Joanna, Grzymski, Joseph J, Metintas, Muzaffer, Akarsu, Muhittin, Morrow, Betsy, Hassan, Raffit, Yang, Haining, Carbone, Michele. \"Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesothelioma.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 33466-33473.", "Kamiya, Hiroyuki, Makino, Tetsuaki, Suzuki, Tetsuya, Kobayashi, Miwako, Matsuoka, Ichiro. \"Mutations induced by 8-oxo-7,8-dihydroguanine in WRN- and DNA polymerase \u03bb-double knockdown cells.\" Mutagenesis, 2018, pp. 301-310."]}, "4. Cell Cycle Checkpoints and Apoptosis": {"keywords": [], "references": []}, "- CHEK1 and TP53 are involved in cell cycle regulation and DNA damage response.": {"keywords": ["(CHEK1[Title]) OR (TP53[Title]) AND (cell cycle regulation[Title])", "(CHEK1[Title]) OR (TP53[Title]) AND (DNA damage response[Title])", "(CHEK1[Title]) OR (TP53[Title]) AND (CHEK1[Title])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (CHEK1[Title/Abstract])"], "references": ["Schultz-Rogers, Laura E, Thayer, Michelle L, Kambakam, Sekhar, Wierson, Wesley A, Helmer, Jordan A, Wishman, Mark D, Wall, Kristen A, Greig, Jessica L, Forsman, Jaimie L, Puchhalapalli, Kavya, Nair, Siddharth, Weiss, Trevor J, Luiken, Jon M, Blackburn, Patrick R, Ekker, Stephen C, Kool, Marcel, McGrail, Maura. \"Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis.\" Developmental dynamics : an official publication of the American Association of Anatomists, 2022, pp. 1267-1290.", "Lindemann, A, Takahashi, H, Patel, A A, Osman, A A, Myers, J N. \"Targeting the DNA Damage Response in OSCC with TP53 Mutations.\" Journal of dental research, 2018, pp. 635-644.", "de Souza, Samara Silva, da Costa, Jaqueline Cust\u00f3dio, da Silva, Grazyelle Sebrenski, de Almeida-Val, Vera Maria Fonseca. \"Malathion alters the transcription of target genes of the tumour suppressor tp53 and cancerous processes in Colossoma macropomum: Mechanisms of DNA damage response, oxidative stress and apoptosis.\" Chemico-biological interactions, 2023, pp. 110405."]}, "- CHEK1 is a kinase that phosphorylates and activates downstream effectors in response to DNA damage, leading to cell cycle arrest.": {"keywords": ["(CHEK1[Title]) AND (kinase[Title])", "(CHEK1[Title]) AND (DNA damage[Title])", "(CHEK1[Title]) AND (cell cycle arrest[Title])", "(CHEK1[Title/Abstract]) AND (kinase[Title/Abstract])", "(CHEK1[Title/Abstract]) AND (DNA damage[Title/Abstract])", "(CHEK1[Title/Abstract]) AND (cell cycle arrest[Title/Abstract])"], "references": ["Bai, Xiaobin, Wang, Jia, Huo, Longwei, Xie, Yuchen, Xie, Wanfu, Xu, Gaofeng, Wang, Maode. \"Serine/Threonine Kinase CHEK1-Dependent Transcriptional Regulation of RAD54L Promotes Proliferation and Radio Resistance in Glioblastoma.\" Translational oncology, 2018, pp. 140-146.", "Fraley, Mark E, Steen, Justin T, Brnardic, Edward J, Arrington, Kenneth L, Spencer, Keith L, Hanney, Barbara A, Kim, Yuntae, Hartman, George D, Stirdivant, Steven M, Drakas, Bob A, Rickert, Keith, Walsh, Eileen S, Hamilton, Kelly, Buser, Carolyn A, Hardwick, James, Tao, Weikang, Beck, Stephen C, Mao, Xianzhi, Lobell, Robert B, Sepp-Lorenzino, Laura, Yan, Youwei, Ikuta, Mari, Munshi, Sanjeev K, Kuo, Lawrence C, Kreatsoulas, Constantine. \"3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.\" Bioorganic & medicinal chemistry letters, 2006, pp. 6049-53.", "Abe, Hironori, Alavattam, Kris G, Kato, Yasuko, Castrillon, Diego H, Pang, Qishen, Andreassen, Paul R, Namekawa, Satoshi H. \"CHEK1 coordinates DNA damage signaling and meiotic progression in the male germline of mice.\" Human molecular genetics, 2018, pp. 1136-1149."]}, "- TP53, a tumor suppressor, promotes cell cycle arrest, DNA repair, or apoptosis in response to DNA damage.": {"keywords": ["(TP53[Title]) AND (cell cycle[Title])", "(TP53[Title]) AND (DNA repair[Title])", "(TP53[Title]) AND (apoptosis[Title])", "(TP53[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Meireles Da Costa, Nathalia, Palumbo, Antonio, De Martino, Marco, Fusco, Alfredo, Ribeiro Pinto, Luis Felipe, Nasciutti, Luiz Eurico. \"Interplay between HMGA and TP53 in cell cycle control along tumor progression.\" Cellular and molecular life sciences : CMLS, 2021, pp. 817-831.", "Bulgakova, O, Kussainova, A, Bersimbaev, R. \"The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis.\" Vavilovskii zhurnal genetiki i selektsii, 2020, pp. 777-784.", "Patterson-Fortin, Jeffrey, Bose, Arindam, Tsai, Wei-Chih, Grochala, Carter, Nguyen, Huy, Zhou, Jia, Parmar, Kalindi, Lazaro, Jean-Bernard, Liu, Joyce, McQueen, Kelsey, Shapiro, Geoffrey I, Kozono, David, D'Andrea, Alan D. \"Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.\" Cancer research, 2022, pp. 3815-3829."]}, "- BUB1B is a kinase involved in the mitotic spindle assembly checkpoint, ensuring proper chromosome segregation during cell division.": {"keywords": ["(BUB1B[Title]) AND (mitotic spindle[Title])", "(BUB1B[Title]) AND (chromosome segregation[Title])", "(BUB1B[Title]) AND (cell division[Title])", "(BUB1B[Title/Abstract]) AND (mitotic spindle[Title/Abstract])", "(BUB1B[Title/Abstract]) AND (chromosome segregation[Title/Abstract])", "(BUB1B[Title/Abstract]) AND (cell division[Title/Abstract])"], "references": ["Matsuura, Shinya, Matsumoto, Yoshiyuki, Morishima, Ken-ichi, Izumi, Hideki, Matsumoto, Hiroshi, Ito, Emi, Tsutsui, Keisuke, Kobayashi, Junya, Tauchi, Hiroshi, Kajiwara, Yoshinori, Hama, Seiji, Kurisu, Kaoru, Tahara, Hidetoshi, Oshimura, Mitsuo, Komatsu, Kenshi, Ikeuchi, Tatsuro, Kajii, Tadashi. \"Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.\" American journal of medical genetics. Part A, 2006, pp. 358-67.", "Lee, Eunjee, Pain, Margaret, Wang, Huaien, Herman, Jacob A, Toledo, Chad M, DeLuca, Jennifer G, Yong, Raymund L, Paddison, Patrick, Zhu, Jun. \"Sensitivity to <i>BUB1B</i> Inhibition Defines an Alternative Classification of Glioblastoma.\" Cancer research, 2017, pp. 5518-5529.", "Hudler, Petra, Britovsek, Nina Kocevar, Grazio, Snjezana Frkovic, Komel, Radovan. \"Association between polymorphisms in segregation genes BUB1B and TTK and gastric cancer risk.\" Radiology and oncology, 2016, pp. 297-307."]}, "- TOP2A is a type II topoisomerase that resolves DNA topological problems during replication, transcription, and chromosome segregation.": {"keywords": ["(TOP2A[Title]) AND (DNA topological problems[Title])", "(TOP2A[Title]) AND (replication[Title])", "(TOP2A[Title]) AND (transcription[Title])", "(TOP2A[Title/Abstract]) AND (DNA topological problems[Title/Abstract])", "(TOP2A[Title/Abstract]) AND (replication[Title/Abstract])", "(TOP2A[Title/Abstract]) AND (transcription[Title/Abstract])"], "references": ["Tian, Tian, Bu, Min, Chen, Xu, Ding, Linli, Yang, Yulan, Han, Jinhua, Feng, Xin-Hua, Xu, Pinglong, Liu, Ting, Ying, Songmin, Lei, Yang, Li, Qing, Huang, Jun. \"The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork Reversal to Promote Genome Stability.\" Molecular cell, 2021, pp. 198-211.e6.", "Uusk\u00fcla-Reimand, Liis, Wilson, Michael D. \"Untangling the roles of TOP2A and TOP2B in transcription and cancer.\" Science advances, 2022, pp. eadd4920.", "Morotomi-Yano, Keiko, Yano, Ken-Ichi. \"Nucleolar translocation of human DNA topoisomerase II by ATP depletion and its disruption by the RNA polymerase I inhibitor BMH-21.\" Scientific reports, 2021, pp. 21533."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is DNA repair and stability, with a focus on homologous recombination repair. These proteins also play roles in cell cycle regulation, apoptosis, and maintenance of genomic integrity.": {"keywords": [], "references": []}, "The system of interacting proteins primarily involves the regulation of the cell cycle, including cell cycle progression, checkpoint control, and DNA repair mechanisms. ": {"keywords": [], "references": []}, "1. Cell cycle progression: Several proteins in this system are involved in the regulation of cell cycle progression. CCND1 and CCNE1 are cyclins that bind to cyclin-dependent kinases (CDKs) to promote cell cycle progression. CDKN1A, CDKN1B, and CDKN2A are CDK inhibitors that negatively regulate the cell cycle. RB1 and RBL1 are retinoblastoma proteins that control the G1/S transition by interacting with E2F1, a transcription factor that regulates the expression of genes required for cell cycle progression.": {"keywords": ["(CCND1[Title]) OR (CCNE1[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (E2F1[Title]) AND (cell cycle progression[Title])", "(CCND1[Title]) OR (CCNE1[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (E2F1[Title]) AND (cyclins[Title])", "(CCND1[Title]) OR (CCNE1[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN2A[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (E2F1[Title]) AND (retinoblastoma proteins[Title])", "(CCND1[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (E2F1[Title/Abstract]) AND (cell cycle progression[Title/Abstract])", "(CCND1[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (E2F1[Title/Abstract]) AND (cyclins[Title/Abstract])", "(CCND1[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (E2F1[Title/Abstract]) AND (retinoblastoma proteins[Title/Abstract])"], "references": ["Liu, Xiaowei, Cai, Yuanxia, Cheng, Cheng, Gu, Yaoyao, Hu, Xiaoxiao, Chen, Kai, Wu, Yeming, Wu, Zhixiang. \"PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis.\" Cell death & disease, 2022, pp. 178.", "Choiniere, Jonathan, Wu, Jianguo, Wang, Li. \"Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins.\" Molecular pharmacology, 2017, pp. 189-196.", "Monteiro, Lu\u00eds Silva, Diniz-Freitas, M\u00e1rcio, Warnakulasuriya, Saman, Garcia-Caballero, Tom\u00e1s, Forteza-Vila, Jer\u00f3nimo, Fraga, M\u00e1ximo. \"Prognostic Significance of Cyclins A2, B1, D1, and E1 and <i>CCND1</i> Numerical Aberrations in Oral Squamous Cell Carcinomas.\" Analytical cellular pathology (Amsterdam), 2018, pp. 7253510."]}, "2. Checkpoint control: BUB1B is a key component of the spindle assembly checkpoint, which ensures proper chromosome segregation during mitosis. TP53 is a tumor suppressor protein that plays a crucial role in the DNA damage response and cell cycle arrest. CKS1B is involved in the regulation of the G2/M transition and is required for proper mitotic progression.": {"keywords": ["(BUB1B[Title]) OR (TP53[Title]) OR (CKS1B[Title]) AND (checkpoint control[Title])", "(BUB1B[Title]) OR (TP53[Title]) OR (CKS1B[Title]) AND (mitotic progression[Title])", "(BUB1B[Title]) OR (TP53[Title]) OR (CKS1B[Title]) AND (DNA damage response[Title])", "(BUB1B[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (checkpoint control[Title/Abstract])", "(BUB1B[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (mitotic progression[Title/Abstract])", "(BUB1B[Title/Abstract]) OR (TP53[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (DNA damage response[Title/Abstract])"], "references": ["Wahl, G M, Linke, S P, Paulson, T G, Huang, L C. \"Maintaining genetic stability through TP53 mediated checkpoint control.\" Cancer surveys, 1997, pp. 183-219.", "Lindemann, A, Takahashi, H, Patel, A A, Osman, A A, Myers, J N. \"Targeting the DNA Damage Response in OSCC with TP53 Mutations.\" Journal of dental research, 2018, pp. 635-644.", "de Souza, Samara Silva, da Costa, Jaqueline Cust\u00f3dio, da Silva, Grazyelle Sebrenski, de Almeida-Val, Vera Maria Fonseca. \"Malathion alters the transcription of target genes of the tumour suppressor tp53 and cancerous processes in Colossoma macropomum: Mechanisms of DNA damage response, oxidative stress and apoptosis.\" Chemico-biological interactions, 2023, pp. 110405."]}, "3. DNA repair and chromatin remodeling: BRCA1 is a tumor suppressor protein involved in DNA repair, particularly in the repair of double-strand breaks through homologous recombination. TOP2A is a DNA topoisomerase that plays a role in the resolution of DNA topological problems during replication, transcription, and chromosomal segregation. HDAC1 is a histone deacetylase that modulates chromatin structure and is involved in the regulation of gene expression. CREBBP and EP300 are histone acetyltransferases that play a role in chromatin remodeling and transcriptional regulation.": {"keywords": ["(BRCA1[Title]) OR (TOP2A[Title]) OR (HDAC1[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (TOP2A[Title]) OR (HDAC1[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (chromatin remodeling[Title])", "(BRCA1[Title]) OR (TOP2A[Title]) OR (HDAC1[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (transcriptional regulation[Title])", "(BRCA1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (TOP2A[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Zhang, Ling, Chen, Hua, Gong, Ming, Gong, Feng. \"The chromatin remodeling protein BRG1 modulates BRCA1 response to UV irradiation by regulating ATR/ATM activation.\" Frontiers in oncology, 2013, pp. 7."]}, "4. Transcriptional regulation and protein stability: MYC is a transcription factor that regulates the expression of genes involved in cell growth, proliferation, and apoptosis. CTNNB1 is a component of the Wnt signaling pathway and is involved in the regulation of gene expression and cell adhesion. HLA-A is involved in antigen presentation and immune response regulation.": {"keywords": ["(MYC[Title]) OR (CTNNB1[Title]) OR (HLA-A[Title]) AND (transcription factor[Title])", "(MYC[Title]) OR (CTNNB1[Title]) OR (HLA-A[Title]) AND (Wnt signaling[Title])", "(MYC[Title]) OR (CTNNB1[Title]) OR (HLA-A[Title]) AND (antigen presentation[Title])", "(MYC[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (HLA-A[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(MYC[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (HLA-A[Title/Abstract]) AND (Wnt signaling[Title/Abstract])", "(MYC[Title/Abstract]) OR (CTNNB1[Title/Abstract]) OR (HLA-A[Title/Abstract]) AND (antigen presentation[Title/Abstract])"], "references": ["Wang, Ruoning, Dillon, Christopher P, Shi, Lewis Zhichang, Milasta, Sandra, Carter, Robert, Finkelstein, David, McCormick, Laura L, Fitzgerald, Patrick, Chi, Hongbo, Munger, Joshua, Green, Douglas R. \"The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.\" Immunity, 2011, pp. 871-82.", "Carroll, Patrick A, Freie, Brian W, Mathsyaraja, Haritha, Eisenman, Robert N. \"The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis.\" Frontiers of medicine, 2018, pp. 412-425.", "Amati, B, Land, H. \"Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.\" Current opinion in genetics & development, 1994, pp. 102-8."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is cell cycle regulation, with key roles in cell cycle progression, checkpoint control, and DNA repair mechanisms.": {"keywords": [], "references": []}, "The primary biological process performed by this system of interacting proteins is chromatin remodeling and transcription regulation. The proteins involved in this process play crucial roles in modulating gene expression, DNA repair, and cell cycle progression.": {"keywords": [], "references": []}, "1. Chromatin Remodeling Complexes: Several proteins in this system are components of chromatin remodeling complexes, such as ARID1A, ARID1B, ARID2, SMARCA1, SMARCA4, SMARCB1, and SMARCE1. These proteins are part of the SWI/SNF family, which is responsible for altering chromatin structure and facilitating access to DNA for transcription factors and other regulatory proteins.": {"keywords": ["(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (chromatin remodeling[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (SWI/SNF family[Title])", "(ARID1A[Title]) OR (ARID1B[Title]) OR (ARID2[Title]) OR (SMARCA1[Title]) OR (SMARCA4[Title]) OR (SMARCB1[Title]) OR (SMARCE1[Title]) AND (transcription factors[Title])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (SWI/SNF family[Title/Abstract])", "(ARID1A[Title/Abstract]) OR (ARID1B[Title/Abstract]) OR (ARID2[Title/Abstract]) OR (SMARCA1[Title/Abstract]) OR (SMARCA4[Title/Abstract]) OR (SMARCB1[Title/Abstract]) OR (SMARCE1[Title/Abstract]) AND (transcription factors[Title/Abstract])"], "references": ["Mardinian, Kristina, Adashek, Jacob J, Botta, Gregory P, Kato, Shumei, Kurzrock, Razelle. \"<i>SMARCA4</i>: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.\" Molecular cancer therapeutics, 2021, pp. 2341-2351.", "Zhang, Shanshan, Zhou, Yu-Feng, Cao, Jian, Burley, Stephen K, Wang, Hui-Yun, Zheng, X F Steven. \"mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.\" Cancer research, 2021, pp. 5652-5665.", "Jiang, Hao, Cao, Hui-Jun, Ma, Ning, Bao, Wen-Dai, Wang, Jing-Jing, Chen, Tian-Wei, Zhang, Er-Bin, Yuan, Yan-Mei, Ni, Qian-Zhi, Zhang, Feng-Kun, Ding, Xu-Fen, Zheng, Qian-Wen, Wang, Yi-Kang, Zhu, Min, Wang, Xiang, Feng, Jing, Zhang, Xue-Li, Cheng, Shu-Qun, Ma, Dan-Jun, Qiu, Lin, Li, Jing-Jing, Xie, Dong. \"Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.\" Proceedings of the National Academy of Sciences of the United States of America, 2020, pp. 4770-4780."]}, "2. Histone Modifying Enzymes: Histone modifying enzymes, such as EZH2, KDM5A, KDM6A, KMT2A, KMT2B, KMT2C, and KMT2D, are involved in adding or removing chemical groups on histone proteins, which can affect chromatin structure and gene expression. For example, EZH2 is a histone methyltransferase that catalyzes the addition of methyl groups to histone H3, leading to gene repression.": {"keywords": ["(EZH2[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) AND (histone modifying enzymes[Title])", "(EZH2[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) AND (chromatin structure[Title])", "(EZH2[Title]) OR (KDM5A[Title]) OR (KDM6A[Title]) OR (KMT2A[Title]) OR (KMT2B[Title]) OR (KMT2C[Title]) OR (KMT2D[Title]) AND (gene expression[Title])", "(EZH2[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) AND (histone modifying enzymes[Title/Abstract])", "(EZH2[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) AND (chromatin structure[Title/Abstract])", "(EZH2[Title/Abstract]) OR (KDM5A[Title/Abstract]) OR (KDM6A[Title/Abstract]) OR (KMT2A[Title/Abstract]) OR (KMT2B[Title/Abstract]) OR (KMT2C[Title/Abstract]) OR (KMT2D[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Xu, Siyuan, Wang, Siqing, Xing, Shenghui, Yu, Dingdang, Rong, Bowen, Gao, Hai, Sheng, Mengyao, Tan, Yun, Sun, Xiaojian, Wang, Kankan, Xue, Kai, Shi, Zhennan, Lan, Fei. \"KDM5A suppresses PML-RAR\u03b1 target gene expression and APL differentiation through repressing H3K4me2.\" Blood advances, 2021, pp. 3241-3253.", "Grandits, Alexander M, Wieser, Rotraud. \"Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.\" Experimental hematology, 2021, pp. 1-11.", "Ma, Xiaoting, Hayes, Emily, Biswas, Anindita, Seger, Christina, Prizant, Hen, Hammes, Stephen R, Sen, Aritro. \"Androgens Regulate Ovarian Gene Expression Through Modulation of Ezh2 Expression and Activity.\" Endocrinology, 2017, pp. 2944-2954."]}, "3. DNA Methylation: DNMT1, DNMT3A, and DNMT3B are DNA methyltransferases that add methyl groups to cytosine residues in DNA, which can lead to gene silencing. This process is essential for maintaining genomic stability and regulating gene expression.": {"keywords": ["(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (DNA methylation[Title])", "(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (methyltransferases[Title])", "(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (gene expression[Title])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (DNA methylation[Title/Abstract])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (methyltransferases[Title/Abstract])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Dura, Mathilde, Teissandier, Aur\u00e9lie, Armand, M\u00e9lanie, Barau, Joan, Lapoujade, Cl\u00e9mentine, Fouchet, Pierre, Bonneville, Lorraine, Schulz, Mathieu, Weber, Michael, Baudrin, Laura G, Lameiras, Sonia, Bourc'his, Deborah. \"DNMT3A-dependent DNA methylation is required for spermatogonial stem cells to commit to spermatogenesis.\" Nature genetics, 2022, pp. 469-480.", "Zhang, Zhi-Min, Lu, Rui, Wang, Pengcheng, Yu, Yang, Chen, Dongliang, Gao, Linfeng, Liu, Shuo, Ji, Debin, Rothbart, Scott B, Wang, Yinsheng, Wang, Gang Greg, Song, Jikui. \"Structural basis for DNMT3A-mediated de novo DNA methylation.\" Nature, 2018, pp. 387-391.", "Weinberg, Daniel N, Papillon-Cavanagh, Simon, Chen, Haifen, Yue, Yuan, Chen, Xiao, Rajagopalan, Kartik N, Horth, Cynthia, McGuire, John T, Xu, Xinjing, Nikbakht, Hamid, Lemiesz, Agata E, Marchione, Dylan M, Marunde, Matthew R, Meiners, Matthew J, Cheek, Marcus A, Keogh, Michael-Christopher, Bareke, Eric, Djedid, Anissa, Harutyunyan, Ashot S, Jabado, Nada, Garcia, Benjamin A, Li, Haitao, Allis, C David, Majewski, Jacek, Lu, Chao. \"The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.\" Nature, 2019, pp. 281-286."]}, "4. Transcription Factors and Co-factors: Several proteins in this system function as transcription factors or co-factors, such as E2F1, GATA3, MYC, and SOX2. These proteins bind to specific DNA sequences and recruit other proteins, such as CREBBP and EP300, to modulate gene expression.": {"keywords": ["(E2F1[Title]) OR (GATA3[Title]) OR (MYC[Title]) OR (SOX2[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (transcription factors[Title])", "(E2F1[Title]) OR (GATA3[Title]) OR (MYC[Title]) OR (SOX2[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (co-factors[Title])", "(E2F1[Title]) OR (GATA3[Title]) OR (MYC[Title]) OR (SOX2[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (gene expression[Title])", "(E2F1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MYC[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (transcription factors[Title/Abstract])", "(E2F1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MYC[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (co-factors[Title/Abstract])", "(E2F1[Title/Abstract]) OR (GATA3[Title/Abstract]) OR (MYC[Title/Abstract]) OR (SOX2[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Ren, Gang, Lai, Binbin, Harly, Christelle, Baek, Songjoon, Ding, Yi, Zheng, Mingzhu, Cao, Yaqiang, Cui, Kairong, Yang, Yu, Zhu, Jinfang, Hager, Gordon L, Bhandoola, Avinash, Zhao, Keji. \"Transcription factors TCF-1 and GATA3 are key factors for the epigenetic priming of early innate lymphoid progenitors toward distinct cell fates.\" Immunity, 2022, pp. 1402-1413.e4.", "Mollaoglu, Gurkan, Jones, Alex, Wait, Sarah J, Mukhopadhyay, Anandaroop, Jeong, Sangmin, Arya, Rahul, Camolotto, Soledad A, Mosbruger, Timothy L, Stubben, Chris J, Conley, Christopher J, Bhutkar, Arjun, Vahrenkamp, Jeffery M, Berrett, Kristofer C, Cessna, Melissa H, Lane, Thomas E, Witt, Benjamin L, Salama, Mohamed E, Gertz, Jason, Jones, Kevin B, Snyder, Eric L, Oliver, Trudy G. \"The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.\" Immunity, 2018, pp. 764-779.e9.", "Kaufhold, Samantha, Garb\u00e1n, Hermes, Bonavida, Benjamin. \"Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication.\" Journal of experimental & clinical cancer research : CR, 2016, pp. 84."]}, "5. DNA Repair and Cell Cycle Regulation: Proteins like BRCA1, BRCA2, PALB2, PARP1, PRKDC, TP53, and XRCC1 are involved in DNA repair pathways, which maintain genomic integrity and prevent mutations. Additionally, proteins like RB1 and CDK12 play roles in cell cycle regulation, ensuring proper cell division and preventing uncontrolled cell growth.": {"keywords": ["(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (TP53[Title]) OR (XRCC1[Title]) OR (RB1[Title]) OR (CDK12[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (TP53[Title]) OR (XRCC1[Title]) OR (RB1[Title]) OR (CDK12[Title]) AND (cell cycle regulation[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (PARP1[Title]) OR (PRKDC[Title]) OR (TP53[Title]) OR (XRCC1[Title]) OR (RB1[Title]) OR (CDK12[Title]) AND (genomic integrity[Title])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XRCC1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDK12[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XRCC1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDK12[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (PARP1[Title/Abstract]) OR (PRKDC[Title/Abstract]) OR (TP53[Title/Abstract]) OR (XRCC1[Title/Abstract]) OR (RB1[Title/Abstract]) OR (CDK12[Title/Abstract]) AND (genomic integrity[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Ray Chaudhuri, Arnab, Nussenzweig, Andr\u00e9. \"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.\" Nature reviews. Molecular cell biology, 2017, pp. 610-621.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299."]}, "6. RNA Processing and Splicing: Proteins like SF1, SF3B1, SRSF2, U2AF1, and ZRSR2 are involved in pre-mRNA splicing, a process that removes introns and joins exons to produce mature mRNA molecules. This process is essential for proper gene expression and protein synthesis.": {"keywords": ["(SF1[Title]) OR (SF3B1[Title]) OR (SRSF2[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (RNA processing[Title])", "(SF1[Title]) OR (SF3B1[Title]) OR (SRSF2[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (splicing[Title])", "(SF1[Title]) OR (SF3B1[Title]) OR (SRSF2[Title]) OR (U2AF1[Title]) OR (ZRSR2[Title]) AND (protein synthesis[Title])", "(SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (RNA processing[Title/Abstract])", "(SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (splicing[Title/Abstract])", "(SF1[Title/Abstract]) OR (SF3B1[Title/Abstract]) OR (SRSF2[Title/Abstract]) OR (U2AF1[Title/Abstract]) OR (ZRSR2[Title/Abstract]) AND (protein synthesis[Title/Abstract])"], "references": ["Hluch\u00fd, Milan, Gajdu\u0161kov\u00e1, Pavla, Ruiz de Los Mozos, Igor, R\u00e1jeck\u00fd, Michal, Kluge, Michael, Berger, Benedict-Tilman, Slab\u00e1, Zuzana, Pot\u011b\u0161il, David, Wei\u00df, Elena, Ule, Jernej, Zdr\u00e1hal, Zbyn\u011bk, Knapp, Stefan, Paruch, Kamil, Friedel, Caroline C, Blazek, Dalibor. \"CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1.\" Nature, 2022, pp. 829-834.", "Li, Kun, Wang, Ziqiang. \"Splicing factor SRSF2-centric gene regulation.\" International journal of biological sciences, 2021, pp. 1708-1715.", "Rahman, Mohammad Alinoor, Lin, Kuan-Ting, Bradley, Robert K, Abdel-Wahab, Omar, Krainer, Adrian R. \"Recurrent SRSF2 mutations in MDS affect both splicing and NMD.\" Genes & development, 2020, pp. 413-427."]}, "In conclusion, this system of interacting proteins is primarily involved in chromatin remodeling and transcription regulation, with additional roles in DNA repair, cell cycle regulation, and RNA processing. These proteins work together to maintain genomic stability, regulate gene expression, and ensure proper cellular function.": {"keywords": [], "references": []}, "The primary biological process performed by this system of interacting proteins is transcriptional regulation and chromatin remodeling. This is supported by the following points:": {"keywords": [], "references": []}, "1. AR (Androgen Receptor) is a nuclear receptor that functions as a transcription factor, regulating gene expression in response to androgen hormones. It interacts with coactivators such as CREBBP and EP300, which possess histone acetyltransferase activity, promoting chromatin relaxation and transcriptional activation.": {"keywords": ["(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (transcription factor[Title])", "(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (gene expression[Title])", "(AR[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (chromatin relaxation[Title])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (gene expression[Title/Abstract])", "(AR[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (chromatin relaxation[Title/Abstract])"], "references": ["Mart\u00edn-Antonio, B, \u00c1lvarez-Laderas, I, Cardesa, R, M\u00e1rquez-Malaver, F, Baez, A, Carmona, M, Falantes, J, Suarez-Lledo, M, Fern\u00e1ndez-Avil\u00e9s, F, Mart\u00ednez, C, Rovira, M, Espigado, I, Urbano-Ispizua, \u00c1. \"A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.\" Bone marrow transplantation, 2012, pp. 1206-11.", "Furlan, Tobias, Kirchmair, Alexander, Sampson, Natalie, Puhr, Martin, Gruber, Martina, Trajanoski, Zlatko, Santer, Fr\u00e9d\u00e9ric R, Parson, Walther, Handle, Florian, Culig, Zoran. \"MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.\" The American journal of pathology, 2021, pp. 1094-1107.", "Shahbazi, Shirin, Khorasani, Maryam, Mahdian, Reza. \"Gene expression profile of FVII and AR in primary prostate cancer.\" Cancer biomarkers : section A of Disease markers, 2016, pp. 353-358."]}, "2. BCL6 is a transcriptional repressor that recruits corepressors, such as HDAC1 and HDAC2, to target gene promoters. HDAC1 and HDAC2 are histone deacetylases that remove acetyl groups from histones, leading to chromatin condensation and transcriptional repression.": {"keywords": ["(BCL6[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (transcriptional repressor[Title])", "(BCL6[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (histone deacetylases[Title])", "(BCL6[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (chromatin condensation[Title])", "(BCL6[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (transcriptional repressor[Title/Abstract])", "(BCL6[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (histone deacetylases[Title/Abstract])", "(BCL6[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (chromatin condensation[Title/Abstract])"], "references": ["Trujillo-Gonzalez, Isis, Cervantes-Roldan, Rafael, Gonzalez-Noriega, Alfonso, Michalak, Colette, Reyes-Carmona, Sandra, Barrios-Garcia, Tonatiuh, Meneses-Morales, Ivan, Leon-Del-Rio, Alfonso. \"Holocarboxylase synthetase acts as a biotin-independent transcriptional repressor interacting with HDAC1, HDAC2 and HDAC7.\" Molecular genetics and metabolism, 2014, pp. 321-330.", "Moreno-Yruela, Carlos, Zhang, Di, Wei, Wei, B\u00e6k, Michael, Liu, Wenchao, Gao, Jinjun, Dankov\u00e1, Daniela, Nielsen, Alexander L, Bolding, Julie E, Yang, Lu, Jameson, Samuel T, Wong, Jiemin, Olsen, Christian A, Zhao, Yingming. \"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.\" Science advances, 2022, pp. eabi6696.", "Kiweler, Nicole, Brill, Boris, Wirth, Matthias, Breuksch, Ines, Laguna, Teresa, Dietrich, Cornelia, Strand, Susanne, Schneider, G\u00fcnter, Groner, Bernd, Butter, Falk, Heinzel, Thorsten, Brenner, Walburgis, Kr\u00e4mer, Oliver H. \"The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.\" Archives of toxicology, 2018, pp. 2227-2243."]}, "3. CREBBP and EP300 are histone acetyltransferases that acetylate histones, promoting chromatin relaxation and transcriptional activation. They also interact with transcription factors, such as MYC and TP53, to modulate gene expression.": {"keywords": ["(MYC[Title]) OR (TP53[Title]) AND (histone acetyltransferases[Title])", "(MYC[Title]) OR (TP53[Title]) AND (chromatin relaxation[Title])", "(MYC[Title]) OR (TP53[Title]) AND (transcriptional activation[Title])", "(MYC[Title/Abstract]) OR (TP53[Title/Abstract]) AND (histone acetyltransferases[Title/Abstract])", "(MYC[Title/Abstract]) OR (TP53[Title/Abstract]) AND (chromatin relaxation[Title/Abstract])", "(MYC[Title/Abstract]) OR (TP53[Title/Abstract]) AND (transcriptional activation[Title/Abstract])"], "references": ["Zhang, Jie, Yang, Peilang, Liu, Dan, Gao, Min, Wang, Jizhuang, Wang, Xiqiao, Liu, Yan, Zhang, Xiong. \"c-Myc Upregulated by High Glucose Inhibits HaCaT Differentiation by S100A6 Transcriptional Activation.\" Frontiers in endocrinology, 2021, pp. 676403.", "Li, Yinghui, Wang, Zhen, Shi, Hui, Li, Hang, Li, Leilei, Fang, Runping, Cai, Xiaoli, Liu, Bowen, Zhang, Xiaodong, Ye, Lihong. \"HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc.\" Cancer research, 2016, pp. 293-304.", "Jin, Jianping, Harper, J Wade. \"A license to kill: transcriptional activation and enhanced turnover of Myc by the SCF(kp2) ubiquitin ligase.\" Cancer cell, 2003, pp. 517-8."]}, "4. KAT6A is a histone acetyltransferase that acetylates histone H3, promoting transcriptional activation. It is involved in chromatin remodeling and interacts with YEATS4, which recognizes acetylated histones and facilitates the recruitment of other chromatin-modifying enzymes.": {"keywords": ["(KAT6A[Title]) OR (YEATS4[Title]) AND (histone acetylation[Title])", "(KAT6A[Title]) OR (YEATS4[Title]) AND (chromatin remodeling[Title])", "(KAT6A[Title]) OR (YEATS4[Title]) AND (transcriptional activation[Title])", "(KAT6A[Title/Abstract]) OR (YEATS4[Title/Abstract]) AND (histone acetylation[Title/Abstract])", "(KAT6A[Title/Abstract]) OR (YEATS4[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(KAT6A[Title/Abstract]) OR (YEATS4[Title/Abstract]) AND (transcriptional activation[Title/Abstract])"], "references": ["Baell, Jonathan B, Leaver, David J, Hermans, Stefan J, Kelly, Gemma L, Brennan, Margs S, Downer, Natalie L, Nguyen, Nghi, Wichmann, Johannes, McRae, Helen M, Yang, Yuqing, Cleary, Ben, Lagiakos, H Rachel, Mieruszynski, Stephen, Pacini, Guido, Vanyai, Hannah K, Bergamasco, Maria I, May, Rose E, Davey, Bethany K, Morgan, Kimberly J, Sealey, Andrew J, Wang, Beinan, Zamudio, Natasha, Wilcox, Stephen, Garnham, Alexandra L, Sheikh, Bilal N, Aubrey, Brandon J, Doggett, Karen, Chung, Matthew C, de Silva, Melanie, Bentley, John, Pilling, Pat, Hattarki, Meghan, Dolezal, Olan, Dennis, Matthew L, Falk, Hendrik, Ren, Bin, Charman, Susan A, White, Karen L, Rautela, Jai, Newbold, Andrea, Hawkins, Edwin D, Johnstone, Ricky W, Huntington, Nicholas D, Peat, Thomas S, Heath, Joan K, Strasser, Andreas, Parker, Michael W, Smyth, Gordon K, Street, Ian P, Monahan, Brendon J, Voss, Anne K, Thomas, Tim. \"Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.\" Nature, 2018, pp. 253-257.", "Voss, Anne K, Thomas, Tim. \"Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals.\" BioEssays : news and reviews in molecular, cellular and developmental biology, 2018, pp. e1800078.", "Han, Yanshuo, Tanios, Fadwa, Reeps, Christian, Zhang, Jian, Schwamborn, Kristina, Eckstein, Hans-Henning, Zernecke, Alma, Pelisek, Jaroslav. \"Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm.\" Clinical epigenetics, 2016, pp. 3."]}, "5. MYC is a transcription factor that regulates the expression of genes involved in cell growth, proliferation, and apoptosis. It interacts with EP300 and CREBBP, which modulate its transcriptional activity.": {"keywords": ["(MYC[Title]) OR (EP300[Title]) OR (CREBBP[Title]) AND (transcription factor[Title])", "(MYC[Title]) OR (EP300[Title]) OR (CREBBP[Title]) AND (cell growth[Title])", "(MYC[Title]) OR (EP300[Title]) OR (CREBBP[Title]) AND (apoptosis[Title])", "(MYC[Title/Abstract]) OR (EP300[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(MYC[Title/Abstract]) OR (EP300[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (cell growth[Title/Abstract])", "(MYC[Title/Abstract]) OR (EP300[Title/Abstract]) OR (CREBBP[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Wang, Ruoning, Dillon, Christopher P, Shi, Lewis Zhichang, Milasta, Sandra, Carter, Robert, Finkelstein, David, McCormick, Laura L, Fitzgerald, Patrick, Chi, Hongbo, Munger, Joshua, Green, Douglas R. \"The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.\" Immunity, 2011, pp. 871-82.", "Carroll, Patrick A, Freie, Brian W, Mathsyaraja, Haritha, Eisenman, Robert N. \"The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis.\" Frontiers of medicine, 2018, pp. 412-425.", "Patange, Simona, Ball, David A, Wan, Yihan, Karpova, Tatiana S, Girvan, Michelle, Levens, David, Larson, Daniel R. \"MYC amplifies gene expression through global changes in transcription factor dynamics.\" Cell reports, 2022, pp. 110292."]}, "6. PML is involved in the formation of nuclear bodies, which are implicated in transcriptional regulation and chromatin remodeling. It interacts with HDAC1 and HDAC2, suggesting a role in transcriptional repression.": {"keywords": ["(PML[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (nuclear bodies[Title])", "(PML[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (transcriptional regulation[Title])", "(PML[Title]) OR (HDAC1[Title]) OR (HDAC2[Title]) AND (chromatin remodeling[Title])", "(PML[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (nuclear bodies[Title/Abstract])", "(PML[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(PML[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])"], "references": ["Corpet, Armelle, Kleijwegt, Constance, Roubille, Simon, Juillard, Franceline, Jacquet, Karine, Texier, Pascale, Lomonte, Patrick. \"PML nuclear bodies and chromatin dynamics: catch me if you can!\" Nucleic acids research, 2020, pp. 11890-11912.", "Lallemand-Breitenbach, Val\u00e9rie, de Th\u00e9, Hugues. \"PML nuclear bodies.\" Cold Spring Harbor perspectives in biology, 2010, pp. a000661.", "Lallemand-Breitenbach, Val\u00e9rie, de Th\u00e9, Hugues. \"PML nuclear bodies: from architecture to function.\" Current opinion in cell biology, 2018, pp. 154-161."]}, "7. RUNX1 is a transcription factor that regulates the expression of genes involved in hematopoiesis. It interacts with EP300, which modulates its transcriptional activity.": {"keywords": ["(RUNX1[Title]) OR (EP300[Title]) AND (transcription factor[Title])", "(RUNX1[Title]) OR (EP300[Title]) AND (hematopoiesis[Title])", "(RUNX1[Title]) OR (EP300[Title]) AND (EP300[Title])", "(RUNX1[Title/Abstract]) OR (EP300[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(RUNX1[Title/Abstract]) OR (EP300[Title/Abstract]) AND (hematopoiesis[Title/Abstract])", "(RUNX1[Title/Abstract]) OR (EP300[Title/Abstract]) AND (EP300[Title/Abstract])"], "references": ["Brown, Anna L, Hahn, Christopher N, Scott, Hamish S. \"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).\" Blood, 2020, pp. 24-35.", "Mehtonen, Juha, Teppo, Susanna, Lahnalampi, Mari, Kokko, Aleksi, Kaukonen, Riina, Oksa, Laura, Bouvy-Liivrand, Maria, Malyukova, Alena, M\u00e4kinen, Artturi, Laukkanen, Saara, M\u00e4kinen, Petri I, Rounioja, Samuli, Ruusuvuori, Pekka, Sangfelt, Olle, Lund, Riikka, L\u00f6nnberg, Tapio, Lohi, Olli, Hein\u00e4niemi, Merja. \"Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.\" Genome medicine, 2020, pp. 99.", "Lappas, Martha. \"Runt-related transcription factor 1 (RUNX1) deficiency attenuates inflammation-induced pro-inflammatory and pro-labour mediators in myometrium.\" Molecular and cellular endocrinology, 2018, pp. 61-71."]}, "8. TBL1XR1 is a component of the NCoR/SMRT corepressor complex, which interacts with nuclear receptors and transcription factors, such as BCL6, to mediate transcriptional repression.": {"keywords": ["(TBL1XR1[Title]) OR (BCL6[Title]) AND (corepressor complex[Title])", "(TBL1XR1[Title]) OR (BCL6[Title]) AND (transcriptional repression[Title])", "(TBL1XR1[Title]) OR (BCL6[Title]) AND (nuclear receptors[Title])", "(TBL1XR1[Title/Abstract]) OR (BCL6[Title/Abstract]) AND (corepressor complex[Title/Abstract])", "(TBL1XR1[Title/Abstract]) OR (BCL6[Title/Abstract]) AND (transcriptional repression[Title/Abstract])", "(TBL1XR1[Title/Abstract]) OR (BCL6[Title/Abstract]) AND (nuclear receptors[Title/Abstract])"], "references": ["Wong, C W, Privalsky, M L. \"Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.\" The Journal of biological chemistry, 1998, pp. 27695-702.", "Huang, Chuanxin, Geng, Huimin, Boss, Isaac, Wang, Ling, Melnick, Ari. \"Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation.\" Blood, 2014, pp. 1012-20.", "Senagolage, Madhavi D, Sommars, Meredith A, Ramachandran, Krithika, Futtner, Christopher R, Omura, Yasuhiro, Allred, Amanda L, Wang, Jianing, Yang, Cynthia, Procissi, Daniele, Evans, Ronald M, Han, Xianlin, Bederman, Ilya R, Barish, Grant D. \"Loss of Transcriptional Repression by BCL6 Confers Insulin Sensitivity in the Setting of Obesity.\" Cell reports, 2018, pp. 3283-3298.e6."]}, "9. TERT is the catalytic subunit of telomerase, which maintains telomere length and is involved in cellular senescence. It interacts with TP53, a tumor suppressor that regulates cell cycle progression and apoptosis.": {"keywords": ["(TERT[Title]) OR (TP53[Title]) AND (telomerase[Title])", "(TERT[Title]) OR (TP53[Title]) AND (cellular senescence[Title])", "(TERT[Title]) OR (TP53[Title]) AND (apoptosis[Title])", "(TERT[Title/Abstract]) OR (TP53[Title/Abstract]) AND (telomerase[Title/Abstract])", "(TERT[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cellular senescence[Title/Abstract])", "(TERT[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["McKelvey, Brittany A, Umbricht, Christopher B, Zeiger, Martha A. \"Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.\" Frontiers in endocrinology, 2020, pp. 485.", "Yuan, Xiaotian, Larsson, Catharina, Xu, Dawei. \"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.\" Oncogene, 2019, pp. 6172-6183.", "Guo, Yuchen, Chen, Yi, Zhang, Lianghui, Ma, Ling, Jiang, Keyu, Yao, Gang, Zhu, Lingjun. \"TERT Promoter Mutations and Telomerase in Melanoma.\" Journal of oncology, 2022, pp. 6300329."]}, "10. TNF is a proinflammatory cytokine that activates signaling pathways involved in inflammation, cell survival, and apoptosis. It interacts with TP53, which modulates its proapoptotic activity.": {"keywords": ["(TNF[Title]) OR (TP53[Title]) AND (inflammation[Title])", "(TNF[Title]) OR (TP53[Title]) AND (cell survival[Title])", "(TNF[Title]) OR (TP53[Title]) AND (apoptosis[Title])", "(TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (inflammation[Title/Abstract])", "(TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell survival[Title/Abstract])", "(TNF[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Zelov\u00e1, Hana, Ho\u0161ek, Jan. \"TNF-\u03b1 signalling and inflammation: interactions between old acquaintances.\" Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013, pp. 641-51.", "Blaser, Heiko, Dostert, Catherine, Mak, Tak W, Brenner, Dirk. \"TNF and ROS Crosstalk in Inflammation.\" Trends in cell biology, 2016, pp. 249-261.", "van Loo, Geert, Bertrand, Mathieu J M. \"Death by TNF: a road to inflammation.\" Nature reviews. Immunology, 2023, pp. 289-303."]}, "11. TP53 is a tumor suppressor that regulates cell cycle progression, apoptosis, and DNA repair. It functions as a transcription factor, interacting with CREBBP and EP300 to modulate gene expression.": {"keywords": ["(TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (tumor suppressor[Title])", "(TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (transcription factor[Title])", "(TP53[Title]) OR (CREBBP[Title]) OR (EP300[Title]) AND (DNA repair[Title])", "(TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(TP53[Title/Abstract]) OR (CREBBP[Title/Abstract]) OR (EP300[Title/Abstract]) AND (DNA repair[Title/Abstract])"], "references": ["Basset-S\u00e9guin, N, Mol\u00e8s, J P, Mils, V, Dereure, O, Guilhou, J J. \"TP53 tumor suppressor gene and skin carcinogenesis.\" The Journal of investigative dermatology, 1994, pp. 102S-106S.", "Xu-Monette, Zijun Y, Medeiros, L Jeffrey, Li, Yong, Orlowski, Robert Z, Andreeff, Michael, Bueso-Ramos, Carlos E, Greiner, Timothy C, McDonnell, Timothy J, Young, Ken H. \"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.\" Blood, 2012, pp. 3668-83.", "Sirotkin, Alexander V, Petrak, Juraj, Alwasel, Saleh, Harrath, Abdel Halim. \"Apoptosis signal-regulating kinase (ASK1) and transcription factor tumor suppressor protein TP53 suppress rabbit ovarian granulosa cell functions.\" Animal reproduction science, 2019, pp. 140-151."]}, "12. YEATS4 is a chromatin reader that recognizes acetylated histones and facilitates the recruitment of chromatin-modifying enzymes, such as KAT6A. It is involved in transcriptional regulation and chromatin remodeling.": {"keywords": ["(YEATS4[Title]) OR (KAT6A[Title]) AND (chromatin reader[Title])", "(YEATS4[Title]) OR (KAT6A[Title]) AND (transcriptional regulation[Title])", "(YEATS4[Title]) OR (KAT6A[Title]) AND (chromatin remodeling[Title])", "(YEATS4[Title/Abstract]) OR (KAT6A[Title/Abstract]) AND (chromatin reader[Title/Abstract])", "(YEATS4[Title/Abstract]) OR (KAT6A[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(YEATS4[Title/Abstract]) OR (KAT6A[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])"], "references": ["Yan, Kezhi, You, Linya, Degerny, Cindy, Ghorbani, Mohammad, Liu, Xin, Chen, Lulu, Li, Lin, Miao, Dengshun, Yang, Xiang-Jiao. \"The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival.\" The Journal of biological chemistry, 2016, pp. 2647-63.", "Kiuchi, Jun, Komatsu, Shuhei, Imamura, Taisuke, Nishibeppu, Keiji, Shoda, Katsutoshi, Arita, Tomohiro, Kosuga, Toshiyuki, Konishi, Hirotaka, Shiozaki, Atsushi, Kubota, Takeshi, Okamoto, Kazuma, Fujiwara, Hitoshi, Ichikawa, Daisuke, Tsuda, Hitoshi, Otsuji, Eigo. \"Overexpression of YEATS4 contributes to malignant outcomes in gastric carcinoma.\" American journal of cancer research, 2018, pp. 2436-2452.", "Millan, Francisca, Cho, Megan T, Retterer, Kyle, Monaghan, Kristin G, Bai, Renkui, Vitazka, Patrik, Everman, David B, Smith, Brooke, Angle, Brad, Roberts, Victoria, Immken, LaDonna, Nagakura, Honey, DiFazio, Marc, Sherr, Elliott, Haverfield, Eden, Friedman, Bethany, Telegrafi, Aida, Juusola, Jane, Chung, Wendy K, Bale, Sherri. \"Whole exome sequencing reveals de novo pathogenic variants in KAT6A as a cause of a neurodevelopmental disorder.\" American journal of medical genetics. Part A, 2016, pp. 1791-8."]}, "The system of interacting proteins primarily performs the biological process of epigenetic regulation and DNA repair. ": {"keywords": [], "references": []}, "1. Epigenetic regulation: Several proteins in the system are involved in chromatin remodeling and histone modification, which are key processes in epigenetic regulation. These include:": {"keywords": [], "references": []}, "   - CHD4: A component of the NuRD complex, which is involved in chromatin remodeling and transcriptional repression.": {"keywords": ["(CHD4[Title]) AND (chromatin remodeling[Title])", "(CHD4[Title]) AND (NuRD complex[Title])", "(CHD4[Title]) AND (transcriptional repression[Title])", "(CHD4[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(CHD4[Title/Abstract]) AND (NuRD complex[Title/Abstract])", "(CHD4[Title/Abstract]) AND (transcriptional repression[Title/Abstract])"], "references": ["Curtis, Carol D, Griffin, Courtney T. \"The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling.\" Molecular and cellular biology, 2012, pp. 1312-20.", "G\u00f3mez-Del Arco, Pablo, Perdiguero, Eusebio, Yunes-Leites, Paula Sofia, Ac\u00edn-P\u00e9rez, Rebeca, Zeini, Miriam, Garcia-Gomez, Antonio, Sreenivasan, Krishnamoorthy, Jim\u00e9nez-Alc\u00e1zar, Miguel, Segal\u00e9s, Jessica, L\u00f3pez-Maderuelo, Dolores, Orn\u00e9s, Beatriz, Jim\u00e9nez-Borreguero, Luis Jes\u00fas, D'Amato, Gaetano, Enshell-Seijffers, David, Morgan, Bruce, Georgopoulos, Katia, Islam, Abul B M M K, Braun, Thomas, de la Pompa, Jos\u00e9 Luis, Kim, Johnny, Enriquez, Jos\u00e9 A, Ballestar, Esteban, Mu\u00f1oz-C\u00e1noves, Pura, Redondo, Juan Miguel. \"The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis.\" Cell metabolism, 2016, pp. 881-92.", "Larsen, Dorthe Helena, Poinsignon, Catherine, Gudjonsson, Thorkell, Dinant, Christoffel, Payne, Mark R, Hari, Flurina J, Rendtlew Danielsen, Jannie M, Menard, Patrice, Sand, Jette Christensen, Stucki, Manuel, Lukas, Claudia, Bartek, Jiri, Andersen, Jens S, Lukas, Jiri. \"The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.\" The Journal of cell biology, 2010, pp. 731-40."]}, "   - CREBBP: A histone acetyltransferase that plays a role in transcriptional activation.": {"keywords": ["(CREBBP[Title]) AND (histone acetyltransferase[Title])", "(CREBBP[Title]) AND (transcriptional activation[Title])", "(CREBBP[Title]) AND (CREBBP[Title])", "(CREBBP[Title/Abstract]) AND (histone acetyltransferase[Title/Abstract])", "(CREBBP[Title/Abstract]) AND (transcriptional activation[Title/Abstract])", "(CREBBP[Title/Abstract]) AND (CREBBP[Title/Abstract])"], "references": ["Cross, Esther, Duncan-Flavell, Philippa J, Howarth, Rachel J, Hobbs, James I, Thomas, Nicholas Simon, Bunyan, David J. \"Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain.\" American journal of medical genetics. Part A, 2020, pp. 2508-2520.", "Veazey, Kylee J, Cheng, Donghang, Lin, Kevin, Villarreal, Oscar D, Gao, Guozhen, Perez-Oquendo, Mabel, Van, Hieu T, Stratton, Sabrina A, Green, Michael, Xu, Han, Lu, Yue, Bedford, Mark T, Santos, Margarida Almeida. \"CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.\" Leukemia, 2020, pp. 3269-3285.", "Zheng, Fei, Kasper, Lawryn H, Bedford, David C, Lerach, Stephanie, Teubner, Brett J W, Brindle, Paul K. \"Mutation of the CH1 Domain in the Histone Acetyltransferase CREBBP Results in Autism-Relevant Behaviors in Mice.\" PloS one, 2016, pp. e0146366."]}, "   - EZH2: A histone methyltransferase that is part of the PRC2 complex, involved in transcriptional repression.": {"keywords": ["(EZH2[Title]) AND (histone methyltransferase[Title])", "(EZH2[Title]) AND (PRC2 complex[Title])", "(EZH2[Title]) AND (transcriptional repression[Title])", "(EZH2[Title/Abstract]) AND (histone methyltransferase[Title/Abstract])", "(EZH2[Title/Abstract]) AND (PRC2 complex[Title/Abstract])", "(EZH2[Title/Abstract]) AND (transcriptional repression[Title/Abstract])"], "references": ["Zhou, Jie, Huang, Shuo, Wang, Zhongyu, Huang, Jiani, Xu, Liang, Tang, Xuefeng, Wan, Yisong Y, Li, Qi-Jing, Symonds, Alistair L J, Long, Haixia, Zhu, Bo. \"Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation.\" Nature communications, 2019, pp. 2427.", "Yu, Minghang, Su, Ziyang, Huang, Xuefeng, Zhou, Yujie, Zhang, Xulong, Wang, Bingbing, Wang, Zihan, Liu, Yi, Xing, Nianzeng, Xia, Miaoran, Wang, Xi. \"Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function.\" Journal of leukocyte biology, 2021, pp. 1033-1045.", "Zhang, Tengrui, Gong, Yueqing, Meng, Hui, Li, Chen, Xue, Lixiang. \"Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.\" Clinical epigenetics, 2020, pp. 72."]}, "   - HDAC1, HDAC2, and HDAC3: Histone deacetylases that are involved in transcriptional repression.": {"keywords": ["(HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) AND (histone deacetylases[Title])", "(HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) AND (transcriptional repression[Title])", "(HDAC1[Title]) OR (HDAC2[Title]) OR (HDAC3[Title]) AND (HDAC[Title])", "(HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) AND (histone deacetylases[Title/Abstract])", "(HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) AND (transcriptional repression[Title/Abstract])", "(HDAC1[Title/Abstract]) OR (HDAC2[Title/Abstract]) OR (HDAC3[Title/Abstract]) AND (HDAC[Title/Abstract])"], "references": ["Moreno-Yruela, Carlos, Zhang, Di, Wei, Wei, B\u00e6k, Michael, Liu, Wenchao, Gao, Jinjun, Dankov\u00e1, Daniela, Nielsen, Alexander L, Bolding, Julie E, Yang, Lu, Jameson, Samuel T, Wong, Jiemin, Olsen, Christian A, Zhao, Yingming. \"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.\" Science advances, 2022, pp. eabi6696.", "Seo, Jinwon, Min, Soo Kee, Park, Hye-Rim, Kim, Dong Hoon, Kwon, Mi Jung, Kim, Lee Su, Ju, Young-Su. \"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.\" Journal of breast cancer, 2014, pp. 323-31.", "Kiweler, Nicole, Brill, Boris, Wirth, Matthias, Breuksch, Ines, Laguna, Teresa, Dietrich, Cornelia, Strand, Susanne, Schneider, G\u00fcnter, Groner, Bernd, Butter, Falk, Heinzel, Thorsten, Brenner, Walburgis, Kr\u00e4mer, Oliver H. \"The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.\" Archives of toxicology, 2018, pp. 2227-2243."]}, "   - HIST3H3: A histone protein that forms the core of the nucleosome, the basic unit of chromatin.": {"keywords": ["(HIST3H3[Title]) AND (histone protein[Title])", "(HIST3H3[Title]) AND (nucleosome[Title])", "(HIST3H3[Title]) AND (chromatin[Title])", "(HIST3H3[Title/Abstract]) AND (histone protein[Title/Abstract])", "(HIST3H3[Title/Abstract]) AND (nucleosome[Title/Abstract])", "(HIST3H3[Title/Abstract]) AND (chromatin[Title/Abstract])"], "references": []}, "   - KDM5A: A histone demethylase that removes methyl groups from histone H3, affecting gene expression.": {"keywords": ["(KDM5A[Title]) OR (H3[Title]) AND (histone demethylase[Title])", "(KDM5A[Title]) OR (H3[Title]) AND (gene expression[Title])", "(KDM5A[Title]) OR (H3[Title]) AND (methyl groups[Title])", "(KDM5A[Title/Abstract]) OR (H3[Title/Abstract]) AND (histone demethylase[Title/Abstract])", "(KDM5A[Title/Abstract]) OR (H3[Title/Abstract]) AND (gene expression[Title/Abstract])", "(KDM5A[Title/Abstract]) OR (H3[Title/Abstract]) AND (methyl groups[Title/Abstract])"], "references": ["Oser, Matthew G, Sabet, Amin H, Gao, Wenhua, Chakraborty, Abhishek A, Schinzel, Anna C, Jennings, Rebecca B, Fonseca, Raquel, Bonal, Dennis M, Booker, Matthew A, Flaifel, Abdallah, Novak, Jesse S, Christensen, Camilla L, Zhang, Hua, Herbert, Zachary T, Tolstorukov, Michael Y, Buss, Elizabeth J, Wong, Kwok-Kin, Bronson, Roderick T, Nguyen, Quang-De, Signoretti, Sabina, Kaelin, William G. \"The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.\" Genes & development, 2019, pp. 1718-1738.", "Yoo, Jung, Kim, Go Woon, Jeon, Yu Hyun, Kim, Ji Yoon, Lee, Sang Wu, Kwon, So Hee. \"Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.\" Experimental & molecular medicine, 2022, pp. 2107-2117.", "Dai, Bin, Huang, Hui, Guan, Feng, Zhu, Guangtong, Xiao, Zhiyong, Mao, Beibei, Su, Haiyang, Hu, Zhiqiang. \"Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.\" Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, pp. 72-80."]}, "   - MTA1: A component of the NuRD complex, involved in chromatin remodeling and transcriptional repression.": {"keywords": ["(MTA1[Title]) AND (chromatin remodeling[Title])", "(MTA1[Title]) AND (transcriptional repression[Title])", "(MTA1[Title]) AND (NuRD complex[Title])", "(MTA1[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(MTA1[Title/Abstract]) AND (transcriptional repression[Title/Abstract])", "(MTA1[Title/Abstract]) AND (NuRD complex[Title/Abstract])"], "references": ["Salot, Shimul, Gude, Rajiv. \"MTA1-mediated transcriptional repression of SMAD7 in breast cancer cell lines.\" European journal of cancer (Oxford, England : 1990), 2013, pp. 492-9.", "Molli, P R, Singh, R R, Lee, S W, Kumar, R. \"MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.\" Oncogene, 2008, pp. 1971-80.", "Lee, M-H, Na, H, Kim, E-J, Lee, H-W, Lee, M-O. \"Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1.\" Oncogene, 2012, pp. 5099-107."]}, "   - PRDM1: A histone methyltransferase that is involved in transcriptional repression.": {"keywords": ["(PRDM1[Title]) AND (histone methyltransferase[Title])", "(PRDM1[Title]) AND (transcriptional repression[Title])", "(PRDM1[Title]) AND (PRDM1[Title])", "(PRDM1[Title/Abstract]) AND (histone methyltransferase[Title/Abstract])", "(PRDM1[Title/Abstract]) AND (transcriptional repression[Title/Abstract])", "(PRDM1[Title/Abstract]) AND (PRDM1[Title/Abstract])"], "references": ["von Hofsten, Jonas, Elworthy, Stone, Gilchrist, Michael J, Smith, James C, Wardle, Fiona C, Ingham, Philip W. \"Prdm1- and Sox6-mediated transcriptional repression specifies muscle fibre type in the zebrafish embryo.\" EMBO reports, 2008, pp. 683-9.", "Li, Qing, Zhang, Liren, You, Wenhua, Xu, Jiali, Dai, Jingjing, Hua, Dongxu, Zhang, Ruizhi, Yao, Feifan, Zhou, Suiqing, Huang, Wei, Dai, Yongjiu, Zhang, Yu, Baheti, Tasiken, Qian, Xiaofeng, Pu, Liyong, Xu, Jing, Xia, Yongxiang, Zhang, Chuanyong, Tang, Jinhai, Wang, Xuehao. \"PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.\" Nature communications, 2022, pp. 7677.", "Yoshikawa, Toshiaki, Wu, Zhiwen, Inoue, Satoshi, Kasuya, Hitomi, Matsushita, Hirokazu, Takahashi, Yusuke, Kuroda, Hiroaki, Hosoda, Waki, Suzuki, Shiro, Kagoya, Yuki. \"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy.\" Blood, 2022, pp. 2156-2172."]}, "2. DNA repair: Several proteins in the system are involved in DNA repair processes, ensuring the maintenance of genomic integrity. These include:": {"keywords": [], "references": []}, "   - BARD1: A protein that forms a complex with BRCA1, playing a role in DNA repair and cell cycle regulation.": {"keywords": ["(BARD1[Title]) OR (BRCA1[Title]) AND (DNA repair[Title])", "(BARD1[Title]) OR (BRCA1[Title]) AND (cell cycle regulation[Title])", "(BARD1[Title]) OR (BRCA1[Title]) AND (protein complex[Title])", "(BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(BARD1[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (protein complex[Title/Abstract])"], "references": ["Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Trivedi, Shalini, Blaz\u00edckov\u00e1, Jitka, Silva, Nicola. \"PARG and BRCA1-BARD1 cooperative function regulates DNA repair pathway choice during gametogenesis.\" Nucleic acids research, 2022, pp. 12291-12308."]}, "   - BRD4: A protein that binds to acetylated histones and is involved in DNA damage response and repair.": {"keywords": ["(BRD4[Title]) AND (DNA damage response[Title])", "(BRD4[Title]) AND (histone binding[Title])", "(BRD4[Title]) AND (repair[Title])", "(BRD4[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(BRD4[Title/Abstract]) AND (histone binding[Title/Abstract])", "(BRD4[Title/Abstract]) AND (repair[Title/Abstract])"], "references": ["Pongas, Georgios, Kim, Marianne K, Min, Dong J, House, Carrie D, Jordan, Elizabeth, Caplen, Natasha, Chakka, Sirisha, Ohiri, Joyce, Kruhlak, Michael J, Annunziata, Christina M. \"BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).\" Oncotarget, 2017, pp. 51402-51415.", "Zhang, Jingwen, Dulak, Austin M, Hattersley, Maureen M, Willis, Brandon S, Nikkil\u00e4, Jenni, Wang, Anderson, Lau, Alan, Reimer, Corinne, Zinda, Michael, Fawell, Stephen E, Mills, Gordon B, Chen, Huawei. \"BRD4 facilitates replication stress-induced DNA damage response.\" Oncogene, 2018, pp. 3763-3777.", "Liu, Liu, Lin, Baicheng, Yin, Shasha, Ball, Lauren E, Delaney, Joe R, Long, David T, Gan, Wenjian. \"Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair.\" Science advances, 2022, pp. eadd8928."]}, "   - EMSY: A protein that interacts with BRCA2, playing a role in DNA repair and homologous recombination.": {"keywords": ["(EMSY[Title]) OR (BRCA2[Title]) AND (DNA repair[Title])", "(EMSY[Title]) OR (BRCA2[Title]) AND (homologous recombination[Title])", "(EMSY[Title]) OR (BRCA2[Title]) AND (protein interaction[Title])", "(EMSY[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(EMSY[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (homologous recombination[Title/Abstract])", "(EMSY[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (protein interaction[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Kwon, Youngho, R\u00f6sner, Heike, Zhao, Weixing, Selemenakis, Platon, He, Zhuoling, Kawale, Ajinkya S, Katz, Jeffrey N, Rogers, Cody M, Neal, Francisco E, Badamchi Shabestari, Aida, Petrosius, Valdemaras, Singh, Akhilesh K, Joel, Marina Z, Lu, Lucy, Holloway, Stephen P, Burma, Sandeep, Mukherjee, Bipasha, Hromas, Robert, Mazin, Alexander, Wiese, Claudia, S\u00f8rensen, Claus S, Sung, Patrick. \"DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation.\" Nature communications, 2023, pp. 432.", "Liu, Lu, Cai, Shurui, Han, Chunhua, Banerjee, Ananya, Wu, Dayong, Cui, Tiantian, Xie, Guozhen, Zhang, Junran, Zhang, Xiaoli, McLaughlin, Eric, Yin, Ming, Backes, Floor J, Chakravarti, Arnab, Zheng, Yanfang, Wang, Qi-En. \"ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>-/-</sup> Ovarian Cancer Cells.\" Molecular cancer therapeutics, 2020, pp. 199-210."]}, "   - PALB2: A protein that interacts with BRCA1 and BRCA2, facilitating their roles in DNA repair and homologous recombination.": {"keywords": ["(PALB2[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) AND (DNA repair[Title])", "(PALB2[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) AND (homologous recombination[Title])", "(PALB2[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) AND (protein interaction[Title])", "(PALB2[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(PALB2[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (homologous recombination[Title/Abstract])", "(PALB2[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) AND (protein interaction[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Kwon, Youngho, R\u00f6sner, Heike, Zhao, Weixing, Selemenakis, Platon, He, Zhuoling, Kawale, Ajinkya S, Katz, Jeffrey N, Rogers, Cody M, Neal, Francisco E, Badamchi Shabestari, Aida, Petrosius, Valdemaras, Singh, Akhilesh K, Joel, Marina Z, Lu, Lucy, Holloway, Stephen P, Burma, Sandeep, Mukherjee, Bipasha, Hromas, Robert, Mazin, Alexander, Wiese, Claudia, S\u00f8rensen, Claus S, Sung, Patrick. \"DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation.\" Nature communications, 2023, pp. 432."]}, "   - PARP1: A protein involved in DNA repair, particularly in single-strand break repair and base excision repair.": {"keywords": ["(PARP1[Title]) AND (DNA repair[Title])", "(PARP1[Title]) AND (single-strand break[Title])", "(PARP1[Title]) AND (base excision[Title])", "(PARP1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(PARP1[Title/Abstract]) AND (single-strand break[Title/Abstract])", "(PARP1[Title/Abstract]) AND (base excision[Title/Abstract])"], "references": ["Ray Chaudhuri, Arnab, Nussenzweig, Andr\u00e9. \"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.\" Nature reviews. Molecular cell biology, 2017, pp. 610-621.", "Zada, David, Sela, Yaniv, Matosevich, Noa, Monsonego, Adir, Lerer-Goldshtein, Tali, Nir, Yuval, Appelbaum, Lior. \"Parp1 promotes sleep, which enhances DNA repair in neurons.\" Molecular cell, 2021, pp. 4979-4993.e7.", "Mao, Zhiyong, Hine, Christopher, Tian, Xiao, Van Meter, Michael, Au, Matthew, Vaidya, Amita, Seluanov, Andrei, Gorbunova, Vera. \"SIRT6 promotes DNA repair under stress by activating PARP1.\" Science (New York, N.Y.), 2011, pp. 1443-6."]}, "   - TP53: A tumor suppressor protein that plays a role in DNA repair, cell cycle regulation, and apoptosis.": {"keywords": ["(TP53[Title]) AND (DNA repair[Title])", "(TP53[Title]) AND (cell cycle regulation[Title])", "(TP53[Title]) AND (apoptosis[Title])", "(TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(TP53[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Patterson-Fortin, Jeffrey, Bose, Arindam, Tsai, Wei-Chih, Grochala, Carter, Nguyen, Huy, Zhou, Jia, Parmar, Kalindi, Lazaro, Jean-Bernard, Liu, Joyce, McQueen, Kelsey, Shapiro, Geoffrey I, Kozono, David, D'Andrea, Alan D. \"Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.\" Cancer research, 2022, pp. 3815-3829.", "Cavic, Milena, Spasic, Jelena, Krivokuca, Ana, Boljevic, Ivana, Kuburovic, Mira, Radosavljevic, Davorin, Jankovic, Radmila. \"<i>TP53</i> and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool.\" Journal of clinical pathology, 2019, pp. 75-80.", "Gal\u00edndez, Mar\u00eda Fernanda, Carrica, Andr\u00e9s, Zarate, Ana Mar\u00eda, Secchi, Dante, Don, Julieta, Barra, Jos\u00e9 Luis, Brunotto, Mabel. \"DNA repair, NFK\u03b2, and TP53 polymorphisms associated with potentially malignant disorders and oral squamous cell carcinoma in Argentine patients.\" Oral surgery, oral medicine, oral pathology and oral radiology, 2021, pp. 339-346."]}, "3. Transcriptional regulation: Some proteins in the system are involved in transcriptional regulation, affecting gene expression. These include:": {"keywords": [], "references": []}, "   - BCL11B: A transcription factor that plays a role in T-cell development and differentiation.": {"keywords": ["(BCL11B[Title]) AND (transcription factor[Title])", "(BCL11B[Title]) AND (T-cell development[Title])", "(BCL11B[Title]) AND (differentiation[Title])", "(BCL11B[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(BCL11B[Title/Abstract]) AND (T-cell development[Title/Abstract])", "(BCL11B[Title/Abstract]) AND (differentiation[Title/Abstract])"], "references": ["Lennon, Matthew J, Jones, Simon P, Lovelace, Michael D, Guillemin, Gilles J, Brew, Bruce J. \"Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease.\" Frontiers in cellular neuroscience, 2017, pp. 89.", "Kominami, Ryo. \"Role of the transcription factor Bcl11b in development and lymphomagenesis.\" Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2012, pp. 72-87.", "Liu, Pentao, Li, Peng, Burke, Shannon. \"Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity.\" Immunological reviews, 2010, pp. 138-49."]}, "   - E2F1: A transcription factor involved in cell cycle regulation and apoptosis.": {"keywords": ["(E2F1[Title]) AND (transcription factor[Title])", "(E2F1[Title]) AND (cell cycle[Title])", "(E2F1[Title]) AND (apoptosis[Title])", "(E2F1[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(E2F1[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(E2F1[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Ertosun, Mustafa Gokhan, Hapil, Fatma Zehra, Osman Nidai, Ozes. \"E2F1 transcription factor and its impact on growth factor and cytokine signaling.\" Cytokine & growth factor reviews, 2016, pp. 17-25.", "Shirakawa, Jun, Togashi, Yu, Basile, Giorgio, Okuyama, Tomoko, Inoue, Ryota, Fernandez, Megan, Kyohara, Mayu, De Jesus, Dario F, Goto, Nozomi, Zhang, Wei, Tsuno, Takahiro, Kin, Tatsuya, Pan, Hui, Dreyfuss, Jonathan M, Shapiro, A M James, Yi, Peng, Terauchi, Yasuo, Kulkarni, Rohit N. \"E2F1 transcription factor mediates a link between fat and islets to promote \u03b2 cell proliferation in response to acute insulin resistance.\" Cell reports, 2022, pp. 111436.", "Manickavinayaham, Swarnalatha, Velez-Cruz, Renier, Biswas, Anup K, Chen, Jie, Guo, Ruifeng, Johnson, David G. \"The E2F1 transcription factor and RB tumor suppressor moonlight as DNA repair factors.\" Cell cycle (Georgetown, Tex.), 2020, pp. 2260-2269."]}, "   - IRF2: A transcription factor that regulates interferon-responsive genes and immune response.": {"keywords": ["(IRF2[Title]) AND (transcription factor[Title])", "(IRF2[Title]) AND (interferon-responsive genes[Title])", "(IRF2[Title]) AND (immune response[Title])", "(IRF2[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(IRF2[Title/Abstract]) AND (interferon-responsive genes[Title/Abstract])", "(IRF2[Title/Abstract]) AND (immune response[Title/Abstract])"], "references": ["Lukhele, Sabelo, Rabbo, Diala Abd, Guo, Mengdi, Shen, Jian, Elsaesser, Heidi J, Quevedo, Rene, Carew, Madeleine, Gadalla, Ramy, Snell, Laura M, Mahesh, Lawanya, Ciudad, M Teresa, Snow, Bryan E, You-Ten, Annick, Haight, Jillian, Wakeham, Andrew, Ohashi, Pamela S, Mak, Tak W, Cui, Weiguo, McGaha, Tracy L, Brooks, David G. \"The transcription factor IRF2 drives interferon-mediated CD8<sup>+</sup> T\u00a0cell exhaustion to restrict anti-tumor immunity.\" Immunity, 2022, pp. 2369-2385.e10.", "Birnbaum, M J, van Zundert, B, Vaughan, P S, Whitmarsh, A J, van Wijnen, A J, Davis, R J, Stein, G S, Stein, J L. \"Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (IRF2) in vitro and in vivo.\" Journal of cellular biochemistry, 1997, pp. 175-83.", "Choo, Ailyn, Palladinetti, Patricia, Holmes, Tiffany, Basu, Shreerupa, Shen, Sylvie, Lock, Richard B, O'Brien, Tracey A, Symonds, Geoff, Dolnikov, Alla. \"siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.\" International journal of oncology, 2008, pp. 175-83."]}, "   - RB1: A tumor suppressor protein that regulates the cell cycle by inhibiting E2F transcription factors.": {"keywords": ["(RB1[Title]) OR (E2F[Title]) AND (cell cycle[Title])", "(RB1[Title]) OR (E2F[Title]) AND (tumor suppressor[Title])", "(RB1[Title]) OR (E2F[Title]) AND (E2F[Title])", "(RB1[Title/Abstract]) OR (E2F[Title/Abstract]) AND (cell cycle[Title/Abstract])", "(RB1[Title/Abstract]) OR (E2F[Title/Abstract]) AND (tumor suppressor[Title/Abstract])", "(RB1[Title/Abstract]) OR (E2F[Title/Abstract]) AND (E2F[Title/Abstract])"], "references": ["Knudsen, Erik S, Pruitt, Steven C, Hershberger, Pamela A, Witkiewicz, Agnieszka K, Goodrich, David W. \"Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.\" Trends in cancer, 2019, pp. 308-324.", "Fischer, Martin, M\u00fcller, Gerd A. \"Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes.\" Critical reviews in biochemistry and molecular biology, 2017, pp. 638-662.", "Johnson, D G, Schneider-Broussard, R. \"Role of E2F in cell cycle control and cancer.\" Frontiers in bioscience : a journal and virtual library, 1998, pp. d447-8."]}, "   - RUNX1: A transcription factor involved in hematopoiesis and leukemogenesis.": {"keywords": ["(RUNX1[Title]) AND (transcription factor[Title])", "(RUNX1[Title]) AND (hematopoiesis[Title])", "(RUNX1[Title]) AND (leukemogenesis[Title])", "(RUNX1[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(RUNX1[Title/Abstract]) AND (hematopoiesis[Title/Abstract])", "(RUNX1[Title/Abstract]) AND (leukemogenesis[Title/Abstract])"], "references": ["Mehtonen, Juha, Teppo, Susanna, Lahnalampi, Mari, Kokko, Aleksi, Kaukonen, Riina, Oksa, Laura, Bouvy-Liivrand, Maria, Malyukova, Alena, M\u00e4kinen, Artturi, Laukkanen, Saara, M\u00e4kinen, Petri I, Rounioja, Samuli, Ruusuvuori, Pekka, Sangfelt, Olle, Lund, Riikka, L\u00f6nnberg, Tapio, Lohi, Olli, Hein\u00e4niemi, Merja. \"Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.\" Genome medicine, 2020, pp. 99.", "Brown, Anna L, Hahn, Christopher N, Scott, Hamish S. \"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).\" Blood, 2020, pp. 24-35.", "Lappas, Martha. \"Runt-related transcription factor 1 (RUNX1) deficiency attenuates inflammation-induced pro-inflammatory and pro-labour mediators in myometrium.\" Molecular and cellular endocrinology, 2018, pp. 61-71."]}, "   - ZBTB2: A transcription factor that regulates gene expression by binding to specific DNA sequences.": {"keywords": ["(ZBTB2[Title]) AND (transcription factor[Title])", "(ZBTB2[Title]) AND (gene expression[Title])", "(ZBTB2[Title]) AND (DNA binding[Title])", "(ZBTB2[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(ZBTB2[Title/Abstract]) AND (gene expression[Title/Abstract])", "(ZBTB2[Title/Abstract]) AND (DNA binding[Title/Abstract])"], "references": ["Olivieri, Daniel, Paramanathan, Sujani, Bardet, Ana\u00efs F, Hess, Daniel, Smallwood, S\u00e9bastien A, Elling, Ulrich, Betschinger, Joerg. \"The BTB-domain transcription factor ZBTB2 recruits chromatin remodelers and a histone chaperone during the exit from pluripotency.\" The Journal of biological chemistry, 2021, pp. 100947.", "Chow, Christalle C T, Kobayashi, Minoru, Kambe, Gouki, Harada, Hiroshi. \"ZBTB2 is Recruited to a Specific Subset of HIF-1 Target Loci to Facilitate Full Gene Expression Under Hypoxia.\" Journal of molecular biology, 2023, pp. 168162.", "Lafaye, C\u00e9line, Barbier, Ewa, Miscioscia, Audrey, Saint-Pierre, Christine, Kraut, Alexandra, Cout\u00e9, Yohann, Plo, Isabelle, Gasparutto, Didier, Ravanat, Jean-Luc, Breton, Jean. \"DNA binding of the p21 repressor ZBTB2 is inhibited by cytosine hydroxymethylation.\" Biochemical and biophysical research communications, 2014, pp. 341-6."]}, "   - ZNF217: A transcription factor that is implicated in oncogenesis and cell survival.": {"keywords": ["(ZNF217[Title]) AND (oncogenesis[Title])", "(ZNF217[Title]) AND (transcription factor[Title])", "(ZNF217[Title]) AND (cell survival[Title])", "(ZNF217[Title/Abstract]) AND (oncogenesis[Title/Abstract])", "(ZNF217[Title/Abstract]) AND (transcription factor[Title/Abstract])", "(ZNF217[Title/Abstract]) AND (cell survival[Title/Abstract])"], "references": ["Littlepage, Laurie E, Adler, Adam S, Kouros-Mehr, Hosein, Huang, Guiqing, Chou, Jonathan, Krig, Sheryl R, Griffith, Obi L, Korkola, James E, Qu, Kun, Lawson, Devon A, Xue, Qing, Sternlicht, Mark D, Dijkgraaf, Gerrit J P, Yaswen, Paul, Rugo, Hope S, Sweeney, Colleen A, Collins, Colin C, Gray, Joe W, Chang, Howard Y, Werb, Zena. \"The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.\" Cancer discovery, 2012, pp. 638-51.", "Mantsou, Aglaia, Koutsogiannouli, Evangelia, Haitoglou, Costas, Papavassiliou, Athanasios G, Papanikolaou, Nikolaos A. \"Regulation of expression of the p21<sup>CIP1</sup> gene by the transcription factor ZNF217 and MDM2.\" Biochemistry and cell biology = Biochimie et biologie cellulaire, 2016, pp. 560-568.", "Oda, Katsutoshi, Hamanishi, Junzo, Matsuo, Koji, Hasegawa, Kosei. \"Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.\" Gynecologic oncology, 2018, pp. 381-389."]}, "4. DNA methylation: DNMT1, DNMT3A, and DNMT3B are DNA methyltransferases that play a role in the addition of methyl groups to cytosine residues in DNA, affecting gene expression and genomic stability.": {"keywords": ["(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (DNA methylation[Title])", "(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (methyltransferases[Title])", "(DNMT1[Title]) OR (DNMT3A[Title]) OR (DNMT3B[Title]) AND (gene expression[Title])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (DNA methylation[Title/Abstract])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (methyltransferases[Title/Abstract])", "(DNMT1[Title/Abstract]) OR (DNMT3A[Title/Abstract]) OR (DNMT3B[Title/Abstract]) AND (gene expression[Title/Abstract])"], "references": ["Dura, Mathilde, Teissandier, Aur\u00e9lie, Armand, M\u00e9lanie, Barau, Joan, Lapoujade, Cl\u00e9mentine, Fouchet, Pierre, Bonneville, Lorraine, Schulz, Mathieu, Weber, Michael, Baudrin, Laura G, Lameiras, Sonia, Bourc'his, Deborah. \"DNMT3A-dependent DNA methylation is required for spermatogonial stem cells to commit to spermatogenesis.\" Nature genetics, 2022, pp. 469-480.", "Zhang, Zhi-Min, Lu, Rui, Wang, Pengcheng, Yu, Yang, Chen, Dongliang, Gao, Linfeng, Liu, Shuo, Ji, Debin, Rothbart, Scott B, Wang, Yinsheng, Wang, Gang Greg, Song, Jikui. \"Structural basis for DNMT3A-mediated de novo DNA methylation.\" Nature, 2018, pp. 387-391.", "Weinberg, Daniel N, Papillon-Cavanagh, Simon, Chen, Haifen, Yue, Yuan, Chen, Xiao, Rajagopalan, Kartik N, Horth, Cynthia, McGuire, John T, Xu, Xinjing, Nikbakht, Hamid, Lemiesz, Agata E, Marchione, Dylan M, Marunde, Matthew R, Meiners, Matthew J, Cheek, Marcus A, Keogh, Michael-Christopher, Bareke, Eric, Djedid, Anissa, Harutyunyan, Ashot S, Jabado, Nada, Garcia, Benjamin A, Li, Haitao, Allis, C David, Majewski, Jacek, Lu, Chao. \"The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.\" Nature, 2019, pp. 281-286."]}, "5. Telomere maintenance: TERT is the catalytic subunit of telomerase, which is involved in the maintenance of telomeres and cellular immortality.": {"keywords": ["(TERT[Title]) AND (telomere maintenance[Title])", "(TERT[Title]) AND (TERT[Title])", "(TERT[Title]) AND (telomerase[Title])", "(TERT[Title/Abstract]) AND (telomere maintenance[Title/Abstract])", "(TERT[Title/Abstract]) AND (TERT[Title/Abstract])", "(TERT[Title/Abstract]) AND (telomerase[Title/Abstract])"], "references": ["Duan, Xiao-Feng, Zhao, Qiang. \"TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.\" Journal of pediatric hematology/oncology, 2018, pp. 1-6.", "Wang, Li-Na, Wang, Li, Cheng, Guanghui, Dai, Mingkai, Yu, Yunhai, Teng, Guoxin, Zhao, Jingjie, Xu, Dawei. \"The association of telomere maintenance and TERT expression with susceptibility to human papillomavirus infection in cervical epithelium.\" Cellular and molecular life sciences : CMLS, 2022, pp. 110.", "Goldstein, Alisa M, Qin, Richard, Chu, Emily Y, Elder, David E, Massi, Daniela, Adams, David J, Harms, Paul W, Robles-Espinoza, Carla Daniela, Newton-Bishop, Julia A, Bishop, D Timothy, Harland, Mark, Holland, Elizabeth A, Cust, Anne E, Schmid, Helen, Mann, Graham J, Puig, Susana, Potrony, Miriam, Alos, Llucia, Nagore, Eduardo, Mill\u00e1n-Esteban, David, Hayward, Nicholas K, Broit, Natasa, Palmer, Jane M, Nathan, Vaishnavi, Berry, Elizabeth G, Astiazaran-Symonds, Esteban, Yang, Xiaohong R, Tucker, Margaret A, Landi, Maria Teresa, Pfeiffer, Ruth M, Sargen, Michael R. \"Association of germline variants in telomere maintenance genes (<i>POT1, TERF2IP, ACD,</i> and <i>TERT</i>) with spitzoid morphology in familial melanoma: A multi-center case series.\" JAAD international, 2023, pp. 43-51."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is epigenetic regulation and DNA repair, with additional roles in transcriptional regulation, DNA methylation, and telomere maintenance.": {"keywords": [], "references": []}, "The system of interacting proteins primarily involves cell cycle regulation and DNA repair mechanisms. The proteins can be grouped into three main categories: cell cycle regulators, DNA repair proteins, and transcription factors.": {"keywords": [], "references": []}, "1. Cell cycle regulators: The proteins CCND1, CCND2, CCND3, CCNE1, CCNE2, CDK4, CDK5, CDK6, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, and CKS1B are involved in cell cycle regulation. Cyclins (CCND1, CCND2, CCND3, CCNE1, and CCNE2) and cyclin-dependent kinases (CDK4, CDK5, and CDK6) form complexes that control cell cycle progression. Cyclin-dependent kinase inhibitors (CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, and CDKN2C) negatively regulate these complexes. CKS1B is involved in the regulation of CDK activity.": {"keywords": ["(CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) OR (CDK4[Title]) OR (CDK5[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN1C[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CDKN2C[Title]) OR (CKS1B[Title]) AND (cell cycle regulation[Title])", "(CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) OR (CDK4[Title]) OR (CDK5[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN1C[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CDKN2C[Title]) OR (CKS1B[Title]) AND (cyclins[Title])", "(CCND1[Title]) OR (CCND2[Title]) OR (CCND3[Title]) OR (CCNE1[Title]) OR (CCNE2[Title]) OR (CDK4[Title]) OR (CDK5[Title]) OR (CDK6[Title]) OR (CDKN1A[Title]) OR (CDKN1B[Title]) OR (CDKN1C[Title]) OR (CDKN2A[Title]) OR (CDKN2B[Title]) OR (CDKN2C[Title]) OR (CKS1B[Title]) AND (cyclin-dependent kinases[Title])", "(CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) OR (CDK4[Title/Abstract]) OR (CDK5[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN1C[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CDKN2C[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) OR (CDK4[Title/Abstract]) OR (CDK5[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN1C[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CDKN2C[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (cyclins[Title/Abstract])", "(CCND1[Title/Abstract]) OR (CCND2[Title/Abstract]) OR (CCND3[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (CCNE2[Title/Abstract]) OR (CDK4[Title/Abstract]) OR (CDK5[Title/Abstract]) OR (CDK6[Title/Abstract]) OR (CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CDKN1C[Title/Abstract]) OR (CDKN2A[Title/Abstract]) OR (CDKN2B[Title/Abstract]) OR (CDKN2C[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (cyclin-dependent kinases[Title/Abstract])"], "references": ["Wang, Qiong, He, Guopei, Hou, Mengmeng, Chen, Liutao, Chen, Shangwu, Xu, Anlong, Fu, Yonggui. \"Cell Cycle Regulation by Alternative Polyadenylation of CCND1.\" Scientific reports, 2018, pp. 6824.", "Zhao, Bosheng, Burgess, Kevin. \"PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.\" Chemical communications (Cambridge, England), 2019, pp. 2704-2707.", "Coulonval, Katia, Vercruysse, Vincent, Paternot, Sabine, Pita, Jaime M, Corman, Robert, Rasp\u00e9, Eric, Roger, Pierre P. \"Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27.\" Cell cycle (Georgetown, Tex.), 2022, pp. 12-32."]}, "2. DNA repair proteins: BARD1, BLM, BRCA1, BRCA2, BUB1B, CHEK1, FANCD2, MSH2, MSH6, RAD51, RAD51C, WRN, and TP53 are involved in DNA repair mechanisms. BARD1 and BRCA1 form a complex involved in DNA double-strand break repair. BLM and WRN are RecQ helicases involved in DNA replication and repair. BRCA2, RAD51, and RAD51C are involved in homologous recombination repair. BUB1B is a mitotic checkpoint protein. CHEK1 is a kinase involved in DNA damage response. FANCD2 is involved in the Fanconi anemia pathway, which repairs DNA interstrand crosslinks. MSH2 and MSH6 are involved in mismatch repair.": {"keywords": ["(BARD1[Title]) OR (BLM[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (BUB1B[Title]) OR (CHEK1[Title]) OR (FANCD2[Title]) OR (MSH2[Title]) OR (MSH6[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (WRN[Title]) OR (TP53[Title]) AND (DNA repair[Title])", "(BARD1[Title]) OR (BLM[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (BUB1B[Title]) OR (CHEK1[Title]) OR (FANCD2[Title]) OR (MSH2[Title]) OR (MSH6[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (WRN[Title]) OR (TP53[Title]) AND (double-strand break[Title])", "(BARD1[Title]) OR (BLM[Title]) OR (BRCA1[Title]) OR (BRCA2[Title]) OR (BUB1B[Title]) OR (CHEK1[Title]) OR (FANCD2[Title]) OR (MSH2[Title]) OR (MSH6[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (WRN[Title]) OR (TP53[Title]) AND (homologous recombination[Title])", "(BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (BUB1B[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (WRN[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (BUB1B[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (WRN[Title/Abstract]) OR (TP53[Title/Abstract]) AND (double-strand break[Title/Abstract])", "(BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (BUB1B[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (FANCD2[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (WRN[Title/Abstract]) OR (TP53[Title/Abstract]) AND (homologous recombination[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Patterson-Fortin, Jeffrey, Bose, Arindam, Tsai, Wei-Chih, Grochala, Carter, Nguyen, Huy, Zhou, Jia, Parmar, Kalindi, Lazaro, Jean-Bernard, Liu, Joyce, McQueen, Kelsey, Shapiro, Geoffrey I, Kozono, David, D'Andrea, Alan D. \"Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.\" Cancer research, 2022, pp. 3815-3829."]}, "3. Transcription factors and other proteins: CTNNB1, E2F1, E2F4, EP300, HDAC1, HLA-A, MYC, RB1, RBL1, RBL2, TERT, and TOP2A are involved in transcription regulation and other cellular processes. CTNNB1 is involved in the Wnt signaling pathway and cell adhesion. E2F1 and E2F4 are transcription factors that regulate cell cycle progression. EP300 and CREBBP are histone acetyltransferases involved in transcription regulation. HDAC1 is a histone deacetylase involved in transcription repression. HLA-A is involved in antigen presentation. MYC is a transcription factor involved in cell growth and proliferation. RB1, RBL1, and RBL2 are tumor suppressor proteins that regulate cell cycle progression. TERT is involved in telomere maintenance. TOP2A is a DNA topoisomerase involved in DNA replication and transcription.": {"keywords": ["(CTNNB1[Title]) OR (E2F1[Title]) OR (E2F4[Title]) OR (EP300[Title]) OR (HDAC1[Title]) OR (HLA-A[Title]) OR (MYC[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (RBL2[Title]) OR (TERT[Title]) OR (TOP2A[Title]) AND (transcription regulation[Title])", "(CTNNB1[Title]) OR (E2F1[Title]) OR (E2F4[Title]) OR (EP300[Title]) OR (HDAC1[Title]) OR (HLA-A[Title]) OR (MYC[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (RBL2[Title]) OR (TERT[Title]) OR (TOP2A[Title]) AND (cell cycle progression[Title])", "(CTNNB1[Title]) OR (E2F1[Title]) OR (E2F4[Title]) OR (EP300[Title]) OR (HDAC1[Title]) OR (HLA-A[Title]) OR (MYC[Title]) OR (RB1[Title]) OR (RBL1[Title]) OR (RBL2[Title]) OR (TERT[Title]) OR (TOP2A[Title]) AND (Wnt signaling[Title])", "(CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HLA-A[Title/Abstract]) OR (MYC[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (RBL2[Title/Abstract]) OR (TERT[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (transcription regulation[Title/Abstract])", "(CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HLA-A[Title/Abstract]) OR (MYC[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (RBL2[Title/Abstract]) OR (TERT[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (cell cycle progression[Title/Abstract])", "(CTNNB1[Title/Abstract]) OR (E2F1[Title/Abstract]) OR (E2F4[Title/Abstract]) OR (EP300[Title/Abstract]) OR (HDAC1[Title/Abstract]) OR (HLA-A[Title/Abstract]) OR (MYC[Title/Abstract]) OR (RB1[Title/Abstract]) OR (RBL1[Title/Abstract]) OR (RBL2[Title/Abstract]) OR (TERT[Title/Abstract]) OR (TOP2A[Title/Abstract]) AND (Wnt signaling[Title/Abstract])"], "references": ["Mimaki, Sachiyo, Mori-Furukawa, Yuko, Katsuno, Hikari, Kishimoto, Toshihiko. \"A transcriptional regulatory element screening system reveals a novel E2F1/pRb transcription regulation pathway.\" Analytical biochemistry, 2005, pp. 268-80.", "Zhu, Qingqing, Zhang, Chongguo, Qu, Tianyu, Lu, Xiyi, He, Xuezhi, Li, Wei, Yin, Dandan, Han, Liang, Guo, Renhua, Zhang, Erbao. \"MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer.\" Cancer research, 2022, pp. 4340-4358.", "Yao, Yang, Liu, Chao, Wang, Bojun, Guan, Xin, Fang, Lin, Zhan, Fei, Sun, Haoxiu, Li, Hengzhen, Lou, Changjie, Yan, Feihu, Lu, Xiaolin, Cui, Luying, Liao, Yuanyu, Han, Shuling, Yao, Yuanfei, Zhang, Yanqiao. \"HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis.\" Cancer letters, 2022, pp. 215595."]}, "In conclusion, the most prominent biological process performed by this system of interacting proteins is cell cycle regulation and DNA repair. The proteins are involved in controlling cell cycle progression, maintaining genomic stability, and repairing DNA damage.": {"keywords": [], "references": []}, "The primary biological process performed by this system of interacting proteins is DNA damage response and repair. The proteins involved in this process work together to maintain genomic stability and prevent the accumulation of mutations that could lead to diseases such as cancer.": {"keywords": [], "references": []}, "1. DNA repair pathways: Several proteins in this system are involved in different DNA repair pathways, including homologous recombination (HR) and mismatch repair (MMR). HR proteins include BRCA1, BRCA2, RAD51, RAD51C, and XRCC2, while MMR proteins consist of MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2. These proteins function to repair DNA double-strand breaks and replication errors, respectively.": {"keywords": ["(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (XRCC2[Title]) OR (MLH1[Title]) OR (MLH3[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (PMS1[Title]) OR (PMS2[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (XRCC2[Title]) OR (MLH1[Title]) OR (MLH3[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (PMS1[Title]) OR (PMS2[Title]) AND (homologous recombination[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (RAD51[Title]) OR (RAD51C[Title]) OR (XRCC2[Title]) OR (MLH1[Title]) OR (MLH3[Title]) OR (MSH2[Title]) OR (MSH3[Title]) OR (MSH6[Title]) OR (PMS1[Title]) OR (PMS2[Title]) AND (mismatch repair[Title])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MLH3[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (PMS1[Title/Abstract]) OR (PMS2[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MLH3[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (PMS1[Title/Abstract]) OR (PMS2[Title/Abstract]) AND (homologous recombination[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (MLH1[Title/Abstract]) OR (MLH3[Title/Abstract]) OR (MSH2[Title/Abstract]) OR (MSH3[Title/Abstract]) OR (MSH6[Title/Abstract]) OR (PMS1[Title/Abstract]) OR (PMS2[Title/Abstract]) AND (mismatch repair[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Zhao, Jiao, Tian, Shanshan, Guo, Qiushi, Bao, Kaiwen, Yu, Guohui, Wang, Xiaodan, Shen, Xilin, Zhang, Jieyou, Chen, Jiaxin, Yang, Ying, Liu, Ling, Li, Xiangchun, Hao, Jihui, Yang, Na, Liu, Zhe, Ai, Ding, Yang, Jie, Zhu, Yi, Yao, Zhi, Ma, Shuai, Zhang, Kai, Shi, Lei. \"A PARylation-phosphorylation cascade promotes TOPBP1 loading and RPA-RAD51 exchange in homologous recombination.\" Molecular cell, 2022, pp. 2571-2587.e9."]}, "2. Cell cycle regulation: Proteins such as CDKN1A, CDKN1B, CCNE1, and RB1 are involved in cell cycle regulation, ensuring that cells only progress through the cell cycle when DNA is intact and properly replicated. This prevents the propagation of damaged DNA and maintains genomic stability.": {"keywords": ["(CDKN1A[Title]) OR (CDKN1B[Title]) OR (CCNE1[Title]) OR (RB1[Title]) AND (cell cycle regulation[Title])", "(CDKN1A[Title]) OR (CDKN1B[Title]) OR (CCNE1[Title]) OR (RB1[Title]) AND (genomic stability[Title])", "(CDKN1A[Title]) OR (CDKN1B[Title]) OR (CCNE1[Title]) OR (RB1[Title]) AND (DNA replication[Title])", "(CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (RB1[Title/Abstract]) AND (cell cycle regulation[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (RB1[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(CDKN1A[Title/Abstract]) OR (CDKN1B[Title/Abstract]) OR (CCNE1[Title/Abstract]) OR (RB1[Title/Abstract]) AND (DNA replication[Title/Abstract])"], "references": ["Andersson, Natalie, Saba, Karim H, Magnusson, Linda, Nilsson, Jenny, Karlsson, Jenny, Nord, Karolin H, Gisselsson, David. \"Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.\" Genes, chromosomes & cancer, 2023, pp. 93-100.", "Liu, Qiang, Niu, Na, Wada, Youichiro, Liu, Ju. \"The Role of Cdkn1A-Interacting Zinc Finger Protein 1 (CIZ1) in DNA Replication and Pathophysiology.\" International journal of molecular sciences, 2016, pp. 212.", "Engeland, Kurt. \"Cell cycle regulation: p53-p21-RB signaling.\" Cell death and differentiation, 2022, pp. 946-960."]}, "3. Checkpoint proteins: CHEK1 and TP53 are critical checkpoint proteins that monitor DNA integrity and halt the cell cycle if damage is detected. This allows time for repair proteins to fix the damage before the cell continues to divide.": {"keywords": ["(CHEK1[Title]) OR (TP53[Title]) AND (checkpoint proteins[Title])", "(CHEK1[Title]) OR (TP53[Title]) AND (DNA integrity[Title])", "(CHEK1[Title]) OR (TP53[Title]) AND (cell cycle[Title])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (checkpoint proteins[Title/Abstract])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA integrity[Title/Abstract])", "(CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle[Title/Abstract])"], "references": ["Meireles Da Costa, Nathalia, Palumbo, Antonio, De Martino, Marco, Fusco, Alfredo, Ribeiro Pinto, Luis Felipe, Nasciutti, Luiz Eurico. \"Interplay between HMGA and TP53 in cell cycle control along tumor progression.\" Cellular and molecular life sciences : CMLS, 2021, pp. 817-831.", "Thiem, Alexander, Hesbacher, Sonja, Kneitz, Hermann, di Primio, Teresa, Heppt, Markus V, Hermanns, Heike M, Goebeler, Matthias, Meierjohann, Svenja, Houben, Roland, Schrama, David. \"IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.\" Journal of experimental & clinical cancer research : CR, 2019, pp. 397.", "Baumhoer, D. \"[Hereditary bone tumors].\" Der Pathologe, 2017, pp. 179-185."]}, "4. DNA replication and stability: Proteins such as BLM, WRN, POLD1, and POLE are involved in DNA replication and maintaining genomic stability. They function to ensure accurate replication of DNA and prevent the formation of DNA structures that could lead to genomic instability.": {"keywords": ["(BLM[Title]) OR (WRN[Title]) OR (POLD1[Title]) OR (POLE[Title]) AND (DNA replication[Title])", "(BLM[Title]) OR (WRN[Title]) OR (POLD1[Title]) OR (POLE[Title]) AND (genomic stability[Title])", "(BLM[Title]) OR (WRN[Title]) OR (POLD1[Title]) OR (POLE[Title]) AND (proteins[Title])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) OR (POLD1[Title/Abstract]) OR (POLE[Title/Abstract]) AND (DNA replication[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) OR (POLD1[Title/Abstract]) OR (POLE[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(BLM[Title/Abstract]) OR (WRN[Title/Abstract]) OR (POLD1[Title/Abstract]) OR (POLE[Title/Abstract]) AND (proteins[Title/Abstract])"], "references": ["Nicolas, Emmanuelle, Golemis, Erica A, Arora, Sanjeevani. \"POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.\" Gene, 2016, pp. 128-41.", "Murdocca, Michela, Spitalieri, Paola, D'Apice, Maria Rosaria, Novelli, Giuseppe, Sangiuolo, Federica. \"From cue to meaning: The involvement of POLD1 gene in DNA replication, repair and aging.\" Mechanisms of ageing and development, 2023, pp. 111790.", "Manthei, Kelly A, Keck, James L. \"The BLM dissolvasome in DNA replication and repair.\" Cellular and molecular life sciences : CMLS, 2013, pp. 4067-84."]}, "5. Aurora kinases: AURKA and AURKB are serine/threonine kinases that play essential roles in mitosis, ensuring proper chromosome segregation and preventing aneuploidy.": {"keywords": ["(AURKA[Title]) OR (AURKB[Title]) AND (mitosis[Title])", "(AURKA[Title]) OR (AURKB[Title]) AND (chromosome segregation[Title])", "(AURKA[Title]) OR (AURKB[Title]) AND (aneuploidy[Title])", "(AURKA[Title/Abstract]) OR (AURKB[Title/Abstract]) AND (mitosis[Title/Abstract])", "(AURKA[Title/Abstract]) OR (AURKB[Title/Abstract]) AND (chromosome segregation[Title/Abstract])", "(AURKA[Title/Abstract]) OR (AURKB[Title/Abstract]) AND (aneuploidy[Title/Abstract])"], "references": ["Moura, David S, Campillo-Marcos, Ignacio, V\u00e1zquez-Cedeira, Marta, Lazo, Pedro A. \"VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis.\" Cellular and molecular life sciences : CMLS, 2018, pp. 2591-2611.", "Plotnikova, Olga V, Nikonova, Anna S, Loskutov, Yuri V, Kozyulina, Polina Y, Pugacheva, Elena N, Golemis, Erica A. \"Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis.\" Molecular biology of the cell, 2012, pp. 2658-70.", "Du, Ruijuan, Huang, Chuntian, Liu, Kangdong, Li, Xiang, Dong, Zigang. \"Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.\" Molecular cancer, 2021, pp. 15."]}, "6. BRCA1-associated proteins: BARD1 and BRIP1 are known to interact with BRCA1, a key protein in HR repair. These interactions are crucial for the proper function of BRCA1 in DNA repair and tumor suppression.": {"keywords": ["(BRCA1[Title]) OR (BARD1[Title]) OR (BRIP1[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BARD1[Title]) OR (BRIP1[Title]) AND (tumor suppression[Title])", "(BRCA1[Title]) OR (BARD1[Title]) OR (BRIP1[Title]) AND (protein interaction[Title])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRIP1[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRIP1[Title/Abstract]) AND (tumor suppression[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BRIP1[Title/Abstract]) AND (protein interaction[Title/Abstract])"], "references": ["Yoshida, Kiyotsugu, Miki, Yoshio. \"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.\" Cancer science, 2004, pp. 866-71.", "Tarsounas, Madalena, Sung, Patrick. \"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.\" Nature reviews. Molecular cell biology, 2020, pp. 284-299.", "Trivedi, Shalini, Blaz\u00edckov\u00e1, Jitka, Silva, Nicola. \"PARG and BRCA1-BARD1 cooperative function regulates DNA repair pathway choice during gametogenesis.\" Nucleic acids research, 2022, pp. 12291-12308."]}, "7. Proliferation marker: MKI67 is a marker of cell proliferation, and its expression is often used to assess the growth rate of tumors.": {"keywords": ["(MKI67[Title]) AND (proliferation marker[Title])", "(MKI67[Title]) AND (cell proliferation[Title])", "(MKI67[Title]) AND (tumor growth[Title])", "(MKI67[Title/Abstract]) AND (proliferation marker[Title/Abstract])", "(MKI67[Title/Abstract]) AND (cell proliferation[Title/Abstract])", "(MKI67[Title/Abstract]) AND (tumor growth[Title/Abstract])"], "references": ["Loibl, Sibylle, Poortmans, Philip, Morrow, Monica, Denkert, Carsten, Curigliano, Giuseppe. \"Breast cancer.\" Lancet (London, England), 2021, pp. 1750-1769.", "Giordano, Mario Vicente, Lucas, Hiram Da Silveira, Fiorelli, Rossano Kepler Alvim, Giordano, Luiz Augusto, Giordano, Mario G\u00e1spare, Baracat, Edmund Chada, J\u00fanior, Jos\u00e9 Maria Soares. \"Expression levels of BCL2 and MKI67 in endometrial polyps in postmenopausal women and their correlation with obesity.\" Molecular and clinical oncology, 2020, pp. 69.", "Wei, Dang, Rui, Bian, Qingquan, Fan, Chen, Cai, Ping, Hu Yun, Xiaoling, Song, Hao, Weng, Jun, Gu. \"KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer.\" International journal of biological sciences, 2021, pp. 514-526."]}, "8. Telomere maintenance: TERT is involved in telomere maintenance, which is essential for preserving genomic stability and preventing cellular senescence.": {"keywords": ["(TERT[Title]) AND (telomere maintenance[Title])", "(TERT[Title]) AND (genomic stability[Title])", "(TERT[Title]) AND (cellular senescence[Title])", "(TERT[Title/Abstract]) AND (telomere maintenance[Title/Abstract])", "(TERT[Title/Abstract]) AND (genomic stability[Title/Abstract])", "(TERT[Title/Abstract]) AND (cellular senescence[Title/Abstract])"], "references": ["Duan, Xiao-Feng, Zhao, Qiang. \"TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.\" Journal of pediatric hematology/oncology, 2018, pp. 1-6.", "Wang, Li-Na, Wang, Li, Cheng, Guanghui, Dai, Mingkai, Yu, Yunhai, Teng, Guoxin, Zhao, Jingjie, Xu, Dawei. \"The association of telomere maintenance and TERT expression with susceptibility to human papillomavirus infection in cervical epithelium.\" Cellular and molecular life sciences : CMLS, 2022, pp. 110.", "Goldstein, Alisa M, Qin, Richard, Chu, Emily Y, Elder, David E, Massi, Daniela, Adams, David J, Harms, Paul W, Robles-Espinoza, Carla Daniela, Newton-Bishop, Julia A, Bishop, D Timothy, Harland, Mark, Holland, Elizabeth A, Cust, Anne E, Schmid, Helen, Mann, Graham J, Puig, Susana, Potrony, Miriam, Alos, Llucia, Nagore, Eduardo, Mill\u00e1n-Esteban, David, Hayward, Nicholas K, Broit, Natasa, Palmer, Jane M, Nathan, Vaishnavi, Berry, Elizabeth G, Astiazaran-Symonds, Esteban, Yang, Xiaohong R, Tucker, Margaret A, Landi, Maria Teresa, Pfeiffer, Ruth M, Sargen, Michael R. \"Association of germline variants in telomere maintenance genes (<i>POT1, TERF2IP, ACD,</i> and <i>TERT</i>) with spitzoid morphology in familial melanoma: A multi-center case series.\" JAAD international, 2023, pp. 43-51."]}, "9. Topoisomerase: TOP2A is a DNA topoisomerase that plays a role in resolving DNA topological problems during replication and transcription.": {"keywords": ["(TOP2A[Title]) AND (DNA topoisomerase[Title])", "(TOP2A[Title]) AND (replication[Title])", "(TOP2A[Title]) AND (transcription[Title])", "(TOP2A[Title/Abstract]) AND (DNA topoisomerase[Title/Abstract])", "(TOP2A[Title/Abstract]) AND (replication[Title/Abstract])", "(TOP2A[Title/Abstract]) AND (transcription[Title/Abstract])"], "references": ["Smith, Paul J, McKeown, Stephanie R, Patterson, Laurence H. \"Targeting DNA topoisomerase II\u03b1 (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).\" IUBMB life, 2023, pp. 40-54.", "Zhou, Yi, Li, Jing, Yang, Xiaoxin, Song, Yu, Li, Haigang. \"Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (<i>TOP2A</i>).\" Bioengineered, 2021, pp. 12003-12022.", "Tian, Tian, Bu, Min, Chen, Xu, Ding, Linli, Yang, Yulan, Han, Jinhua, Feng, Xin-Hua, Xu, Pinglong, Liu, Ting, Ying, Songmin, Lei, Yang, Li, Qing, Huang, Jun. \"The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork Reversal to Promote Genome Stability.\" Molecular cell, 2021, pp. 198-211.e6."]}, "10. Spindle assembly checkpoint: BUB1B and CKS1B are involved in the spindle assembly checkpoint, ensuring proper chromosome segregation during mitosis.": {"keywords": ["(BUB1B[Title]) OR (CKS1B[Title]) AND (spindle assembly checkpoint[Title])", "(BUB1B[Title]) OR (CKS1B[Title]) AND (chromosome segregation[Title])", "(BUB1B[Title]) OR (CKS1B[Title]) AND (mitosis[Title])", "(BUB1B[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (spindle assembly checkpoint[Title/Abstract])", "(BUB1B[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (chromosome segregation[Title/Abstract])", "(BUB1B[Title/Abstract]) OR (CKS1B[Title/Abstract]) AND (mitosis[Title/Abstract])"], "references": ["Koyuncu, Dilara, Sharma, Utsav, Goka, Erik T, Lippman, Marc E. \"Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.\" Breast cancer research and treatment, 2021, pp. 331-341.", "Hahn, Marc-Manuel, Vreede, Lilian, Bemelmans, Sonja A S A, van der Looij, Erica, van Kessel, Ad Geurts, Schackert, Hans K, Ligtenberg, Marjolijn J L, Hoogerbrugge, Nicoline, Kuiper, Roland P, de Voer, Richarda M. \"Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with early-onset colorectal cancer.\" Genes, chromosomes & cancer, 2016, pp. 855-63.", "Abal, Miguel, Obrador-Hevia, Antonia, Janssen, Klaus-Peter, Casadome, Laura, Menendez, Mireia, Carpentier, Sabrina, Barillot, Emmanuel, Wagner, Mechthild, Ansorge, Wilhelm, Moeslein, Gabriela, Fsihi, Hafida, Bezrookove, Vladimir, Reventos, Jaume, Louvard, Daniel, Capella, Gabriel, Robine, Sylvie. \"APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 up-regulation.\" Gastroenterology, 2007, pp. 2448-58."]}, "In summary, this system of interacting proteins is primarily involved in the DNA damage response and repair process, which is crucial for maintaining genomic stability and preventing the accumulation of mutations that could lead to diseases such as cancer.": {"keywords": [], "references": []}, "The primary biological process performed by this system of interacting proteins is the DNA damage response and repair. This process is crucial for maintaining genomic stability and preventing the accumulation of mutations that can lead to cancer and other diseases.": {"keywords": [], "references": []}, "1. ATM, ATR, and CHEK1 are key kinases involved in the DNA damage response. They are activated in response to DNA damage and phosphorylate various downstream targets, including TP53 and BRCA1, to initiate cell cycle arrest and DNA repair.": {"keywords": ["(ATM[Title]) OR (ATR[Title]) OR (CHEK1[Title]) OR (TP53[Title]) OR (BRCA1[Title]) AND (DNA damage response[Title])", "(ATM[Title]) OR (ATR[Title]) OR (CHEK1[Title]) OR (TP53[Title]) OR (BRCA1[Title]) AND (kinases[Title])", "(ATM[Title]) OR (ATR[Title]) OR (CHEK1[Title]) OR (TP53[Title]) OR (BRCA1[Title]) AND (cell cycle arrest[Title])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (kinases[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (CHEK1[Title/Abstract]) OR (TP53[Title/Abstract]) OR (BRCA1[Title/Abstract]) AND (cell cycle arrest[Title/Abstract])"], "references": ["Blackford, Andrew N, Jackson, Stephen P. \"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.\" Molecular cell, 2017, pp. 801-817.", "Foo, Tzeh Keong, Xia, Bing. \"BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.\" Cancer research, 2022, pp. 3191-3197.", "Lindemann, A, Takahashi, H, Patel, A A, Osman, A A, Myers, J N. \"Targeting the DNA Damage Response in OSCC with TP53 Mutations.\" Journal of dental research, 2018, pp. 635-644."]}, "2. TP53 is a tumor suppressor protein that plays a central role in the DNA damage response. Upon activation by ATM and ATR, TP53 induces cell cycle arrest, allowing time for DNA repair. If the damage is irreparable, TP53 can initiate apoptosis to prevent the propagation of damaged cells.": {"keywords": ["(ATM[Title]) OR (ATR[Title]) OR (TP53[Title]) AND (DNA damage response[Title])", "(ATM[Title]) OR (ATR[Title]) OR (TP53[Title]) AND (cell cycle arrest[Title])", "(ATM[Title]) OR (ATR[Title]) OR (TP53[Title]) AND (apoptosis[Title])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (TP53[Title/Abstract]) AND (DNA damage response[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (TP53[Title/Abstract]) AND (cell cycle arrest[Title/Abstract])", "(ATM[Title/Abstract]) OR (ATR[Title/Abstract]) OR (TP53[Title/Abstract]) AND (apoptosis[Title/Abstract])"], "references": ["Blackford, Andrew N, Jackson, Stephen P. \"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.\" Molecular cell, 2017, pp. 801-817.", "Zhang, Jingjing, Wu, Qiong, Zhu, Lucheng, Xie, Shujun, Tu, Linglan, Yang, Yuhong, Wu, Kan, Zhao, Yanyan, Wang, Yuqing, Xu, Yasi, Chen, Xueqin, Ma, Shenglin, Zhang, Shirong. \"SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.\" Cancer letters, 2022, pp. 268-283.", "Lindemann, A, Takahashi, H, Patel, A A, Osman, A A, Myers, J N. \"Targeting the DNA Damage Response in OSCC with TP53 Mutations.\" Journal of dental research, 2018, pp. 635-644."]}, "3. BRCA1 and BRCA2 are essential for homologous recombination (HR) repair, a high-fidelity DNA repair pathway. They interact with PALB2, RAD51, and other RAD51 paralogs (RAD51B, RAD51C, RAD51D) to facilitate the formation of RAD51 nucleoprotein filaments on single-stranded DNA, promoting strand invasion and repair.": {"keywords": ["(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) AND (homologous recombination[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) AND (DNA repair[Title])", "(BRCA1[Title]) OR (BRCA2[Title]) OR (PALB2[Title]) OR (RAD51[Title]) OR (RAD51B[Title]) OR (RAD51C[Title]) OR (RAD51D[Title]) AND (RAD51[Title])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) AND (homologous recombination[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BRCA2[Title/Abstract]) OR (PALB2[Title/Abstract]) OR (RAD51[Title/Abstract]) OR (RAD51B[Title/Abstract]) OR (RAD51C[Title/Abstract]) OR (RAD51D[Title/Abstract]) AND (RAD51[Title/Abstract])"], "references": ["Zhao, Jiao, Tian, Shanshan, Guo, Qiushi, Bao, Kaiwen, Yu, Guohui, Wang, Xiaodan, Shen, Xilin, Zhang, Jieyou, Chen, Jiaxin, Yang, Ying, Liu, Ling, Li, Xiangchun, Hao, Jihui, Yang, Na, Liu, Zhe, Ai, Ding, Yang, Jie, Zhu, Yi, Yao, Zhi, Ma, Shuai, Zhang, Kai, Shi, Lei. \"A PARylation-phosphorylation cascade promotes TOPBP1 loading and RPA-RAD51 exchange in homologous recombination.\" Molecular cell, 2022, pp. 2571-2587.e9.", "Demeyer, A, Benhelli-Mokrani, H, Ch\u00e9nais, B, Weigel, P, Fleury, F. \"Inhibiting homologous recombination by targeting RAD51 protein.\" Biochimica et biophysica acta. Reviews on cancer, 2021, pp. 188597.", "Zhu, Qian, Huang, Jinzhou, Huang, Hongyang, Li, Huan, Yi, Peiqiang, Kloeber, Jake A, Yuan, Jian, Chen, Yuping, Deng, Min, Luo, Kuntian, Gao, Ming, Guo, Guijie, Tu, Xinyi, Yin, Ping, Zhang, Yong, Su, Jun, Chen, Jiayi, Lou, Zhenkun. \"RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination.\" Nature communications, 2021, pp. 6653."]}, "4. The MRN complex, composed of MRE11, RAD50, and NBN, is involved in the detection and processing of DNA double-strand breaks (DSBs). This complex recruits ATM to DSBs and initiates DNA end resection, generating single-stranded DNA for HR repair.": {"keywords": ["(MRE11[Title]) OR (RAD50[Title]) OR (NBN[Title]) OR (ATM[Title]) AND (DNA double-strand breaks[Title])", "(MRE11[Title]) OR (RAD50[Title]) OR (NBN[Title]) OR (ATM[Title]) AND (MRN complex[Title])", "(MRE11[Title]) OR (RAD50[Title]) OR (NBN[Title]) OR (ATM[Title]) AND (HR repair[Title])", "(MRE11[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (NBN[Title/Abstract]) OR (ATM[Title/Abstract]) AND (DNA double-strand breaks[Title/Abstract])", "(MRE11[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (NBN[Title/Abstract]) OR (ATM[Title/Abstract]) AND (MRN complex[Title/Abstract])", "(MRE11[Title/Abstract]) OR (RAD50[Title/Abstract]) OR (NBN[Title/Abstract]) OR (ATM[Title/Abstract]) AND (HR repair[Title/Abstract])"], "references": ["Pennisi, Rosa, Antoccia, Antonio, Leone, Stefano, Ascenzi, Paolo, di Masi, Alessandra. \"Hsp90\u03b1 regulates ATM and NBN functions in sensing and repair of DNA double-strand breaks.\" The FEBS journal, 2017, pp. 2378-2395.", "Williams, Rhys M, Zhang, Xiaodong. \"Roles of ATM and ATR in DNA double strand breaks and replication stress.\" Progress in biophysics and molecular biology, 2021, pp. 109-119.", "Williams, Rhys M, Zhang, Xiaodong. \"Roles of ATM and ATR in DNA double strand breaks and replication stress.\" Progress in biophysics and molecular biology, 2021, pp. 27-38."]}, "5. BARD1 forms a stable complex with BRCA1, enhancing its stability and function in HR repair. BLM and WRN are RecQ helicases that unwind DNA structures during HR repair and replication fork restart.": {"keywords": ["(BRCA1[Title]) OR (BARD1[Title]) OR (BLM[Title]) OR (WRN[Title]) AND (HR repair[Title])", "(BRCA1[Title]) OR (BARD1[Title]) OR (BLM[Title]) OR (WRN[Title]) AND (RecQ helicases[Title])", "(BRCA1[Title]) OR (BARD1[Title]) OR (BLM[Title]) OR (WRN[Title]) AND (DNA structures[Title])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (HR repair[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (RecQ helicases[Title/Abstract])", "(BRCA1[Title/Abstract]) OR (BARD1[Title/Abstract]) OR (BLM[Title/Abstract]) OR (WRN[Title/Abstract]) AND (DNA structures[Title/Abstract])"], "references": ["Kitano, Ken. \"Structural mechanisms of human RecQ helicases WRN and BLM.\" Frontiers in genetics, 2014, pp. 366.", "Zhu, Mingzhang, Wu, Wenwen, Togashi, Yukiko, Liang, Weixin, Miyoshi, Yasuo, Ohta, Tomohiko. \"HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN.\" Scientific reports, 2021, pp. 360.", "Mendez-Bermudez, Aaron, Hidalgo-Bravo, Alberto, Cotton, Victoria E, Gravani, Athanasia, Jeyapalan, Jennie N, Royle, Nicola J. \"The roles of WRN and BLM RecQ helicases in the Alternative Lengthening of Telomeres.\" Nucleic acids research, 2012, pp. 10809-20."]}, "6. FANCA and FANCD2 are part of the Fanconi anemia (FA) pathway, which is involved in the repair of DNA interstrand crosslinks. The FA pathway cooperates with HR repair to maintain genomic stability.": {"keywords": ["(FANCA[Title]) OR (FANCD2[Title]) AND (DNA repair[Title])", "(FANCA[Title]) OR (FANCD2[Title]) AND (Fanconi anemia pathway[Title])", "(FANCA[Title]) OR (FANCD2[Title]) AND (genomic stability[Title])", "(FANCA[Title/Abstract]) OR (FANCD2[Title/Abstract]) AND (DNA repair[Title/Abstract])", "(FANCA[Title/Abstract]) OR (FANCD2[Title/Abstract]) AND (Fanconi anemia pathway[Title/Abstract])", "(FANCA[Title/Abstract]) OR (FANCD2[Title/Abstract]) AND (genomic stability[Title/Abstract])"], "references": ["Zhao, Simin, Huang, Chengzi, Yang, Yajuan, Xu, Weiwei, Yu, Yongze, Wen, Canxin, Cao, Lili, Gao, Fei, Qin, Yingying, Chen, Zi-Jiang, Guo, Ting, Zhao, Shidou. \"DNA repair protein FANCD2 has both ubiquitination-dependent and ubiquitination-independent functions during germ cell development.\" The Journal of biological chemistry, 2023, pp. 102905.", "Alc\u00f3n, Pablo, Shakeel, Shabih, Chen, Zhuo A, Rappsilber, Juri, Patel, Ketan J, Passmore, Lori A. \"FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of FANCD2 during DNA repair.\" Nature structural & molecular biology, 2020, pp. 240-248.", "Seki, Sohsuke, Ohzeki, Mioko, Uchida, Akiko, Hirano, Seiki, Matsushita, Nobuko, Kitao, Hiroyuki, Oda, Tsukasa, Yamashita, Takayuki, Kashihara, Naoki, Tsubahara, Akio, Takata, Minoru, Ishiai, Masamichi. \"A requirement of FancL and FancD2 monoubiquitination in DNA repair.\" Genes to cells : devoted to molecular & cellular mechanisms, 2007, pp. 299-310."]}, "7. MSH6 is involved in mismatch repair (MMR), a process that corrects base mismatches and small insertion/deletion loops that arise during DNA replication.": {"keywords": ["(MSH6[Title]) AND (mismatch repair[Title])", "(MSH6[Title]) AND (DNA replication[Title])", "(MSH6[Title]) AND (MSH6[Title])", "(MSH6[Title/Abstract]) AND (mismatch repair[Title/Abstract])", "(MSH6[Title/Abstract]) AND (DNA replication[Title/Abstract])", "(MSH6[Title/Abstract]) AND (MSH6[Title/Abstract])"], "references": ["DuPrie, Matthew L, Palacio, Tatiana, Calil, Felipe A, Kolodner, Richard D, Putnam, Christopher D. \"Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair.\" DNA repair, 2022, pp. 103405.", "Stark, Andreas M, Doukas, Alexander, Hugo, Heinz-Herrmann, Hedderich, J\u00fcrgen, Hattermann, Kirsten, Maximilian Mehdorn, H, Held-Feindt, Janka. \"Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.\" Neurological research, 2015, pp. 95-105.", "Salem, Mohamed E, Bodor, J Nicholas, Puccini, Alberto, Xiu, Joanne, Goldberg, Richard M, Grothey, Axel, Korn, W Michael, Shields, Anthony F, Worrilow, William M, Kim, Edward S, Lenz, Heinz-Josef, Marshall, John L, Hall, Michael J. \"Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.\" International journal of cancer, 2020, pp. 2948-2956."]}, "8. POLH is a translesion synthesis (TLS) polymerase that can bypass certain types of DNA damage, allowing replication to continue despite the presence of lesions.": {"keywords": ["(POLH[Title]) AND (translesion synthesis[Title])", "(POLH[Title]) AND (DNA damage[Title])", "(POLH[Title]) AND (replication[Title])", "(POLH[Title/Abstract]) AND (translesion synthesis[Title/Abstract])", "(POLH[Title/Abstract]) AND (DNA damage[Title/Abstract])", "(POLH[Title/Abstract]) AND (replication[Title/Abstract])"], "references": ["Zhang, Jin, Sun, Wenqiang, Ren, Cong, Kong, Xiangmudong, Yan, Wensheng, Chen, Xinbin. \"A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.\" Cancer research, 2019, pp. 3714-3724.", "Wilson, David M, Duncton, Matthew A J, Chang, Caleb, Lee Luo, Christie, Georgiadis, Taxiarchis M, Pellicena, Patricia, Deacon, Ashley M, Gao, Yang, Das, Debanu. \"Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH).\" Frontiers in oncology, 2021, pp. 778925."]}, "9. AURKA and BUB1B are involved in the regulation of mitosis and the spindle assembly checkpoint, ensuring proper chromosome segregation during cell division.": {"keywords": ["(AURKA[Title]) OR (BUB1B[Title]) AND (mitosis[Title])", "(AURKA[Title]) OR (BUB1B[Title]) AND (spindle assembly checkpoint[Title])", "(AURKA[Title]) OR (BUB1B[Title]) AND (chromosome segregation[Title])", "(AURKA[Title/Abstract]) OR (BUB1B[Title/Abstract]) AND (mitosis[Title/Abstract])", "(AURKA[Title/Abstract]) OR (BUB1B[Title/Abstract]) AND (spindle assembly checkpoint[Title/Abstract])", "(AURKA[Title/Abstract]) OR (BUB1B[Title/Abstract]) AND (chromosome segregation[Title/Abstract])"], "references": ["Abal, Miguel, Obrador-Hevia, Antonia, Janssen, Klaus-Peter, Casadome, Laura, Menendez, Mireia, Carpentier, Sabrina, Barillot, Emmanuel, Wagner, Mechthild, Ansorge, Wilhelm, Moeslein, Gabriela, Fsihi, Hafida, Bezrookove, Vladimir, Reventos, Jaume, Louvard, Daniel, Capella, Gabriel, Robine, Sylvie. \"APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 up-regulation.\" Gastroenterology, 2007, pp. 2448-58.", "Plotnikova, Olga V, Nikonova, Anna S, Loskutov, Yuri V, Kozyulina, Polina Y, Pugacheva, Elena N, Golemis, Erica A. \"Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis.\" Molecular biology of the cell, 2012, pp. 2658-70.", "Koyuncu, Dilara, Sharma, Utsav, Goka, Erik T, Lippman, Marc E. \"Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.\" Breast cancer research and treatment, 2021, pp. 331-341."]}, "10. CDC73 is a component of the PAF1 complex, which is involved in transcriptional regulation and chromatin remodeling. MDM2 is an E3 ubiquitin ligase that negatively regulates TP53 by targeting it for proteasomal degradation.": {"keywords": ["(CDC73[Title]) OR (PAF1[Title]) OR (MDM2[Title]) OR (TP53[Title]) AND (transcriptional regulation[Title])", "(CDC73[Title]) OR (PAF1[Title]) OR (MDM2[Title]) OR (TP53[Title]) AND (chromatin remodeling[Title])", "(CDC73[Title]) OR (PAF1[Title]) OR (MDM2[Title]) OR (TP53[Title]) AND (proteasomal degradation[Title])", "(CDC73[Title/Abstract]) OR (PAF1[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (TP53[Title/Abstract]) AND (transcriptional regulation[Title/Abstract])", "(CDC73[Title/Abstract]) OR (PAF1[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (TP53[Title/Abstract]) AND (chromatin remodeling[Title/Abstract])", "(CDC73[Title/Abstract]) OR (PAF1[Title/Abstract]) OR (MDM2[Title/Abstract]) OR (TP53[Title/Abstract]) AND (proteasomal degradation[Title/Abstract])"], "references": ["Truong, Amandine H L, Cervi, David, Lee, Jane, Ben-David, Yaacov. \"Direct transcriptional regulation of MDM2 by Fli-1.\" Oncogene, 2005, pp. 962-9.", "Ard, Penny G, Chatterjee, Chandrima, Kunjibettu, Sudeesha, Adside, Leon R, Gralinski, Lisa E, McMahon, Steven B. \"Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes.\" Molecular and cellular biology, 2002, pp. 5650-61.", "Herr, Patrick, Lundin, Cecilia, Evers, Bastiaan, Ebner, Daniel, Bauerschmidt, Christina, Kingham, Guy, Palmai-Pallag, Timea, Mortusewicz, Oliver, Frings, Oliver, Sonnhammer, Erik, Helleday, Thomas. \"A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair.\" Cell discovery, 2015, pp. 15034."]}, "11. TOP2A is a topoisomerase that resolves topological DNA issues during replication, transcription, and chromosome segregation. XRCC2 and XRCC3 are involved in HR repair and the maintenance of chromosome stability.": {"keywords": ["(TOP2A[Title]) OR (XRCC2[Title]) OR (XRCC3[Title]) AND (topoisomerase[Title])", "(TOP2A[Title]) OR (XRCC2[Title]) OR (XRCC3[Title]) AND (DNA replication[Title])", "(TOP2A[Title]) OR (XRCC2[Title]) OR (XRCC3[Title]) AND (chromosome stability[Title])", "(TOP2A[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (XRCC3[Title/Abstract]) AND (topoisomerase[Title/Abstract])", "(TOP2A[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (XRCC3[Title/Abstract]) AND (DNA replication[Title/Abstract])", "(TOP2A[Title/Abstract]) OR (XRCC2[Title/Abstract]) OR (XRCC3[Title/Abstract]) AND (chromosome stability[Title/Abstract])"], "references": ["Dong, Yinying, Sun, Xiangyin, Zhang, Kong, He, Xinjia, Zhang, Qian, Song, Hao, Xu, Mingjin, Lu, Haijun, Ren, Ruimei. \"Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression.\" Bioengineered, 2021, pp. 12967-12979.", "J\u00e4rvinen, T A H, Liu, E T. \"Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.\" Cytopathology : official journal of the British Society for Clinical Cytology, 2003, pp. 309-13.", "J\u00e4rvinen, Tero A H, Liu, Edison T. \"Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.\" Current cancer drug targets, 2006, pp. 579-602."]}, "In summary, this system of interacting proteins is primarily involved in the DNA damage response and repair, ensuring the maintenance of genomic stability and preventing the accumulation of mutations that can lead to diseases such as cancer.": {"keywords": [], "references": []}}